 
    
Protocol Title: A Phase 2 Multicenter, Randomized, 
Placebo  Controlled,  Double-Blind Study To Assess  
The Safety And Efficacy  Of CC-486 (Oral Azacitidine) 
In Combination  With Pembrolizumab  (Mk-3475) 
Versus Pembrolizumab  Plus Placebo In Subjects 
With Previously Treated  Locally Advanced  Or 
Metastatic Non-Small Cell  Lung Cancer 
 
NCT Number:  NCT 02546986  
Original Protocol  Date:  15 May 2015  

',6&/2685(
5('$&7('25,*,1$/[ZIP_CODE]&2/
&&16&/
$3+$6(08/7,&(17(55$1'20,=(' 3/$&(%2&[ZIP_CODE]//(''28%/(
%/,1'678'<72$66(667+( 6$)(7<$1'()),&$&<2)&&25$/
$=$&,7,',1(,1&20%,1$7,21:,7+3(0%52/,=80$%0.9(5686 
3(0%52/,=80$%3/863/$&(%2,168%-(&76:,7+35(9,286/<75($7('
/2&$//<$'9$1&('250(7$67$7,&12160$//&(///81*&$1&(5
ã»Œ
7KHLQIRUPDWLRQFRQWDLQHGLQWKHDWWDFKHGUHSRUWLVWKHSURSHUW \RI&HOJHQHDQGVKRXOGQRWEHVKDUHGRU
XVHGIRUDQ\SXUSRVHRWKHUWKDQWKDWIRUZKLFKLWZDVSURYLGHG 

&HOJHQHLVFRPPLWWHGWRSURYLGLQJLQIRUPDWLRQDERXWLWVFOLQLFD OWULDOVWRUHVHDUFKHUVDQGSDWLHQWVZLWKWKH
JRDORIIXUWKHULQJVFLHQFHDQGHQKDQFLQJKHDOWKFDUHZRUOGZLGH /DZVDQGUHJXODWLRQVUHTXLUHKRZHYHU
WKDW&HOJHQHSURWHFWVSDWLHQWSULYDF\7KHFRPSDQ\PD\IXUWKHU KDYHOHJDORUFRQWUDFWXDOREOLJDWLRQVQRW
WRGLVFORVHFRPPHUFLDORUWHFKQLFDOLQIRUPDWLRQSURYLGHGE\RU UHODWHGWRFHUWDLQSDUWQHUFRPSDQLHVRU
YHQGRUV

7KHDWWDFKHGUHSRUWLVSUHVHQWHGLQLWVRULJLQDOIRUPDWEXWFH UWDLQLQIRUPDWLRQKDVEHHQUHGDFWHGLQRUGHU
WRFRPSO\ZLWKWKHDIRUHPHQWLRQHGREOLJDWLRQVRUWRSURWHFW&HO JHQHÂ¶VFRQILGHQWLDOFRPPHUFLDO
LQIRUPDWLRQ7KHUHGDFWLRQVDUHEDVHGRQWKHIROORZLQJSULQFLS OHV

x5HGDFWHGLQIRUPDWLRQKDVEHHQUHSODFHGE\JUH\VSDFHPDLQWDLQL QJRULJLQDOVSDFLQJDQGSDJLQDWLRQ
x$Q\LQIRUPDWLRQWKDWPLJKWDOORZWKHLGHQWLILFDWLRQRILQGLYLGX DOVKDVEHHQUHGDFWHGIRU
DQRQ\PL]DWLRQ
x$WWDFKPHQWVWRWKLVUHSRUWWKDWFRQWDLQFRQILGHQWLDOLQIRUPDWLR QDUHQRWPDGHDYDLODEOH6XFK
DWWDFKPHQWVLQFOXGHWKRVHWKDWFRQWDLQLGHQWLILDEOHSDWLHQWLQI RUPDWLRQVXFKDVVXEMHFWOLVWLQJV
QDUUDWLYHVDQGSURILOHV7KH\DOVRPD\FRQWDLQFRQILGHQWLDOF RPPHUFLDOLQIRUPDWLRQVXFKDV
PHWKRGRORJLHVDQGK\SRWKHVLVJHQHUDWLQJDQGH[SORUDWRU\DQDO\V HV
x&URVVUHIHUHQFHVWRWKHVHDWWDFKPHQWVVXFKDVOLQNVWRVXEMHFW OLVWLQJVLQ6HFWLRQDUHQRW
UHGDFWHGIURPWKHERG\RIWKHUHSRUW+RZHYHUWKHK\SHUOLQNV LQWKHHOHFWURQLFGRFXPHQWDUHQR
ORQJHUIXQFWLRQDO
x,QIRUPDWLRQDERXW&HOJHQHYHQGRUVDQGWKHLUVHUYLFHVDUHUHGDFW HGEHFDXVHPDQ\FRQWUDFWVSURKLELW
GLVFORVXUHRIWKDWLQIRUPDWLRQ)XUWKHUODZVDQGUHJXODWLRQV SUHYHQWXVIURPGLVFORVLQJFHUWDLQ
LQIRUPDWLRQDERXWRXUYHQGRUVRUWKHLUVHUYLFHVEHFDXVHLWLVS URWHFWHGE\FRS\ULJKW
,QIRUPDWLRQDERXW&HOJHQHÂ¶VUHGDFWLRQSROLFLHVDQGWKHDYDLODEL OLW\RIDGGLWLRQDOGDWDIURPWKLVUHSRUWPD\
EHIRXQGDWKWWSZZZFHOJHQHFRPUHVHDUFKGHYHORSPHQWFOLQLFD OWULDOVFOLQLFDOWULDOVGDWDVKDULQJ

&(/*(1([ZIP_CODE],(7$5<,1)250$7,21(
56865686
5($7('5($7('
&$1&(5&$1&(5
OGQRWEHVKDOGQRWEHVK
HDUFKHUVDQGHDUFKHUVDQ
GUHJXOGUHJXODWLRQDWLR
OHJDORUFJDORUFRQRQ
WHGWRFHUWDLWHGWRFHU
FHUWDLQLQIRUHUWDLQLQIRU
WHFW&HOJHQHWHFW&HOJHQ
QJSULQFLSOHQJSULQFLSOH
JUH\JUH\VSDFHVSDFH
HQWLILHQWLILFDWLRQFDWL
QWDLQFRQILGHDLQFRQILG
RQWDLQLGHQRQWDLQLGHQ
\DOVRPD\\DOVRPD\
WKHVLVJHQH[LOCATION_006]HVLVJHQH
HVHDWWDFKPHHVHDWWDFKP
RG\RIWKHURG\RIWKH
O
ERXW&HOJHQERXW&HOJHQ
RIWKDWLQIRUIWKDWLQIR
LRQDERXWRLRQDERXWR
PDWLRQDERXWPDWLRQDERXW
IRXQGDWKWWSRXQGDWKWWS
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 1 CC-486-NSCL-001 Final: 15 May 2015TITLE PAGE
A PHASE 2 MULTICENTER, RANDOMIZED, PLACEBO 
CONTROLLED, DOUBLE-BLIND STUDY TO ASSESS 
THE SAFETY AND EFFICACY OF CC-486 (ORAL 
AZACITIDINE) IN COMBINATION WITH 
PEMBROLIZUMAB (MK-3475) VERSUS 
PEMBROLIZUMAB PLUS PLACEBO IN SUBJECTS 
WITH PREVIOUSLY TREATED LOCALLY ADVANCED 
OR METASTATIC NON-SMALL CELL LUNG CANCER
PROTOCOL NUMBER: CC-486-NSCL-001
DATE FINAL: [ADDRESS_1024256] NUMBER: 2014-005614-29
IND NUMBER: 123160
SPONSOR NAME / ADDRESS: Celgene Corporation
86 Morris AvenueSummit, NJ [ZIP_CODE]
[LOCATION_002]
CONFIDENTIAL
This protocol is provided to you as an Investigator, potential Investigator, or consultant for review by 
[CONTACT_10825], your staff, and ethics committee/institutional review board.  The information contained in this 
document is regarded as confidential and, except to the extent necessary to obtain informed consent, 
may not be disclosed to another party unless such disclosure is required by [CONTACT_27614].  
Persons to whom the information is disclosed must be informed that the information is confidential 
and may not be further disclosed by [CONTACT_476].
&(/*(1(35provided to yoprovided to yo
aff, and ethicf, and ethic
nt is regarded nt is regarded
ay not be discy not be disc
Persons to whersons to wh35235,(7$5<,1)250$7,21CTS CTS 
VANCEVANCE
G CANCCAN
NSCLC-[ZIP_CODE]
ayay201520
20142014 -005-005
123123
CC
3535
(/(/(/(/(/(/(/*
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 2 CC-486-NSCL-001 Final: 15 May 2015MEDICAL MONITOR / EMERGENCY CONTACT [CONTACT_27615]:
Name :
[CONTACT_1641]:
Address: Route de Perreux 1, 
Boudry, Switzerland  2017
Phone:
E-mail :
Note: The back-up 24-hour global emergency contact [CONTACT_184636](s) or Medical Monitor or designee for 
emergency calls.
Back-up 24-hour Global Emergency Contact [CONTACT_184637]: 
&(/*(1([ZIP_CODE],(7$5<,1)250$7,2105000
2
1)should onlyshould onl
dical Moniical Mon
er: : 5<$5$5<
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 3 CC-486-NSCL-001 Final: 15 May 2015CELGENE THERAPEUTIC AREA HEAD SIGNATURE [CONTACT_1783]
{See appended electronic signature [CONTACT_3264]}
Signature [CONTACT_72655] [CONTACT_27616], I indicate I have reviewed this protocol and find its content to be 
acceptable.  ,1,1)250$7,210$0$5000
content to content to
,1
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 4 CC-486-NSCL-001 Final: 15 May 2015SITE PRINCIPAL INVESTIGATOR [INVESTIGATOR_27503]:_______________________________________
By [CONTACT_27616], I agree to personally supervise the conduct of this study at my study 
site and to ensure its conduct is in compliance with the protocol, informed consent, Institutional Review Board (IRB)/Ethics Committee (EC) procedures, instructions from 
Celgene representatives, the Declaration of Helsinki, International Conference on 
Harmonisation (ICH) Good Clinical Practices Guidelines, and local regulations governing the conduct of clinical studies.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,210$0$5000
s studys study at matyy
, informed nformed
ocedures, inedures, i
national Cnationa
nes, and locs, and lo
7$7$
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 5 CC-486-NSCL-001 Final: 15 May 2015COORDINATING PRINCIPAL INVESTIGATOR [INVESTIGATOR_27504]:_______________________________________
By [CONTACT_27616], I agree the protocol has been written to comply with ICH Good 
Clinical Practices guidelines and agree to offer guidance throughout the study as needed.
&(/*(1([ZIP_CODE],(7$5<5<5<,1)wiwi1)250$7,210$0$[ADDRESS_1024257]
5<
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 6 CC-486-NSCL-001 Final: 15 May 2015PROTOCOL SUMMARY
Study Title
A Phase 2 multicenter, randomized, placebo contro lled, double-blind study to  assess the safety 
and efficacy of CC-486 (oral azacitidine ) in combination with pembrolizumab (MK-3475) versus 
pembrolizumab plus placebo in subjects with previously treated locally advanced or metastatic non-small cell lung cancer
Indication  
Second-line treatment of locally advanced or metastatic non-small cell l ung cancer (NSCLC). 
ObjectivesPrimary Objective:
!To estimate the efficacy of CC-486 plus pembrolizumab versus pembrolizumab plus 
placebo based on progression-free survival (PFS) as measured using Response 
Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Secondary Objectives:
!To estimate disease control rate (DCR) of CC-486 plus pembrolizumab versus 
pembrolizumab plus placebo
!To estimate overall survival (OS) of CC-486 plus pem brolizumab versus 
pembrolizumab plus placebo
!To estimate overall response rate (ORR) o f CC-486 plus pem brolizumab versus 
pembrolizumab plus placebo
!To evaluate safety and tolerability of CC-486 plus pembrolizumab versus 
pembrolizumab plus placebo
!To evaluate the impact of pembrolizumab on the pharmacokinetics of CC-486 
Exploratory Objectives:
!To determine the preliminary efficacy (immune-related [ir] PFS, irD CR, irORR) of 
CC-[ADDRESS_1024258] criteria 
!To explore mechanism and biomarkers associated with efficacy of CC-[ADDRESS_1024259] received one prior platinum-based chemotherapy regimen. &(/*(1([ZIP_CODE],(7$5<,1)250$7,21SCLCSCLC )). 
us s pembrolpemb
ured using red using R
ia
[ADDRESS_1024260] usslp
(ORR)(ORR) ofof
erabiliterabilit yyof
aceboeb
mppact of pemact of pe
mine the preine the p
[ADDRESS_1024261] oreore
combinacombin
Study DeStudy D(/*(/
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 7 CC-486-NSCL-001 Final: 15 May 2015Approximately 90 subjects will be randomized 1:[ADDRESS_1024262] 1 cycle of treatment.
The rando mization w ill be stratified by [CONTACT_27183] (non-squamous versus squamous).
An independent Data Monitoring Committee (iDMC) will be established to evaluate safety. 
Following the initial iDMC data review meeting, the iDMC will meet approximately every 6 
months per DMC charter (or more often if requested by [CONTACT_748986]) to assess safety data.  Details are outlined in the DMC charter.
The conduct of this trial will be overseen by a Steering Committee which will serve in an 
advisory capacity to the Sponsor.  
The study will be conducted in compliance wi th International Conference on Harmonisation 
(ICH) Good Clinical Practices (GCPs).
Study Population
Adult subjects with histologically confirmed d iagnosis of locally advanced or metastatic 
NSCLC, lacking anaplastic lymphoma kinase (A LK) or endothelial growth factor receptor 
(EGFR) mutations, who have been treated with [ADDRESS_1024263] that is 
required for primary, secondary and/or exploratory an alysis, as pre-specified in the protocol,
whichever is the later date.  
Study Treatments
CC-486/placebo w ill be administered at a dose of 300 mg orally daily on days 1-14 of a 21-day 
cycle. Pembrolizumab will be administered as a 30-minute intravenous (IV) i nfusion at a dose of 
200 mg (4 x 50 mg vials) on day 1 of a 21-day cycle. 
Subjects may remain on treatment until radiologic  disease progression (for exceptions refer to 
Section 6.4.3 ), unacceptable toxicity, initiation of a new anticancer therapy, withdrawal of 
consent, subject refusal, physician decision, or death.
Overview of Efficacy Assessments
All subjects will be evaluated for tumor response and progression by [CONTACT_748987] 1.1 guidelines at screening and every 6 weeks (Â± 5 days) from 
randomization for the first 24 weeks, and every  9 weeks thereafter until documented disease 
progression (for exceptions refer to Section 6.4.3 ), start of new anticancer therapy, or 
withdrawal of consent. Subjects will also be ev aluated according to irRECIST guidelines in cases 
of progressive disease (PD) per RECIST 1.1.monisatonisat ioion n
nced ced or ormetm
growth facrowth fac
based as chemchem
ths to compths to comp
proximatelyproximatel
d. 
e of the laste of the last
eceipt of theceipt of th
r explorator explorato
ministered ministered
will be admwill be adm
ials)als)on dayon d
main on tremain on tre
), unacceptunaccep
bject refusabject refus
iew of Effiiew of Effi
subjects wsubjects w
accoccrding ding 
andoando mm
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 8 CC-486-NSCL-001 Final: 15 May 2015Response assessments will include computed tomography (CT) scan or magnetic resonance 
imaging (MRI) of the chest and abdomen/pelvis. Bone scans will only be  performed at baseline 
if clinically indicated. If the baseline bone scan is suggestive of metastasis, a CT or MRI should 
be performed and further follow-up of these lesions will follow the protocol schedule. Bone scans during the trial will only be performed if clinically indicated.  If suggestive of new lesions, 
a CT or MRI will be performed to confirm progression.
In the follow-up phase, anticancer treatmen t administered following the last dose of 
investigational product (IP) and survival will be followed every 8 weeks (Â± 5 days) until death, 
withdrawal of consent, or lost-to-follow-up, whichever occurs first, or the End of Trial.
Overview of Safety Assessments
All subjects will be monitored for adverse events, starting from the time the subject signs the 
informed consent form (ICF) until [ADDRESS_1024264] dose of either study drug. A thorough 
evaluation of medical conditions will be conducted during screening for eligibility. Documentedphysical examination (PE), vital signs, labor atory assessments, (eg, serum chemistry, 
hematology), 12-lead electrocardiogram (ECG), urinalysis, and Eastern Cooperative Oncology 
Group (ECOG) performance status will be monitored regularly. Preventative measures will be taken to avoid pregnancy in study subjects or their partners, and females of child-bearing 
potential will have regular pregnancy testing performed. The full schedu le of assessments is 
described in Table 2 and Section 6.
Overview of Statistical Methods
This is a doubl e-blind, placebo-controlled, randomized, phase  2 trial designed to evaluate the 
efficacy and safety/tolerability of  CC-486 plus pembrolizumab versus pembrolizumab plus 
placebo, in subjects with previously tr eated locally a dvanced or metastatic non-small cell l ung 
cancer. The primary endpoint is PFS based on Investigator review.
Sample Size
The primary goal of this study is to provide estimates of the difference in efficacy and safety 
between CC-486 + pembrolizumab and placebo + pembrolizumab. Approximately 90 subjects 
will be randomized 1:1 to receiv e CC-486 plus pembrolizumab or placebo plus pembrolizumab. 
Primary analysis will be conducted when 70 PFS events occur. In this particular setting, a formal 
power calculation was not conducted.
Efficacy Analysis
Efficacy analyses will be performed us ing the intent-to- treat (ITT) population.
The median PFS in each stratum and treatment arm will be calculated based on Kaplan-Meier 
estimates along with corresponding two-sided 90% confidence interval (CI).  In addition, the 
Cox proportional hazards regression model with treatment and any stratification factors w ill be 
performed to obtain the point estimate of hazard ratio (HR) and two-sided 90% CI.  
The secondary efficacy endpoint of OS will be analyzed sim ilarly to PFS.  Ot her secondary 
endpoints of overall res ponse rate (ORR), and disease control rate (DCR) will be evaluated as 
well. A two-sided 90% CI of the difference in  ORR and DCR between the two treatment arms 
will be provided. &(/*(1([ZIP_CODE],(7$5<,1)250$7,21signs the signs the 
gg. A thorou. A thorou
bilitbility. DDocuoc
chemistry, chemistry, 
Cooperativoopera
entative mentative m
emales of cmales of c
ll schedulel sch
zed, phase zed, phase
embrolizumembrolizu
cally advancally advan
on on IInvestignvest
o provide esrovide e
mabmab and plaand pla
eive CCeive CC -44
onducted wnducted w
not conducnot condu
ses will be es will b
n PFS PFS in eain ea
s alos alo ng wing w
proportionaproportion
erformerform ed toed to
The secoThe sec
dpod
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 9 CC-486-NSCL-001 Final: 15 May 2015Safety Analysis
Safety analysis will be performed using the safe ty population. Safety and tolerability will be 
monitored through continuous reporting of adverse events (AEs) and serious adverse events 
(SAEs), laboratory abnormalities, and inciden ce of subjects experiencing adverse events 
resulting in dose reductions, dose interruptions, and/or premature discontinuation of study drugs. 
Treatment-emergent adverse events (TEAEs), TEAEs leading to death or discontinuation from 
treatment, events assessed as Grade 3 or Gr ade 4,  vital signs, weight, clinical laboratory 
information, and concomitant medications/ procedures will be tabulated and summarized.
All AEs will be coded according to the Medical Dictionary for Regulatory Activities (MedDRA). 
All TEAEs will be summarized by [CONTACT_6657], frequency, severity grade based on the Common Terminology Criteria for Adverse Events (CTCAE) (Version 4.0) 
and relationship to treatment. Serious TEAEs, TEAEs of interest, and TEAEs leading to 
discontinuation, dose reduction, or interruption, or death will be summarized/ listed separately.DRA)DRA) . . 
veritverity y 
ersion 4.0) ersion 4.0) 
ding to ng to 
listed separisted sep
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 10 CC-486-NSCL-001 Final: [ADDRESS_1024265] IVES ...........................................................................................26
2.1. Primary Objective ...................................................................................................26
2.2. Secondary Ob jectives .............................................................................................26
2.3. Exploratory Objectives ...........................................................................................26
3. STUDY ENDPOI NTS............................................................................................27
3.1. Primary Endpoint ....................................................................................................27
3.2. Secondary Endpoints ..............................................................................................27
3.3. Exploratory Endpoint(s) ..........................................................................................27
4. OVERALL STUDY DESIGN ................................................................................28
4.1. Study Desi gn ..........................................................................................................28
4.2. Study Dur ation .......................................................................................................29
4.3. End of Tr ial ............................................................................................................29
5. TABLE OF EVENTS.............................................................................................30
6. PROCEDURES......................................................................................................35
6.1. Screening Pe riod.....................................................................................................35
6.2. Treatment Peri od ....................................................................................................36
6.2.1. End of Treatment....................................................................................................37
6.3. Follow-up Pe riod....................................................................................................38
6.3.1. Efficacy Follow-up .................................................................................................38
6.3.2. Survival Follow-up .................................................................................................38
6.4. Response Assessments ............................................................................................38&(/*(1([ZIP_CODE],(7$5<,1)250$7,2188
.......2020
..................... 212
.........................
..........................
.........................
..........................
.......... ...........
......................
.................
........................
..........................
......................... ..
......................
IGNIGN ........
...........................
.......................
......................
OF EVENTOF EVEN
CEDURESCEDURES
Screening PScreening P
TreatmeTreatm
.. EndEn
.3..3.
.3.1..3.1.
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 11 CC-486-NSCL-001 Final: [ADDRESS_1024266] UDY TREATM ENTS........................................................46
8.1. Description of Investigational Products ...................................................................46
8.1.1. CC-486 (Oral Azacitidine)/Placebo .........................................................................46
8.1.2. Pembrolizumab .......................................................................................................46
8.2. Treatment Administration and Schedule .................................................................46
8.2.1. Dose Adjustmen t Guidelin es................................ ................................................... 47
[IP_ADDRESS]. CC-486 (oral azacitidi ne)/Placeb o ..........................................................................47
[IP_ADDRESS]. Pembrolizumab .......................................................................................................[ADDRESS_1024267] Compliance ........................................................................52
9. CONCOMITANT MEDICATI ONS AND PROC EDURES ....................................53
9.1. Permitted Concomitant Med ications and P rocedure s...............................................53
9.1.1. CC-486 (oral azaciti dine)........................................................................................53
9.1.2. Pembrolizumab Supportive Care .............................................................................53
[IP_ADDRESS]. Management of pneumonitis ...................................................................................54
[IP_ADDRESS]. Management of Diarrhea/Colitis .............................................................................54
[IP_ADDRESS]. Management of type 1 diabetes mellitus (if new onset, including diabetic 
ketoacidosis [DKA]) or â‰¥ Grade 3 Hyperglycemia, if associated with ketosis 
(ketonuria) or metabolic acidosis (DKA) ................................................................54
[IP_ADDRESS]. Management of hypophysitis ..................................................................................54&(/*(1([ZIP_CODE],(7$5<,1)250$7,[ADDRESS_1024268] C
MITANT MITANT
tted Concotted Conco
C-486 (ora486 (ora
PembrolPembro
1.1. ManMa
.1.2.2..1.2.2.
[IP_ADDRESS]..1.2.3
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 12 CC-486-NSCL-001 Final: 15 May [ZIP_CODE].1.2.5. Management of hyperthyroidi sm or hypothy roidism...............................................55
[IP_ADDRESS]. Management of he patic abnormalities .....................................................................55
[IP_ADDRESS]. Management of renal failure or nephritis .................................................................55
[IP_ADDRESS]. Management of infusion reactions ..........................................................................[ADDRESS_1024269] Disposition .................................................................................................58
10.6. Efficacy Analysis ....................................................................................................58
10.6.1. Primary Efficacy  Endpoint ......................................................................................58
10.6.2. Secondary Endpoints ..............................................................................................59
[IP_ADDRESS]. Overall Survi val .....................................................................................................5 9
[IP_ADDRESS]. Overall Response Rate (ORR) ................................................................................59
[IP_ADDRESS]. Disease Control Rate (DCR) ...................................................................................59
[IP_ADDRESS]. irPFS, irORR and irD CR per irRE CIST ..................................................................59
10.6.3. Subgroup Analysis ..................................................................................................59
10.7. Safety Analy sis.......................................................................................................59
10.8. Pharmacokinetic Analysis .......................................................................................60
10.8.1. Plasma Concen trations ............................................................................................60
10.8.2. Pharmacokinetic Parameters ...................................................................................61
10.8.3. PK Analys es...........................................................................................................62
10.9. Interim Analy sis .....................................................................................................62
10.10. Other Topi [INVESTIGATOR_1102]...........................................................................................................62
10.10.1. Data Monitoring Committee ...................................................................................62
10.10.2. Steering Co mmittee ................................................................................................6266
.......575
..............575
.........................
..........................
..........................
..........................
..........................
..................
.........................
..........................
.........................
........................
.......................
.................
e (ORR)e (ORR) .
Rate (DCR)Rate (DCR
and ind irDCRrDCRiii
AnalysisAnalysi
y y AnalysisAnalysis
harmacokinarmacoki
PlPasma Casma 
2.2. PharPh
[IP_ADDRESS].8.3.
[IP_ADDRESS].
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 13 CC-486-NSCL-001 Final: 15 May 201511. ADVERSE EV ENTS..............................................................................................64
11.1. Monitoring, Recording and Re porting of Advers e Even ts ....................................... 64
11.2. Evaluation of Adve rse Events.................................................................................65
11.2.1. Se riousness............................................................................................................. 65
11.2.2. Severity / In tensity..................................................................................................[ADDRESS_1024270]/Independent Ethics Committee Review and 
Approval ................................................................................................................[ADDRESS_1024271] / Ethics Committee ................76
14.8. Termination of the Study ........................................................................................76&(/*(1([ZIP_CODE],(7$5<,1)250$7,[ADDRESS_1024272] 
ConCo
[IP_ADDRESS].
[IP_ADDRESS].
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 14 CC-486-NSCL-001 Final: 15 May 201515. DATA HANDLING AND RECORDKEEPI[INVESTIGATOR_1645] .....................................................77
15.1. Data/Documen ts .....................................................................................................[ADDRESS_1024273] Retention ....................................................................................................77
16. QUALITY CONTROL AND QUALITY ASSURANCE ........................................79
16.1. Study Monitoring and S ource Data Veri ficatio n......................................................79
16.2. Audits and Ins pections............................................................................................79
17. PUBLICATIONS ...................................................................................................80
18. REFERENCES.......................................................................................................81
19. APPENDICES ........................................................................................................84
19.1. Appendix A: RE CIST 1.1 .......................................................................................84
19.1.1. Definiti ons............................................................................................................. .84
[IP_ADDRESS]. Measurable Di sease ................................................................................................84
19.1.2. Tumor Response Evaluation ...................................................................................84
[IP_ADDRESS]. Target Les ions ........................................................................................................ 84
[IP_ADDRESS]. Non-target Le sions .................................................................................................85
[IP_ADDRESS]. Response Criteria ....................................................................................................85
[IP_ADDRESS]. Symptomatic Deter ioration.....................................................................................87
19.2. Appendix B: irRECIST...........................................................................................88
19.3. Appendix C: Events of Clinical Interest (ECI) Guidance Document ........................98
19.3.1. Overvi ew................................................................................................................ 98
[IP_ADDRESS]. Dose Modificatio n/Discontinuation ......................................................................100
19.3.2. ECI Reporting Guidelines .....................................................................................100
19.3.3. ECI Categories and Terms ....................................................................................100
[IP_ADDRESS]. Pneumoniti s..........................................................................................................1 00
[IP_ADDRESS]. Diarrhea/Colitis ....................................................................................................102
[IP_ADDRESS]. Endocrine .............................................................................................................104
19.3.4. Hematologi c ................................................................ ......................................... 106
19.3.5. Hepati c ................................................................................................................. 108
19.3.6. Neurologic ............................................................................................................10 9
19.3.7. Ocular .................................................................................................................. .110
19.3.8. Renal ................................................................................................................... .111
19.3.9. Skin .................................................................................................................... ..112&(/*(1([ZIP_CODE],(7$5<,1)250$7,2199
.......797
..............808
.........................
..........................
..........................
..........................
................... .....
..................
.........................
..........................
.........................
........................
.......................
inical Interinical Inter
...................... .
n/Discont/Discont ini
g Guidelineg Guideline
gories and Tgories an
momonitnitisis......
iarrhea/Coarrhea/Co
EndocrinEndocri
4.4. HemHe
[IP_ADDRESS].3.5.
[IP_ADDRESS].3.6.
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 15 CC-486-NSCL-001 Final: 15 May 201519.3.9.1. Immediate Evaluation for Potential Skin ECIs ......................................................113
19.3.10. Other .................................................................................................................. ..114
19.3.11. Infusio n Reactions ................................................................................................115
19.3.12. Follow-up to Re solution ....................................................................................... 117
19.3.13. Referen ces............................................................................................................1 17
19.4. Appendix D: Table of Abbreviations ....................................................................119
&(/*(1([ZIP_CODE],(7$5<,1)250$7,2199
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 16 CC-486-NSCL-001 Final: [ADDRESS_1024274] OF TABLES
Table 1: Main Data in Pr etreated NSCLC Subjects ...............................................................19
Table 2: Table of Events.......................................................................................................30
Table 3: Imaging and Treatment after Site- Assessed 1st Radiologic Evidence of PD ............40
Table 4: Schedule of Pharmacokinetic Blood Sample Collection in the 
Pharmacokinetics Phase..........................................................................................41
Table 5: CC-486/Placebo Dose Adjustment and Dose Delays for Toxicity ...........................48
Table 6: Dose Modification Guidelines for Pembrolizumab Drug-Related Adverse 
Events.....................................................................................................................50
Table 7: Hypothetical Power and Resulting Two-sided 90% CI of Hazard Ratio ..................58
Table 8: Time Point Response: Subjects With Target (Â± Non-target) Disease .......................86
Table 9: Time Point Response: Subjects With Non-target Disease Only ...............................87
Table 10: Imaging Guidance for Standard RECIST 1.1 and Immune-related (ir) 
RECIST..................................................................................................................88
Table 11: Events of Clinical Interest.......................................................................................98
Table 12: Infusion Reactions ................................................................................................116
Table 13: Abbreviations and Specialist Terms .....................................................................119
&(/*(1([ZIP_CODE],(7$5<,1)250$7,211
......48
.................... 55
o..............
sese...................
lyy.................
e--related (irelated (
........................
..........................
.......................
........................
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 17 CC-486-NSCL-001 Final: [ADDRESS_1024275] OF FIGURES
Figure 1: Overall Study Design ..............................................................................................29
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 18 CC-486-NSCL-001 Final: 15 May [ZIP_CODE]. INTRODUCTION 
1.1. Disease Background
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths in both men 
and women. Globally, approximately 1,825,000 new cases of lung cancer were diagnosed in
2012, and 1,590,000 deaths occurre d due to this disease ( Globocan, 2012 ). The World Health
Organization (WHO) divides lung cancer into 2 major classes based on its biology, therapy, and prognosis: NSCLC and small cell lung cancer. NSCLC accounts for more than 85% of all lung 
cancer cases and includes 2 major types: (1) non-squamous carcinoma (including 
adenocarcinoma, large-cell carcinoma, other cell types); and (2) squamous cell (epi[INVESTIGATOR_015]) carcinoma. Adenocarcinoma (40% of lung cancers) is the most common type of lung cancer seen 
in the [LOCATION_002] (US) and is also the mo st frequently occurring cell type in nonsmokers 
(Speicher, 2000 ).
Cigarette smoking remains the most impor tant risk factor for lung cancer, although 
approxima tely 15% of all lung cancers are diagnosed in patients who never smoked.
One reason for the high mortality r ate of lung can cer is the advanced stage at diagnosis; only 25-
30% of new NSCLC cases are diagnosed with localized disease that is potentially curable with 
surgery ( Fossella, 2000 ; Lang-Lazdunski, 2013 ). The majority of patients are diagnosed with 
locally advanced or metastatic disease and are not candidates for surgery.
1.2. Treatment Options in Second-line Metastatic NSCLC
In patients with metastatic NSCLC who have experienced disease progression either during or after first-line therapy and have an Easte rn Cooperative Oncology Group (ECOG) performance 
score of 0-2, single agent docetaxel, gemcitabine, or erlotinib is recommended if not previously 
given. Pemetrexed is another option for the non-squamous subtype of NSCLC ( NCCN, 2014 , 
ESMO, 2014 ).  
Docetaxel was shown to be superior to best supportive care (BSC), vinorelbine and ifosfamide; 
nevertheless, using either the weekly or three-weekly schedule in multiple randomized studies 
the observed response rate with docetaxel ranged from 3% to 12%, progression-free survival (PFS) from 1.9 to 3.4 months, and overall survival (OS) from 5.4 to 9.2 months ( Shepherd, 2000 ; 
Fossella, 2000 ; Bria, 2006 ).
Recently, nintedanib, a triple angiokinase inhib itor, was approved in the European Union (EU) in 
combination with docetaxel as second-line therapy for NSCLC. The results showed that 
compared to docetaxel alone, nintedanib plus docetaxel significantly extended the median OS
from 10.[ADDRESS_1024276]-line 
chemotherapy (P=0.0359; hazard ratio [HR]: 0.83) ( Reck, 2014 ). In addition, ramucirumab was 
approved in the US in combination with docetaxel  as second-line therapy. The phase 3 REVEL 
trial compared ramucirumab, a vascular e ndothelial growth factor (VEGFR)-[ADDRESS_1024277], plus 
docetaxel with placebo plus  docetaxel in NSCLC patients who experienced disease progression 
after treatment with platinum-based chemother apy for locally advanced or metastatic disease.
Median OS was better in the ramucirumab group than in the placebo group (10.5 vs 9.1 months; &(/*(1([ZIP_CODE],(7$5<,1)250$7,21nd d
lung lung 
ermoermo id) id) 
ung cancerng cancer
nonsmnonsm okerok
er, althoughalthou
never smonever sm
nced stage aed stage 
se that is pose that is
ritytyi ofofyy patpatffie
dates for sudates for 
nne eMetasMetas
experienceexperience
CooperativCooperati
mmcicitabinetabineiii , o
fofor the nonr the 
perior to beperior to b
he e weekly oweekly
ate with docate with d
months, anmonths, 
aa, 2006, 2006 ).).
edanibdanib , a tra 
n win withthiii docedocehh
d to docetao docet
10.3 to 12.10.3 to 12
emotherapymotherapy
approved ipproved i
ririalal co coll
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 19 CC-486-NSCL-001 Final: 15 May 2015HR, 0.857; P = .0235), as was median PFS (4.5 vs 3.0 months; HR, 0.762; P < .0001) ( Perol,
2014 ).
Gemcitabine showed modest activ ity in a phase II study with a 6.2% partial response and [ADDRESS_1024278]-line cisplatin-containing therapy ( Sculier, 2000 ).  Another phase II study found a partial response in
19% of subjects treated with gemcitabine as a second-line agent, and a median duration of 
response of 29 weeks ( Crino, 1999 ).  In a third trial evaluating gemcitabine plus BSC versus 
BSC alone, tumor response was seen in 19% of gemcitabine-tr eated subj ects while response was 
not measured in subjects treated with BSC alone ( Anderson, 2000 ).  There was no difference in 
OS (5.7 versus 5.9 months, respectively).   The differe nce in the results between the trials may be 
due to the percentage of stage III versus stage IV subjects included in the trials.  In the study by 
[CONTACT_748988]. 96% of subjects had stage IV disease compared to 59% and 40% in Crino et al. and 
Anderson et al., respectively.
Erlotinib has been proven to be superior to BSC with significantly improved survival (6.7 vs. 4.7 
months), PFS (2.2 vs. 1.8 months), and delayed time to symptom deterioration ( Shepherd, 2005 ).
Gefitinib is approved in the EU for the treatment of advanced and metastatic NSCLC with 
activating mutations of endothelial growth factor receptor (EGFR) only. Although a higher 
response rate was in favor of gefitinib compared to placebo (8% vs. 1%), median time to 
progression (TTP) (3.0 vs. 2.6 months) and survival (5.6 vs. 5.1 months) were similar in the 2groups ( Thatcher, 2005 ). A non-inferiority trial compared gefitinib to docetaxel in NSCLC 
patients after 1 or 2 lines of chemotherapy ( Kim, 2008 ). A similar median survival (7.6 vs. 8 
months) and TTP (2.2 vs. 2.7 months) were observed, but less toxicity and better quality of life favored the gefitinib arm.
Pemetrexed showed clinically equivalent efficacy  outcomes but better tolerability when 
compared to docetaxel in p atients with the non-squamous subtype of NSCLC ( Hanna, 2004 ; 
Peterson, 2007 ). 
An overview of the published data with the above described agents are summarized in Table 1 .
Table 1: Main Data in Pretreated NSCLC Subjects
CompoundLine of 
treatment Histology N RR (%)Median 
TTP/PFS 
(months)OS 
(months)
Docetaxel 2ndAll 2557 2.7-12.6 1.9-3.4 5.4-9.2
Gemcitabine 2ndAll 65 6.21-- 4.22
Erlotinib 2nd3rdAll 806 6.2-9 1.7-2.2 6.7-9.2
Gefitinib 2nd3rdAll 1862 8.0-9.1 2.2-3.0 5.6-7.6
Pemetrexed 2ndAll3871 4.3-9.1 2.6-2.9 6.7-8.3
1This value represents partial response.
2This value represents median duration of survival.
3A retrospective analysis found that pemetrexed only showed significantly higher survival when compared to docetaxel in the 
non-squamous subgroup.  Docetaxel had statistically better survival in the squamous cell subgroup&(Pemetrexedemetrexed&(/*(1([ZIP_CODE],(7$5<,1)250$7,21as as 
e in in 
may may be be 
e studystudy  by [CONTACT_748989]. aino et al. a
d survival (6d survival 
ration (ation ( Shep
tastatic NStastatic N
)onlyonly. AltAlth
% vs. 1%), mvs. 1
5.15.1momntthh
d gefitgefitinib tinib t
). A s). A s imilaimila
ed, but less ed, but les
ficacyficacy ououytctcu
e none non --squasqua
a with the abwith the a
Pretreatedretreate
f f 
mentment HH35(22ndnd1((((
22ndd(1*22n***(/*inibinib/*/*/*/*
&(&This vaThis va
is
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 20 CC-486-NSCL-001 Final: [ADDRESS_1024279] of care.  In addition to the above gui delines, patients whose tumors are positive for the 
EGFR and/or anaplastic lymphoma kinase (ALK) mutation(s) should receive targeted therapy.  
The EGFR mutation which results in the activat ion of the EGFR tyrosine kinase domain has 
been reported in about 20-25% of non-squamous NSCLC cases and less than 5% in tumors with 
squamous histology.  Erlotinib and afatinib are EGFR tyrosine kinase inhibitors (TKIs) indicated 
for first-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substituti on mutations, the most commonly f ound mutations in 
NSCLC ( Tarceva
Â®Package Insert ; GilotrifÂ®Package Insert ; NCCN, 2014 ).  Patients who 
progress after first-line therapy are still recommended to be continued on erlotinib or afatinib as 
part of second-line therapy ( NCCN, 2014 ).  Anaplastic lymphoma kinase translocation, another 
key driver mutation, occurs in roughly 5% of NSCLC cases ( Shaw, 2013 ), and it is mostly 
associated with the adenocarcinoma subtype ( Bang, 2011 ; Xalkori Package I nsert ).  Tumors with 
this mutation are amenable to treatment with criz otinib, an ALK, MET, and ROS1 tyrosine 
kinase inhibitor, and thus, crizotinib is used in first-line therapy for metastatic ALK-positive 
NSCLC patients.  For patients who progress after first-line therapy, crizotinib or the recently approved ALK inhibitor, ceritinib, is recommended as part of second-line therapy ( NCCN, 
2014 ).  This trial will focus on second-line therapy for subjects who do not possess these 2 driver 
mutations.  Thus, EGFR-positive and ALK-positive subjects will be excluded from this trial.  
The reported response rate to second-line therapy has generally been less than 10% ( NCCN, 
2014 ), and many patients who respond to second-line therapy eventually develop resistance.  The 
limited effective second-line therapy options  available call for the investigation of novel 
approaches to drug therapy in advanced NSCLC.
1.3. Overview of CC-486
CC-486 is an orally bioav ailable formulation of a zacitidine (AZA).  A zacitidine, an analog of the 
pyrimidine nucleoside cytidine, has effects on cell differentiation, gene expression, and deoxyribonucleic acid (DNA) synthesis and metabolism, and causes cytotoxicity.
VidazaÂ® (azacitidine injection) is approved by [CONTACT_3133] (FDA) for 
five subtypes of the French American British (FAB) classification system of myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMMoL). Vidaza is also approved by 
[CONTACT_748990], acute myeloid leukemia (AML) and 
CMMoL patients who are not eligible for hematopoietic stem cell transplantation.  Vidaza can be administered by [CONTACT_33980] (IV) or subcutaneous (SC) routes as designated by [CONTACT_72627].
After its incorporation into a cellâ€™s DNA during the S-phase of the cell cycle, AZA forms 
covalent adducts with DNA methyltransferase 1 (DNMT1) and depletes this enzyme required for 
the maintenance of DNA methylation patterns, thereby [CONTACT_748991][INVESTIGATOR_72594].   
Epi[INVESTIGATOR_72595] (DNA and histone proteins) that mediate the stable transmission of a geneâ€™s transcriptional status through cell division.  One of 
the first recognized epi[INVESTIGATOR_72596].  The addition of a 
methyl group to cytosine in the dinucleotide CpG is catalyzed by [CONTACT_72629] (DNMTs) and is associated with tran scriptional suppresion of genes ( Miranda, 2007 ). Genomic 
methylation patterns are precisely regulated during normal embryonic development and &(/*(1([ZIP_CODE],(7$5<,1)250$7,21nib as nib as 
another another 
mmostlyostly
).  Tumors  Tumors
OS1 tyS1 ty rosinrosyyy
tic ALKtic ALK --pop
tinib or theinib or
line therapline therap
o do not poo do not p
ll be excludll be exclud
ally been leally been le
erapy eventrapy eve
call for thcall for th
ioion n ofofaffzac
fects on cefects on ce
hesis and msis and m
) iissapproveapprove
American BAmerican
ronic myeloronic my
sision fon for thehfff
who are not who are not 
iintntravenouravenou
incorporatiorporati
nt adducts t adducts 
maintenancmaintenan
Epi[INVESTIGATOR_748954] i rfi
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 21 CC-486-NSCL-001 Final: [ADDRESS_1024280] been found to be altered in specific ways in cancer.  Specifically, cancer 
cell genomes are typi[INVESTIGATOR_748955]1 as well as genes encoding proteins required for apoptosis, including caspase 8, DAPK and Apaf-1.  DNA methylation-based gene  silencing can thus contribute to the 
establishment and maintenance of the transformed state and limit the effectiveness of anticancer 
therapi[INVESTIGATOR_014].
CC-486 entered clinical testing in 2006 in subjects with MDS, CMMoL, and AML.  The AZA 
PH US 2007 CL 005 study has shown that CC-486 is bioavailable and a maximum tolerated dose 
(MTD) of 480 mg daily for 7 days of a 28-day cycle was defined based on dose- limiting dia rrhea 
at the 600 mg dose ( Garcia-Manero, 2011 ).  As expected, reversible and manageable 
myelosuppression was observed.  Pharmacodynamic activity (DNA hypomethylation) and 
clinical responses were obse rved with CC-486, although the cros s-over design (with SC Vidaza 
administered during Cycle 1) confounded the interpretation of these responses in Part 1 of the 
study.
The second part of the AZA PH US 2007 CL 005 study explored both daily and twice daily 
extended dosing schedules of 14 and 21 days out of 28 days in a non-crossover design.  CC-486 
administered at 300 mg once daily (QD) for 14 or 21 days of a 28-day cycle produces cumulative 
exposures (area under the concentration-time curve [AUC] per cycle) that are approximately 40% and 60% of the exposure achieved with the labeled dose and schedule of Vidaza, 
respectively.  Daily doses of [ADDRESS_1024281] proven to  be tolerated on both the 14 and 21 out of 28-
day schedules with myelosuppression, gastroin testinal (GI) symptoms, and fatigue being the 
most common toxicities ( Garcia-Manero, 2011 ).
In the AZA PH US [ADDRESS_1024282] udy, DNA methylation levels in blood were measured as a 
pharmacodynamic (PD) endpoint, to determine DNA hypomethylating activity of CC-486.  In summary, it was confirmed that CC-486 is biol ogically active, reducing DNA methylation when 
administered at low doses on extended schedules.
CC-486 is also under clinical investigation, either as monot herapy or in combination with other 
investigational products, for the treatment of ly mphoma, multiple myeloma, and relapsed or 
refractory solid tumors (eg, urothelial carcinoma of the bladder, renal pelvis, ureter, or urethra; 
pancreatic carcinoma; breast cancer; ovarian cancer; nasopharyngeal carcinoma; cervical carcinoma; anal carcinoma; and merkel cell carcinoma).   
 There are 2 ongoing studies 
evaluating PK of CC-486 (AZA-ST-001 and CC-223-NSCL-001).
1.3.1. CC-[ADDRESS_1024283] atin or nab-paclitaxel, or as a single 
agent in subjects with relapsed or refractory so lid tumors (AZA-ST-001) was initiated on 30 Nov 
2011.  In Part 1 of this two-part study, CC-486 at escalating doses of 200 or 300 mg was 
administered on Days 1 to 14 of a 21-day cycle in three separate arms of the study (Arm A, Arm 
B, Arm C). 
In Arm A of AZA-ST-001, subjects received carboplatin (AUC = 4) on Day 8 of each cycle and 
in Arm B, subjects received nab-paclitaxel 100 mg/m
2beginning on Day 8.  For Arm A, both &(/*(1of CCof CC -486 48
CCC--1([ZIP_CODE],(7$5<,1)250$7,21dose dos
diiarrhea arrhea 
oon) and n) and 
wiwiththii SC ViSC Vihh
s in Part 1 s in Part 1 
daily and tdaily and 
n-crossorosso ve
8-dayda cyclecly
er cyer cy cle) thacle) t
se and sche and sc
tolerated otolerated o
al (GI) symal (GI) sy
mmethylatethylat ioio
mine DNA ine DNA
iis bis biolologicog
d scheduled sched
estestigatigatioionn
he treatmenhe treatme
, urothelial urothelia
reast cancereast canc
nonomama; and; an
486 E486 E
ase 1 studyase 1 study
ent in subjent in subje
2011.  In P011.  In P
adminisdmini
A(1(
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 22 CC-486-NSCL-001 Final: 15 May 2015200 mg and 300 CC-486 mg were well tolerated with carboplatin AUC = 4.  For Arm B, 
initially, nab-paclitaxel was administered weekly s tarting on Cycle [ADDRESS_1024284] dose level of CC-486.  The protocol 
was amended to administer nab-paclitaxel on Days 8 and 15 of each cycle (ie, 2 out of 3 weeks) 
and this was well tolerated in combination wi th CC-486 at 200 mg.  When the CC-486 dose was 
escalated to 300 mg, dose- limiting neut ropenia was again encountered, making the 200 mg the 
MTD of CC-486 in combination with nab-paclitaxel 100 mg/m2on a 2- out of 3-week schedule.  
Arm C of study AZA-ST-[ADDRESS_1024285]-001 were observed in Arm B.  Of 8 evaluable
subjects with relapsed pancreatic carcinoma, 1 h ad a partial response (PR) and 3 others had 
stable disease (SD) > 16 weeks for a disease control rate (DCR) of 50%.  CC-486 has also shown 
promising efficacy in subjects with relapsed or refractory NSCLC (N = 20).  Although the 
efficacy data are not yet fully mature, objective responses were observed, including [ADDRESS_1024286] by [INVESTIGATOR_6875]-486.
Please refer to the Azacitidine IB for detailed information concerning the available 
pharmacology, toxicolo gy, drug metabolism,  clinical studies, and adverse event (AE) profile of 
the azacitidine/CC-486.
1.4. Overview of Pembrolizumab
The programmed cell death protein-1 (PD-1) is an immune-checkpoint receptor expressed by T cells upon activation.  The normal function of PD-1 upon binding by [CONTACT_344752], programmed death-ligand 1 (PD-L1) and PD-L2, is to moderate ongoing immune responses and prevent 
autoimmunity ( Harvey, 2014 ).  Some tumor cells up-regulate the PD-1 ligands to evade active T-
cell immune surveillance. Pembrolizumab is a highly selective humanized monoclonal antibody (mAb) that binds to the PD-1 receptor and dir ectly blocks the interaction between PD-1 and its 
ligands, thereby [CONTACT_748992] (pembrolizumab
IB).  Pembrolizumab is being investigated in various oncology indications including melanoma, NSCLC, renal cell carcinoma (RCC), breast cancer , multiple myeloma (MM), microsatellite 
unstable tumors, and head and neck cancer. Pembrolizumab was recently approved in the US for 
the treatment of advanced, unresectable or metastatic malignant melanoma, and for use in melanoma patients with dis ease progression after prior treatment with (a) ipi[INVESTIGATOR_90913] (b) a 
BRAF inhibitor, in the case of BRAF V600-mutant disease ( Nishimura, 2000 ). It is the first anti-&(/*(1([ZIP_CODE],(7$5<,1ved ind ArArmm
esponse (esponse ( PR
DCR) of 50CR) of 5
ryyNSCLC NSCLCy
onses were onses we
SCLC had SCLC had
ectctivive respe resp
These obhese ob serser
netnetic ic momodifydif
detailed detailed in
metaboetab lism,sm
f fPembroemb
l death protdeath pr
oon.  The non.  The no
((PDPD-L1L1))an
y(y(HarveyHarvey
une surveille surveil
thhat abinds inds
andsnds, , ththerebereb
BB).)  PPembrembr
NSCLC,NSCLC
stab250$7,212.  2.  
daily for daily for 
e 2 dose foe 2 dose fo
)251)21)
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 23 CC-486-NSCL-001 Final: 15 May 2015PD-1 therapy to receive regulatory approval in the US, and pembrolizumab for the melanoma 
indication is currently under regulatory review in the EU.
1.4.1. Pembrolizumab Experience in Solid Tumors and Safety
An open-label phase 1 trial (Keynote 001) is being conducted to evaluate the safety and clinical 
activity of single ag ent pembrolizumab. The dose escalation portion of this trial evaluated three 
dose levels, 1 mg/kg, 3 mg/kg, and 10 mg/kg, admin istered every 2 weeks, in subjects with 
advanced solid tumors. All 3 dose levels were well tolerated and no dose- limiting toxicities
(DLTs) were observed. Based on PK data showing a half-life of  21 days, the dosing frequency 
in the expansion cohort has been changed to every 3 weeks. 
The choice of the 200 mg every 3 weeks as an appropriate dose for the switch to fixed dosing is 
based on simulations performed using the population PK model of pembrolizumab showing that 
the fixed dose of 200 mg every 3 weeks will provide exposures that 1) are optimally consistent 
with those obtained with the 2 mg/kg dose every 3 weeks, 2) will maintain individual patient exposures in the exposure range established in melanoma as associated with maximal efficacy 
response and 3) will maintain individual patients exposure in the exposure range established in 
melanoma that are well tolerated and safe. 
The ongoing expansion cohort in Keynote 001 is enrolling subjects with NSCLC.
Keynote 001, Part C enrolled 38 subjects with NSCLC (adenocarcinoma, squamous cell 
carcinoma, and large cell carcinoma) who experienced progression of cancer after initiation of their second line of systemic therapy to receiv e monotherapy pembrolizumab. By [CONTACT_10670]-
assessed immune-related Evaluation Criteria in So lid Tumors (irRECIST), the overall response 
rate (ORR) (confirmed and unconfirmed) was 24%. Similar results were obtained using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, yielding an ORR (confirmed and 
unconfirmed) of 21%. Most responses by [CONTACT_748993] 9. The median duration of response by [CONTACT_748994] a median duration of follow-up of 62 weeks. The median OS for all 38 patients treated with 
pembrolizumab was 51 weeks.
Pembrolizumab has been generally well-tolerated in  subjects with solid tumors at doses up to 10 
mg/kg every other week without DLTs.  Of the [ADDRESS_1024287] commonly reported treatment-em ergent AEs experienced were fatigue 
(43.8%), nausea (26.7%), cough (25.3%), pruritus (24.6%), diarrhoea (22.3%), and rash (21.5%).   466 subjects (97.3%) experienced treatment-emergent AEs of which 368 (76.8%) were 
considered drug-related. Serious adverse events (SAEs) were reported in 30.1% of patients, but 
SAEs that were attributed as potentially (possibly, probably, or definitely) drug-related by [CONTACT_458526] 6.7% of patients overall. Five patients died within [ADDRESS_1024288] dose of pembrolizumab; none of the deaths were considered drug-related.
Preliminary results from Part C only (previously-treated NSCLC pa tients) reported the incidence 
of drug-r elated AEs to be 53%, usually Grade 1-[ADDRESS_1024289] commonly 
rash (21.1%), pruritus (18.4%), fatigue (15.8%), diarrhea (13.2%), and arthralgia (10.5%). 
Serious AEs were reported in 34.2% of all NSCLC patients, but SAEs that were attributed as potentially drug-related by [CONTACT_748995] 2.6% of NSCLC patients. Most 
patients continued treatment in spi[INVESTIGATOR_748956]; 21.1% discontinued due to an AE. The 
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21cycy
d dosing is d dosing is 
showing tshowing t
mally consimally con
ndividual pndividual 
ith maximath maxima
sure range eure range
ects with Nects with N
enocarcinonocarcin
rogression ogressio
therapytherapy pempemyy
id Tumid Tum orsors
4%. Simila4%. Simi
rs (RECISTrs (RECIST
irRECISTrRECIST
ation of restion of re
2 weeks. Thweeks. 
nerally wellnerally well
ithhiout DLTout DLT
momonlynreprepy
.7%), coug7%), coug
3%) experi3%) experi
ugg--related. related
were attribuwere attribu
ators were rs were
ose of pembose of pem
reliminary reliminary
ofof drug drugff -rere
sh (2sh (2
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 24 CC-486-NSCL-001 Final: 15 May 2015incidence of Grade 3/4 drug related AEs was 2.6%. Thus, the overall AE summary suggests that 
pembrolizumab is generally tolerable and AEs are generally manageable in NSCLC patients
(pembrolizumab IB).
In Part C of the study, 2 patients developed pneum onitis and 1 patient was reported with steroid-
responsive pulmonary edema. Two cases were Gr ade 2; the case of pulmonary edema was Grade 
3. These cases began as early as [ADDRESS_1024290] dose to several cycles (Week 18) after the 
first dose. It is not clear the role of prior thor acic radiation to the development of this AE. The 
Grade 3 epi[INVESTIGATOR_748957], whereas the Grade 2 cases did not. The Grade 3
pulmonary edema and a case of Grade 2 pneumonitis were considered drug-related; the third 
case was considered not drug-related. All [ADDRESS_1024291] shown pro mising activity and acceptable tolerability in 
patients with relapsed or refractory NSCLC as detailed in Sections 1.3.1 and 1.4.1 .
The reported response rate to second-line therapy in NSCLC has generally been less than 10% 
(NCCN, 2014 ), and many patients who do respond eventually develop resistance.  The limited 
availability of effective second-line therapy options call for the investigation of novel approaches 
to drug therapy in advanced NSCLC.  One potential strategy is the use of epi[INVESTIGATOR_366870], such as CC-486, to prime the tumor to become more responsive to immunotherapy. This approach is 
proposed by [CONTACT_748996]-[ADDRESS_1024292] shown that epi[INVESTIGATOR_748958] a role in  tumor progression in lung cancer ( Topaloglu, 2004 ).  
Importantly, unlike gene mutations, DNA methylation is reversible and can be inhibited by a 
DNMTi ( Zeng, 2013 ).  There are currently [ADDRESS_1024293] been 
approved by [CONTACT_748997], i.e., 2 DNMT inhibitors for 
myelodysplastic syndrome (azacitidine and decitabine) and 2 histone deacetylase (HDAC) 
inhibitors for cutaneous T- cell lymphoma (vorinostat and romidepsin).  A recent study using the 
combination epi[INVESTIGATOR_748959], an HDAC inhibitor, in subjects 
with recurrent metastatic NSCLC who had ex tensive prior systemic therapy yielded some 
interesting results ( Juergens, 2011 ).  Though only two of the [ADDRESS_1024294] responded to various subsequent therapeutic regimens ( Juergens, 2011 ). Five 
of these subjects received 1 of 2 investigational immunotherapy drugs, anti-PD1 or anti-PD-L1antibody.  Preliminary data revealed that 3 sub jects experienced durable partial responses for 
over a year while the other two subjects had stab le disease on therapy for more than 6 months 
(Brahmer, 2013 ).  
Previous PD-1 immune-checkpoint targeting monot herapy studies in subjects with advanced 
NSCLC who received previous systemic therapy reported only a 16 to 17% response rate 
(Brahmer, 2012 ; Topalian, [ADDRESS_1024295] , Garon 2014 ). 
The results of the above study led to the hy pothesis that azacitidine may  prime the tumor to 
become more responsive to immunotherapy.  There are several possible mechanisms as to how 
this may occur ( Brahmer 2013 ): (&(/*(1(35235aa35,(7$5<,1)250$7,21d 
le tole tolerabilerab
[IP_ADDRESS].1 .
lly ybeen lesbeen
op resistancp resistan
vestesigatgatioionn
thhe use of e us
o o immunothimmunot
his trialhis tria .
permethylapermethyla
in inlung calung ca
ylatioylatio n nis ris 
drugs targdrugs targ
ogigic malignc malign
nd decitand decit
phohoma (vorma (vo
of azacitof azacit ididini
CLC who hCLC who h
s, 2011 201 ).  T
ses to this tses to this
sponded to ponded to
eceived 1 oceived 1 o
minaryminary datdyy
while the otwhile the o
r, 2013013).  ).  
ous PDous PD -1 i1
SCLC whoSCLC who
Brahmer,Brahmer,
he rehe re
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 25 CC-486-NSCL-001 Final: 15 May 2015!Azacitidine induces the type I IFN path way and subsequently upregulates suppressed 
antigen-presenting molecules, enhancing intratumoral inflammatory response.
!Azacitidine r eactivates the production of tumor antigens, such as cancer testes antigens, 
that are found in lung cancer.
!Azacitidine activ ates silenced effector cytokine genes in anergized T cells.  
Further support for using CC-[ADDRESS_1024296] inhibitor would shift the balance in favor of the immune-
enhancing effects of epi[INVESTIGATOR_748960] T cells ( Brahmer, 2013 ).  Thus, the combination 
of azacitidine and a PD-[ADDRESS_1024297] patients that would benefit from this therapeutic 
regimen, tissue samples will be collected from patients pre-therapy and during therapy for cellular and molecular analyses. Submission of ar chival or fresh tumor tissue pre-therapy is 
mandatory. Blood, se rum and saliva will also be collected. 
 
 
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21natatioion n 
othertherfofor r 
on firston first --linl
to overcoto overc
e we propowe pro
pembropembro lizumlizu
mbrolizumbrolizu mm
enefit fronefit f m
hherapyerapy andnd
r fresh tumr fresh tum
ted. ted. 7$5(7$,(75,(35,(
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 26 CC-486-NSCL-001 Final: 15 May [ZIP_CODE]. STUDY OBJECTIVES
2.1. Primary Objective
The primary ob jective of the study is:
!To estimate the efficacy of CC-[ADDRESS_1024298] 1.1 criteria
2.2. Secondary Objectives
The secondary objectives of the study are:
!To estimate DCR of CC-486 plus pembroliz umab versus pembrolizumab plus 
placebo
!To estimate OS of CC-486 plus pembrolizumab versus pembrolizumab plus placebo
!To estimate ORR of CC-486 plus pembroliz umab versus pembrolizumab plus 
placebo
!To evaluate safety and tolerability of CC-486 plus pembrolizumab versus 
pembrolizumab plus placebo
!To evaluate the impact of pembrolizumab on the pharmacokinetics of CC-486
2.3. Exploratory Objectives
The exploratory objectives of the study are:
!To determine the preliminary efficacy (immune-related [ir] PFS, irD CR, irORR) of 
CC-[ADDRESS_1024299]
criteria 
!To explore mechanism and biomarkers a ssociated with effi cacy of CC-486 plus 
pembrolizumab versus pembrolizumab plus placebo,mab plus mab plus 
oolizumab plizumab p
pembroembro lizulizu
pembrolizupembrol
on the pharmn the pharm
y efefficacyficacyfff (i
ababversus ver
ism and bim and b
versus pemversus pe
(3
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 27 CC-486-NSCL-001 Final: 15 May [ZIP_CODE]. STUDY ENDPOINTS
3.1. Primary Endpoint
!PFS measured as time from rando mization to progression according to RECIST 1.1 
(based on Investigator assessment) 
3.2. Secondary Endpoints
!Number (%) of subjects with SD for â‰¥ 18 weeks, co mplete respons e (CR) or PR 
(DCR). 
!Overall survival.
!Number (%) of subjects who achieve an objective CR or PR (ORR).
!Safety to include the incidence of treatmen t-emergent adverse events (TEAEs), 
serious TEAEs, Grade 3-[ADDRESS_1024300], and laboratory 
abnormalities and other safety parameters.
!Plasma PK parameters such as maximum observed concentration (C max), area under 
the concentration-time curve (AUC), time to maximum concentration (T max), terminal 
half-life (t 1/2), apparent total body clearance (CL/F) and apparent volume of
distribution (Vz/F) for CC-486.
3.3. Exploratory Endpoint(s)
!Exploratory efficacy as measured by [CONTACT_748998],  irDCR, and irORR based on Investigator 
assessment using irRECIST.
 
!DNA analys es, gene expression and soluble factors in blood.
&(/*(1(alyses, genyses, gen35235,(7$5<,1)250$7,21PR R 
R).)
events (events TE
estst,,and laband lab
concentrationcen
ximum conximum con
L/F) and apL/F) and ap
d byd by [CONTACT_748999],PFS,
2352335(3
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 28 CC-486-NSCL-001 Final: [ADDRESS_1024301] received one prior platinum-based chemotherapy regimen.
Approximately 90 subjects will be rando mized 1:1 to r eceive CC-486 plus pembrolizumab or 
placebo plus pembrolizumab as follows:
!Arm A: CC-486 300 mg administered orally daily on days 1-14 plus pembrolizumab
200 mg administered as a 30-minute IV i nfusion on day 1 of  a 21-day cycle 
!Arm B: Placebo administered orally daily on days 1-[ADDRESS_1024302] has completed 1 cycle of treatment.
Randomization will be stratified between treatment arms by:
!Histology (non-squamous versus squamous)
The decision to discontinue a subject, which will not be delayed or refused by [CONTACT_1034], 
remains the responsibility of the treating physic ian. However, prior to discontinuing a subject, 
the Investigator may contact [CONTACT_749000].
The study will be conducted in compliance wi th the International Council on Harmonisation 
(ICH) of Technical Requirements for Registrati on of Pharmaceut icals for Human Use/Good 
Clinical Practice (GCP) and applicable regulatory requirements.
Primary analysis will be conducted when [ADDRESS_1024303] occurred.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21bbor o
embrombro lizumlizum
ayy cycle cycle yy
mbrolizumambrolizum
y cycle cycle y
rmmafafter thter thfff
t be delayet be delay
n. Howeven. Howev
or and fr and f orworfff
ance wince w ththi ththh
r Registratir Registr
cable regulcable regu
ducted whenducted whe
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 29 CC-486-NSCL-001 Final: 15 May 2015Figure 1: Overall Study Design
4.2. Study Duration 
Enrollment is expected to take approximately [ADDRESS_1024304] that is 
required for primary, secondary and/or exploratory  analysis, as pre-specified in the protocol, 
whichever is the later date.
&(/*(1([ZIP_CODE],(7$1212months months 
xpectexpecte d to d to
years.years.
either the deither the
r the date othe date
condarycondary andayy$7,21
date.date.

('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 30 CC-486-NSCL-001 Final: 15 May [ZIP_CODE]. TABLE OF EVENTS
Table 2: Table of Events
Screening 
PeriodTreatment Perioda
Events Screening Cycle 1 Cycle 2Subsequent 
cyclesFollow-up 
Period
Day -21 to -1 1b14 1 14 1 EOTDisease 
Progression/ 
Survival
Informed consent X
Demographics X
Prior cancer history X
Prior cancer therapi[INVESTIGATOR_748961] X
Prior/ concomitant medication evaluation
dX (â‰¤ 28d from 
screening)Continuous, until [ADDRESS_1024305] dose
Prior/ concomitant 
procedures evaluationeX (â‰¤ 28d from 
screening)Continuous, until [ADDRESS_1024306] dose
Inclusion/exclusion criteria X
IRT registration X
IRT randomization Xf
Adverse event evaluation Continuous after informed consent signature. See Section 11for additional details on AE reporting 
timeframe
Physical examination (source documented only)XX X X X
&(/*(priprietetnly)ly)*(1([ZIP_CODE],(7$5<,1)250$7,21e Corporae Corpora
21
0$0$0$0$
ent nt 
lesles2225)2
11)2)2)2
<)2
<<<<5<<<
$<
$$$57$7$7$7$7$(75C555,
[PHONE_15623](((((ContinuousContinuou1(
XX*(
(//*//
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 31 CC-486-NSCL-001 Final: 15 May 2015Table 2: Table of Events (Continued)
Screening 
PeriodTreatment Perioda
Events Screening Cycle 1 Cycle 2Subsequent 
cyclesFollow-up 
Period
Day -21 to -1 1b14 1 14 1 EOTDisease 
Progression/ 
Survival
Weight X X X X X
Height X
Vital signs XX X X X
ECOG performance status XX X X X
Hematology laboratorygXX X X X X X
CoagulationhX
HBV and HCV serologies 
(HBsAg, HBeAg, HBsAb, 
HBeAb, HBcAb, HCVAb)XX
Chemistry laboratoryiXX X X X X X
Lipid paneljX Every 4th
cycleX
Thyroid test XX
Cycle 3 Day 
1 then every 
6 weeks
UrinalysiskXX X X X
12-lead electrocardiogram X X
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21e Corporae Corpora
21
priprietet7,2
0$0$0$0$
[ZIP_CODE]
XX1),1<<<<<5<<<
$<
XX$$$57$7$7$7$7$(75XX3555
25
[PHONE_15624]
(5
XX(1XX*(/*/*/*/*
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 32 CC-486-NSCL-001 Final: 15 May 2015Table 2: Table of Events (Continued)
Screening 
PeriodTreatment Perioda
Events Screening Cycle 1 Cycle 2Subsequent 
cyclesFollow-up Period
Day -21 to -1 1b14 1 14 1 EOTDisease 
Progression/ 
Survival
Serum Î²-hCG (for all 
FCBP)lX
Serum or Urine Î²-hCG (for 
all FCBP)lX
(w/in72 hours)XX X X
PK blood draws sampling
(See Section 6.5for 
timepoints)XX
Tumor biopsy for 
Biomarker AnalysesX
(Mandatory â€“
archival or 
fresh tumor 
collection)X
(Optional )
Blood for Biomarker DNA 
AnalysesX X
Blood for Biomarker RNA 
AnalysesXX X
Serumfor Biomarker 
AnalysesX X XmX
Saliva for Germline DNA 
AnalysisX
&(/*(priprietet*(1([ZIP_CODE],(7$5<,1)250$7,21e Corporae Corpora
217,2
0$FoFolll0$0$0$
1 EE50
)21)))
<)
<<<,<
$57$(777
25,7
X X 22252XX35(3(3(3(3(31(
*(
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 33 CC-486-NSCL-001 Final: 15 May 2015Table 2: Table of Events (Continued)
Screening 
PeriodTreatment Perioda
Events Screening Cycle 1 Cycle 2Subsequent 
cyclesFollow-up 
Period
Day -21 to -1 1b14 1 14 1 EOTDisease 
Progression/ 
Survival
Tumor evaluation 
(CT/MRI)X RECIST 1.1 algorithm: Every 6 weeks (Â± 5 days) from randomization for the first 24 
weeks then every 9 weeks until disease progression (for exceptions refer to Section 
6.4.3 ) or start of a new anticancer treatment, or withdrawal of consent
The irRECIST will be evaluated as exploratory efficacy assessment. For additional 
details, see Sections 6.4.[ADDRESS_1024307] Scan of the Head or 
Brain MRIX Only if clinically indicated
Administer                    
CC-486/placeboDaily on Days 1-14
Administer 
pembrolizumabXnX On Day 1 
only
IP accountability X X X X
Survival follow-up Every 8 weeks 
(+/- 5 days)
Anticancer therapy since IP discontinuationAt every survival 
follow-up visit
Abbreviations:  Î²-hCG = beta human chorionic gonadotropin; C1D1 = Cycle 1 Day 1; CT = computed tomography; ECOG = Eastern Cooperative Oncology 
Group; EOT = End of Treatment; FCBP = females of child bearing potential; IP = investigational product; irRECIST = immune-relate d Response Evaluation 
Criteria in Solid Tumors; IRT = interactive response technology; MRI = magnetic resonance imaging; PK = pharmacokinetic; RECIST  = Response Evaluation 
Criteria in Solid Tumors
aAll visits have a Â± 2-day window, except Cycle [ADDRESS_1024308] occur within 21 days from Informed Consent Form signature, and survival follow-up 
which has a Â±5-day window.
&(/priprietet/*(1([ZIP_CODE],(7$5<,1)250$7,21e Corporae Corpora
217,2
0$0$0$0$
1 EE50
)2 5 days) from5 days) from
 progressionrogress
ncer treatmeer treatm
as exploratas explor
[IP_ADDRESS].2 ,,[IP_ADDRESS])))
y indicatedy indicated$5 nly if clinicaly if clinica7$
Daily on DDaily on ,(
3555
25
XX22252555
(35
(3(3(3
(1(3
orionic gonadrionic gonad
CBP = femaleCBP = femal
nteractive resteractive res
ndow, excepndow, excep
owow.
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 34 CC-486-NSCL-001 Final: 15 May 2015bCycle 1 Day 1 evaluations can be omitted if Screening evaluations are performed within 72 hours of Cycle 1 Day 1.
cPrior cancer therapi[INVESTIGATOR_748962], radiation, systemic or any other therapy (eg, hormonal, locoregional) for the subject's  cancer
dPrior/concomitant medication evaluation â‰¤[ADDRESS_1024309] dose.
ePrior/concomitant procedures evaluation â‰¤[ADDRESS_1024310] dose.
gHematology includes complete blood count (CBC) with differential, including but not limited to red blood cell (RBC) count, hemo globin, hematocrit, white 
blood cell (WBC) count with differential (neutrophil count including lymphocyte, monocyte, eosinophil, basophil counts and bands ), absolute neutrophil count 
(ANC), and platelet count. ANC should be measured with automated count where available.
hCoagulation tests, including prothrombin time (PT), partial thromboplastin time (PTT), activated partial thromboplastin time (aP TT) and international 
normalized ration (INR)
IChemistry includes (but is not limited to) sodium, potassium, calcium, phosphorus,  chloride, magnesium, bicarbonate, blood urea nitrogen (BUN) or urea, 
serum creatinine, fasting glucose, uric acid, albumin, total protein, alkaline phosphatase, lactate dehydrogenase, total bilirub in (indirect and direct), aspartate 
aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT), alanine aminotransferase/serum glutamic pyruvic transamina se (ALT/SGPT)
jLipid Panel parameters include total cholesterol, high-density lipoprotein, low-density lipoprotein, triglycerides
kUrinalysis (a urine dipstick may be used) at scr eening and D1 of each cycle if abnormal at baseline.
lSerum Î²-hCG (for all FCPB) performed at screening; remaining pregnancy tests may be serum or urine at the Investigatorâ€™s discretion. P regnancy testing (for 
all FCPB) must be done within [ADDRESS_1024311] is performed > [ADDRESS_1024312] should be performed (Investigatorâ€™s discretion) .  The subject may not receive IP 
until the Investigator has verified that the result of the pregnancy test is negative.
mDay [ADDRESS_1024313] cycle thereafter (C6D1, C9D1, C12D1)
nOn Cycle 1 Day 1, pembrolizumab will be administered after the 6 hour CC-486 PK sample collection. For all subsequent pembroliz umab administration, 
pembrolizumab will be co-administered with CC-486.
&(/*(1([ZIP_CODE],(7priprietet(7$5<,1)250$7,21e Corporae Corpora
21
, hehemoglobinmoglobi
and bands),and bands),
astin tstin t ime (aPi[INVESTIGATOR_048] (
arbonate, bloarbonate, blo
nase, total bise, total
m glutamic pm glutamic p
glyceridesglycerides
e.
or urine at thor urine a
sing on Day sing on Day
erformed (Inerformed (In
PK sample cPK sample c
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 35 CC-486-NSCL-001 Final: [ADDRESS_1024314] (IP) dosing can be made based on a local lab draw if the central lab results have not been 
received. Central labs should be drawn at all t imes sp ecified within the protocol. Screening 
laboratory values must demonstr ate subject eligibility, but may be repeated within the screening 
window if necessary.
The following will be performed at screening as specified in the Table of Events ( Table 2 ), after
informed consent has been obtained:
!Demographics 
!Prior cancer history (including specific information regarding diagnosis, staging, and 
histology)
!Prior cancer therapi[INVESTIGATOR_014]: includes surgery, radiation, systemic or any other therapy for
the subjectâ€™s cancer
!Complete medical history (all relevant medical conditions occ urring â‰¥ 28 days before
Screening should be included)
!Prior and concomitant medication ev aluation (including those taken â‰¤28 days before
screening, except for those taken for cancer which are recorded as part of prior cancer therapy)
!Prior and concomitant procedures (including all procedures occurring â‰¤ 28 days 
before screening)
!Interactive response technology (IRT) for subject number 
!Adverse event evaluation (begins after the subject signs the informed consent form 
[ICF])
!Physical examination (source documented only), weight, height
!Vital signs (including blood pressure, temper ature, respi[INVESTIGATOR_697], and heart rate)
!Eastern Cooperative Oncology Group (ECOG) performance status
!Hematology panel: Complete blood count (CBC) with differential, including but not 
limited to red blood cell (RBC) count, hemoglobin, hematocrit, white blood cell &(/*(1([ZIP_CODE],(7$5<,1)250$7,21investnvest igatigatii
sults have nults have
tocol.ocol. ScreeScre
teddwitwithin th
Table of Evable of Ev
formatformat ioion re
gerygery, radi, radi aa
alllrelevant relevanll
uded)uded)
nt mnt medicatedicat ii
for those tafor those ta
concomitanconcomit
screening)creening)
eractive resractive re
AAdverse edverse e
[ICF])ICF])
!!PhPh
!!
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 36 CC-486-NSCL-001 Final: 15 May 2015(WBC) count with differential (neutrophil count including lymphocyte, monocyte, 
eosinophil, basophil counts and bands), absolute neutrophil count (ANC), and platelet 
count.
!Coagulation tests including, prothrombin time (PT), partial thromboplastin time 
(PTT), activated partial thromboplastin time (aPTT), international normalized ratio 
(INR).
!Chemistry panel including, but not limited to sodium, potassium, calcium, 
phosphorus,  chloride, magnesium, bicarbonate, blood urea nitrogen (BUN) or urea, serum creatinine, fasting glucose, uric acid, albumin, total protein, alkaline 
phosphatase, lactate dehydrogenase (LDH), total  bilirubin (indirect and direct), 
aspartate aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT), alanine aminotransferase/serum glutamic pyruvic transaminase (ALT/SGPT)
!Lipid panel including total cholesterol, high-density lipoprotein, low-density 
lipoprotein, and triglycerides
!Thyroid test
!Hepatitis B virus (HBV) and hepatitis C virus (HCV) serologies (hepatitis B surface 
antigen [HBsAg], hepatitis B e antigen [HBeAg], hepatitis B surface antibody [HBsAb], hepatitis B e antibody [HBeAb],  hepatitis B core  antibody [HBcAb], 
hepatitis C virus antibody [HCVAb]
!Urinalysis (a urine dipstick may be used) at screening (and Day 1 of each cycle if 
abnormal at baseline).
!12-lead electrocardiogram (ECG)
!Pregnancy test is required for all female subjects of childbearing potential. Serum
beta subunit of human chorionic gonadotropin ( Î²-hCG) pregnancy test will be 
performed at screening. Urine (or serum) pregnancy test will be performed to assess subject eligibility within [ADDRESS_1024315] did not already occur within 72 hours of dosing (negative results 
required for IP administration).
!Submission of archival or newly obtained tumor biopsy specimen for biomarker 
analysis is mandatory.
!Response assessment/tumor evaluation (see Section 6.4)
6.2. Treatment Period
The subjects must start treatment wi thin 21 days of signing the ICF. For all subsequent visits, an 
administrative window of Â± 2 days is permitted.
Treatment cycles are 21 days in duration, and will occur as described in Section 8.2.
The following evaluations will be performed at the frequency specified in Table 2 .  The 
evaluations should be performed prior to dosing on the visit day, unless otherwise specified:
!IRT for subject randomization (prior to first dose)&(/*(1([ZIP_CODE],(7$5<,1)250$7,21ea, 
ct), 
T/SGOT), T/SGOT), 
SGPT)GPT)
ww--densitnsiy
serologies (rologies 
epatepatititis B sis
ititis B core is B core
at scrat sc eenineen
all female all female 
rionic gonarionic gona
UrineUrine (or s(or 
hhin [ADDRESS_1024316] smum
miinistrativnistrativ
TreatmenTreatmen
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 37 CC-486-NSCL-001 Final: 15 May 2015!Concomitant medications evaluation (continuously)
!Concomitant procedures evaluation (continuously)
!Adverse event evaluation (continuously)
!Physical examination (source documented only) including weight
!Vital signs: on-treatment vital sign measur ements will be source documented only.  
However, if an abnormal (out of range) value is reported at any given visit, that
parameter should be collected in the case report form (CRF) at every subsequent
scheduled visit until it returns to normal, and as an AE if appropriate.
!ECOG Performance status
!Hematology panel
!Chemistry panel
!Lipid panel
!Thyroid test
!Urinalysis
!Urine (or serum) pregnancy test (prior to dosing on Day 1 of each cycle)
!PK sampling
!Tumor biopsy for biomarker analyses [Optional, but strongly recommended]
!Blood for biomarker analyses
!Serum for biomarker analyses
!Saliva for Germline DNA Analysis
!Response assessment/tumor evaluation (see Section 6.4)
!IP accountability
6.2.1. End of Treatment
An end of treatment (EOT) evaluation should be performed for subjects who are withdrawn from
treatment for any reason as soon as possible af ter the decision to permanently discontinue
treatment has been made. Subjects must also be discontinued in the IRT system.
The following evaluations will be performed as specified in the Table 2 :
!Concomitant medications evaluation
!Concomitant procedures evaluation
!Adverse event evaluation (monitored t hrough [ADDRESS_1024317] dose of either 
study drug)
!Physical examination including weight
!Vital signs&(/*(1([ZIP_CODE],(7$5<,1)250$7,21on Dayon Day 1yoo
Optional, buOptional, b
Analysisnalysi
umor evaluumor evalu
mentment
(EOT) evaEOT) ev
reason as sreason as s
been made.een mad
wing evaluang evalua
!!Concoonco
!!CC
!
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 38 CC-486-NSCL-001 Final: 15 May 2015!ECOG performance status
!Hematology panel
!Hepatitis B virus (HBV) and HCV se rologies (HBsAg, HBeAg, HBsAb, HBeAb, 
HBcAb, HCVAb
!Chemistry panel
!Lipid panel
!Urinalysis
!12-lead ECG
!Urine (or serum) Î²-hCG level for females of childbearing potential
!Blood for biomarker analyses
!Serum for biomarker analyses
!Response assessment/tumor evaluation will be continued at the schedule defined in
Table 2 , and does not need to be performed specifically for the EOT visit except as 
specified in Section 6.4.
!IP accountability
6.3. Follow-up Period
6.3.1. Efficacy Follow-up
All subjects who discontinue treatment for reasons other than disease progression, start of new
anticancer therapy, or withdrawal of consent from the entire study will be followed for tumor
response assessments and subsequent anticancer therapi[INVESTIGATOR_72602] 6.4.
6.3.2. Survival Follow-up
After the end of treatment (EOT) v isit, all subjects will be followed every 8 weeks (Â± 5 days) for 
survival until withdrawal of consent, death, or lost to follow-up, whichever occurs first, or until 
the End of Trial. Subsequent anticancer therapie s should be collected at the same schedule. New 
anticancer therapy includes (but is not limited to) any systemic or local medication, surgery, radiation, or any other therapy inte nded to treat the subjectâ€™s cancer.
Survival follow-up may be conducted by [CONTACT_72634] (including public records) and/or
telephone contact [CONTACT_1155], family, or the subjectâ€™s treating physician.
6.4. Response Assessments
Response assessments (tumor evaluations) shoul d be performed at Screen ing within 21 days 
before the start of IPs, and every 6 weeks (Â± 5 days) from randomization for the first 24 weeks, 
then every 9 weeks thereafter until disease progression (for exceptions refer to Section 6.4.3 ), 
start of a new anticancer therapy, or withdra wal of consent from the entire study. Tumor 
assessments should also be performed at any time, if clinically indicated.  Subjects with 
historical tumor scans eval uable per RECIST 1.1 performed â‰¤ [ADDRESS_1024318] dose need &(/*(1([ZIP_CODE],(7$5<,1)250$7,21the scheduthe sched
for the EOTfor the E
easons otheeasons othe
nt fromnt from  ththmm
ntticancer ticancer 
OTOT))visit, avisit, a
f consent, consent,f
quent antiquent anti c
ncludes (butcludes (bu
other therapother therap
w-w-up mayup may
contact [CONTACT_749001] a
befobefre thre 
n
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 39 CC-486-NSCL-001 Final: [ADDRESS_1024319] Version 1.1
Response assessments include computed tomography (CT) scan or MRI.  The regions to be 
imaged are the chest and abdomen/pelvis, including whole liver and kidney. In case of 
metastases to other organs not covered with these scans, the regions need to be included in the 
scans as well. If brain metastases are documented at baseline, brain imaging should be continued throughout the study. Bone scans will only be performed at baseline if clinically indicated. If at 
baseline, the bone scan is suggestive of bone lesi ons, CT or MRI will be used both at baseline 
and subsequent scans. Bone scans during the trial will only be performed if clinically indicated and if suggestive of new lesions, a CT or MRI w ill be performed to confirm the new lesion. Any 
skeletal lesions identified at baseline should be fo llowed at the same schedule. The same mode of 
imaging for lesion evaluation at Screening mu st be used consistently throughout the study. 
Adherence to the planned imaging schedule is critical regardless of dose delays or unscheduled 
or missed assessments; scans must follow the cal endar and not be adjusted for delays in 
treatment.
The CT imaging should include contrast unless medically contraindicated. Conventional CT 
should be performed with contiguous cuts of [ADDRESS_1024320] should be 
performed by [CONTACT_2363] a 5 mm c ontiguous reconstruction algorithm.
All subjects with evidence of objective tumor response (CR or PR) should have the response 
confirmed with repeat assessments at the next scheduled scan, but after no less than [ADDRESS_1024321] 1.1, tumor assessment should be repeated â‰¥4 weeks 
later in order to confirm PD (per irRECIST) with the option of continuing treatment per below 
while awaiting radiologic confirmation of progression.  If repeat imaging shows a reduction in 
the tumor burden compared to the init ial scan demonstr ating PD, treatment may be continued as 
per treatment calendar.  If repeat imaging confirms progressive disease, subjects will be discontinued from study therapy (exception noted in Table 3 ).  In determining whether or not the 
tumor burden has increased or decreased, Investigators should consider all target lesions as well 
as non-target lesions. Refer to Appendix B for additional information.&(/*(1([ZIP_CODE],(7$5<,1)250$7,21ed d 
fat a
line line 
ndicated ndicated 
w l lesiesionon..AnA
he same me same m
out the studout the stud
elays or ulays or u nsn
ed for deld for d a
indicated. Cdicated. 
slice thicknslice thic
orithm.ithm.
(CR or PR(CR or PR
duled scan,uled scan
ng to irREng to irRE
med using ied using 
nitnitioions ons offi
ease and Tase and T
such as pemuch as pe
s cancers cancer --sps
yy extend be extend yy
anifest as anifest as a
of new lesiof new lesi
c imaging c imaging 
rder to conr to co
awaitawait ing rng
 tumor burtumor bur
per treatmper treatm
diiscontiscont
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 40 CC-486-NSCL-001 Final: 15 May 2015When feasible, subjects should not be discontinued until progression is confirmed; however, the 
decision to continue study tr eatment after the 1st evidence of  disease progression is at the 
Investigatorâ€™s discretion based on the clinical status of the subject as described in Table 3 .  
Subjects may receive study treatment while waiti ng for confirmation of PD if they are clinically 
stable as defined by [CONTACT_4868]:
!Absence of signs and symptoms indicating disease progression
!No decline in ECOG performance status
!Absence of rapid progression of disease
!Absence of progressive tumor at crit ical anato mical sites (eg, cord compression) 
requiring urgent alternative medical intervention
Table 3: Imaging and Treatment after Site-Assessed 1st Radiologic Evidence of PD
Clinically Stable Clinically Unstable
Imaging Treatment Imaging Treatment
Site based 
assessment 
indicates PDRepeat imaging at 
â‰¥4 weeks at site to 
confirm PDMay continue 
study treatment at 
the Investigatorâ€™s 
discretion while awaiting 
confirmatory scan 
by [CONTACT_749002] 
â‰¥4 weeks to 
confirm PD per 
physician discretion onlyDiscontinue 
treatment
Repeat scan 
confirms PDNo additional 
imaging required
Exceptions as per 
note*Discontinue 
treatment
Exceptions as per 
note*No additional 
imaging requiredN/A
Repeat scan shows 
SD, PR or CRContinue regularly 
scheduled imaging 
assessmentsContinue study 
treatment at the 
Investigatorâ€™s discretionContinue regularly 
scheduled imaging 
assessmentsMay restart study 
treatment if 
condition has improved and/or 
clinically stable 
per Investigatorâ€™s discretion
* Note:  If progression is confirmed per irRECIST, the subject remains clinically stable and per the Principal 
Investigator [INVESTIGATOR_748963], the Principal Investigator [INVESTIGATOR_748964] a potential exception.
6.5. Pharmacokinetics
At specific sites, for the first 10-12 subjects randomized to each Arm, mandatory 
pharmacokinetics will be collected. Blood samples for CC-486 PK assessment will be collected on Day 1 of Cycle 1 and Cycle 2 prior to the dose administration of CC-486/placebo, known as 
predose, and over the 8-hour period following each dose administration of CC-486/placebo at 
0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and [ADDRESS_1024322]-dose (see Table 4 ).  These samples will be 
analyzed centrally.&(tt(/*(1([ZIP_CODE],(7$5<,1)250$7,21ion) n) 
dence of Pdence of P
ally Unstabally Unstab25
g))2)21)2
an an maging at aging a
eeks to k
nfirm PD penfirm PD
physician physician
discretiodiscretio11
7$1
nue nue 
entent
xceptions asxceptions as
notenot**(777
27
ly y 
aging aging
sContinContin
treatrea
I2223
152
ion is confirmion is confirm
achieving exchieving ex
otential exceotential exce
Pharhar
 specific s specific s
pharmacopharmaco
n DaynD a y
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 41 CC-486-NSCL-001 Final: 15 May 2015Table 4: Schedule of Pharmacokinetic Blood Sample Collection in the 
Pharmacokinetics Phase
Nominal Times Acceptable Deviation Window
Predose â‰¤ 60 min
0.25 hr Â± 3 min
0.5 hr Â± 3 min
1 hr Â± 3 min
1.5 hr Â± 3 min
2 hr Â± 3 min
2.5 hr Â± 3 min
Nominal Times Acceptable Deviation Window
3 hr Â± 3 min
3.5 hr Â± 3 min
4 hr Â± 3 min
6 hr Â± 20 min
8 hr Â± [ADDRESS_1024323] patients that 
would benefit from this therapeutic regimen. Fresh tumor biopsy is the preferred tissue for these analyses; however archival formalin fixed, paraffin embedded (FFPE) blocks may be provided 
instead. Archival or fresh tumor tissue is mandatory at screening, but it is optional at Cycle 2 
Day 14 -/+ 7 days. Blood, serum and saliva will also be collected at time point detailed in the 
schedule of events.
Details regarding the collection, storage, and shipment of the samp les are provided in the 
Laboratory Manual. A separate consent will be provided.
6.7. 12-lead Electrocardiogram
Triplicate 12-lead ECGs will be recorded at screening and EOT and will be assessed locally.  
The 12-lead ECGs (12-lead at 25 mm/sec reporting rhythm, ventricular rate, PR-interval, QRS complex, QT interval, and QTc interval) will be performed after the subject has been in the 
supi[INVESTIGATOR_21683] 5 minutes.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,[ZIP_CODE]$7$7$7$70$50ion Windowion Wind25minmin)2Â± 3 minÂ± 3 min1)Â± 3 mm<, 1Â±Â±5<$57$
explore the explore the
otentially idotentially i
men. Freshmen. Fre
fixed, parafixed, pa
ssuessue is manm
mmand salivand saliv
llectllection, ston, s
A separate A separat
lead Eead E leclec
122--lead EClead EC
lead ECGs lead ECGs
plex, QT intplex, QT in
pi[INVESTIGATOR_748965] p osiosititiii
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 42 CC-486-NSCL-001 Final: [ADDRESS_1024324] satisfy the following criteria to be enrolled in the study:
1. Subject is â‰¥ [ADDRESS_1024325] has stage IIIB or IV NSCLC (American Joint Committee on Cancer [AJCC] 
Staging Manual, 7th edition [ Edge, 2009 ])  and was pretreated with [ADDRESS_1024326] has provided a formalin fixed tumor tissue sample from a biopsy of a tumor 
lesion either at the time of or after the diagnosis  of metastatic disease has been made 
AND from a site not previously irradiated to  assess for PD-L1 status. Fine needle 
aspi[INVESTIGATOR_4026], endobronchial ultrasound (EBUS) or cell blocks are not acceptable. Needle or 
excisional biopsies, or resected tissue is required.  Archival tissue may be acceptable. Submission of formalin-fixed paraffin embedded tumor tissue sample blocks are 
preferred; if submitting unstained slides, the slides should be freshly cut and submitted to 
the testing laboratory within [ADDRESS_1024327] has adequate organ functions, evidenced by [CONTACT_716]:
a. AST (SGOT), ALT (SGPT) â‰¤ 2.5 x upper limit of normal range (ULN), or â‰¤ [ADDRESS_1024328] 
range if liver metastasis present
b. Total bilirubin â‰¤ 1.[ADDRESS_1024329]
c. Serum creatinine â‰¤ 1.[ADDRESS_1024330] has adequate bone marrow function, evidenced by [CONTACT_716]:
a. Absolute neutrophil count â‰¥ 1.5 x 10
9cells/L
b. Platelets â‰¥ 100 x 109cells/L 
c. Hemoglobin â‰¥ 9 g/dL
d. International normalized ratio (INR) or prothrombin time (PT) â‰¤1.[ADDRESS_1024331] is receiving anticoagulant therapy as long as PT or PTT is within therapeutic 
range of intended use of anticoagulants&(/*(1([ZIP_CODE],(7$5<,1)250$7,21mm..
squamoussquamou
ee on Canceee on Can
ed withwith 11p
mple fromple fro mm
metastatietastati cc
essessfofor PDr PD
or cell blocor cell bl
equired.  Arquired.  A
embedded embedded 
ides, the slides, the sl
days from siays from
llylly-documdocum
performanperforman
uate organ fuate orga
OT), ALT (OT), ALT
f liver metaf liver meta
ll bili bilillrubin rubin i
erumerum ccmmreatrea
PotassiPotassi ui
Subject hSubject
a.aAA
b.b
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 43 CC-486-NSCL-001 Final: 15 May 2015e. Activated partial thromboplastin time (aPTT) â‰¤1.[ADDRESS_1024332] is receiving 
anticoagulant therapy as long as PT or PTT is within therapeutic range of intended 
use of anticoagulants
9. Female of childbearing potential (FCBP) (defined as a sexually mature woman who 1) 
has not undergone a hysterectomy (the surgical removal of the uterus) or bilateral 
oophorectomy (the surgical removal of both ovaries) or, 2) if â‰¥ [ADDRESS_1024333] 24 consecu tive months (ie, has had menses at any 
time during the preceding 24 consecutive months)) must:
a. Have two negative pregnancy tests as verified by [CONTACT_72636]. She must agree to ongoing pregnancy testing during the course of the 
study, and after end of study treatment. This applies even if the subject practices true 
abstinence* from heterosexual contact.
b. Either commit to true abstinence* from heterosexual contact (which must be 
reviewed on a monthly basis) or agree to  use, and be able to comply with two 
effective methods of contraception without interruption, 28 days prior to starting IP, 
during the study therapy (including dose interruptions), and for 120 days after 
discontinuation (or longer if required by [CONTACT_5277]) of study therapy. The 
two methods of contraception can either be two barrier methods or a barrier method plus a hormonal method to prevent pregnancy.
10. Male subjects must practice true abstinence* (which must be reviewed on a monthly 
basis) or agree to the use a condom during sexual contact [CONTACT_4490] a pregnant female or a female of childbearing potential while participating in the study, during dose 
interruptions and for at least [ADDRESS_1024334] discontinuation 
(or longer if required by [CONTACT_5277]), even if he has undergone a successful 
vasectomy. 
* True abstinence is acceptable when this is in line with the preferred and usual lifestyle 
of the subject. Note: Periodic abstinence (e g, calendar, ovulation, symptothermal, post-
ovulation  methods) and withdrawal are not acceptable methods of contraception.
11. Subject is willing to adhere to the study visit schedule and other protocol requirements.
12. Subject understands and voluntarily signs an informed consent document prior to any 
study related assessments/procedures are conducted.
7.3. Exclusion Criteria
The presence of any of the following will exclude a subject from enrollment:
1. Subject has known sensitizing EGFR and/or positive ALK mutation.
2. Subject has been previously treated with azacitidine (any formulation), decitabine, or any 
other hypomethylating agent.
3. Subject has received prior therapy with any other anti-PD-1, or PD-L1 or PD-L2 agent or 
an antibody targeting other immuno-regulatory  receptors or mechanism, including 
participation in any other pembrolizumab trial and treatment with pembrolizumab.&(/*(1([ZIP_CODE],(7$5<,1)250$7,21arting arting 
e of the of the 
actices trueactices true
which must which mus
mply witmply wit h htt
days prior toys prio
nd for d for 120 d120 d
ments) of stuents) of st
ier methoder m
hich must bch must
xual contacxual contac
ccipatipaing ining in
ollollowing inwing i
ements), evments), ev
le when thile when
dic abstinabstin en
d wiwiththiidrawadrawa
 adhere to adhere to
ands and voands and v
assesasses smensmen
clusion Cclusion 
nce of any oce of any 
Subject Subject hh
2.2.SubjeSubje
othoth
33
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 44 CC-486-NSCL-001 Final: 15 May 2015a. Examples of such antibodies include (but are not limited to) antibodies against 
indoleamine 2,3-dioxygenase (IDO), PD-L1, IL-2R, glucocorticoid-induced 
tumor necrosis factor receptor (GITR).
4. Subject has had a prior monoclonal antibody within 4 weeks prior to study Day 1 or who 
has not recovered (i.e. â‰¤ Grade 1 or at baseline) from adverse events due to agents 
administered more than [ADDRESS_1024335] has previous severe hypersensitivity reaction to another monoclonal antibody 
(mAb).
7. Subject has a known or suspected hypersensitivi ty to azacitidine, mannitol, or any other 
ingredient used in the manufacture of CC-486 (see the Azacitidine IB).
8. Subject has had radiotherapy â‰¤ 4 weeks or limited field radiation for palliation â‰¤ 2 weeks 
prior to starting IP, and/or from whom â‰¥ 30% of the bone marrow was irradiated.
9. Subject has received radiation therapy to th e lung that is > [ADDRESS_1024336] has not recovered from the acute toxic effects of prior anticancer therapy, 
radiation, or major surgery/significant trauma.
12. Subject has an active infection requiring therapy.13. Subject has had an allogenetic tissue/solid organ transplant.
14. Subject has active autoimmune disease that has required systemic treatment within the 
past 2 years (eg, with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic 
corticosteroid replacement therapy for adrena l or pi[INVESTIGATOR_13002], etc.) is not 
considered a form of systemic treatment.
15. Subject has known active Hepatitis B, Hepatitis C or tuberculosis. Active Hepatitis B is 
defined as a known positive HBsAg result.  Active Hepatitis C is defined by a known 
positive Hep C Ab result and known quantitative HCV ribonucleic acid (RNA) results greater than the lower limit s of detection of the assay.
16. Subject has had any other malignancy within 5 years prior to randomization, with the 
exception of adequately treated in situ carcinoma of the cervix, uterus, or non-melanomatous skin cancer (all tr eatment of which should have been comp leted 6 months 
prior to enrollment).
17. Subject has a history of inflammatory bowel disease (eg, Crohnâ€™s disease, ulcerative 
colitis), celiac disease (ie, sprue), prior gastrectomy or upper bowel removal, or any other 
gastrointestinal disorder or defect that would interfere with the absorption, distribution, &(/*(1([ZIP_CODE],(7$5<,1)250$7,21tibodyibody
olol, or any, or an
B).B).
fofor palliatr pal i
row was irrow was ir
> 30 Gy30 Gy wiwiytii
n 30 days on 30 days 
rus are permrus are per
xic effects xic effects
auma.auma.
ring therapring therap
ssue/sossue/so lid olid
une diseasene diseas
of disease of disease
rugs). Replrugs). Rep
cement theement th
m of sysm of sys temte
known actinown acti
s a known ps a known 
ve Hep C AHep C A
ater than thter than th
Subject haSubject ha
exceptiexcepti
melamel
p
1
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 45 CC-486-NSCL-001 Final: 15 May 2015metabolism, or excretion of the IP and/or predispose the subject to an increased risk of 
gastrointestinal toxicity.
18. Subject has persistent diarrhea or clin ically significant malabsorption syndrome or known 
sub-acute bowel obstruction â‰¥ Grade 2, despi[INVESTIGATOR_45862]
19. Subject has significant active cardiac disease within the previous 6 months including 
unstable angina or angina requiring surgical or medical intervention, significant cardiac 
arrhythmia, or [LOCATION_001] Heart Association (NYHA) class [ADDRESS_1024337] has history of interstitial lung disease (ILD) OR a history of pneumonitis that has 
required oral or IV steroids. Subjects whose pneumonitis was solely as a result of 
radiation therapy for their NSCLC would not be excluded from the study unless they 
received oral/IV steroids to manage the pneumonitis.
21. Subject has a known history or current diagnosis of human immunodeficiency virus 
(HIV) infection, regardless of treatment status.
22. Subject has any other concurrent severe and/or uncontrolled medical condition that 
would, in the Investigatorâ€™s judgment, contraindicate patient participation in the clinical study (eg, chronic pancreatitis, etc.).
23. Subject with uncontrolled or symptomatic central nervous system (CNS) metastases
and/or carcinomatous meningitis
!Subjects with controlled and asymptomatic CNS metastases may participate in this 
trial. The patient must have completed any prior treatment for CNS metastases (must 
include radiotherapy and/or surgery) â‰¥ 28 days ( â‰¥ 14 days for stereotactic 
radiosurgery) and, if on corticosteroid ther apy, should be  receiving a stable dose of no 
greater than 4 mg/d dexamethasone (or equivalent anti-inflammatory potency of 
another corticosteroid) for at least [ADDRESS_1024338] has not recovered from the acute toxic effects (Common Terminology Criteria for 
Adverse Events [CTCAE] grade â‰¤ 1) of prior anticancer therapy, radiation, or major 
surgery/significant trauma (except alopecia or other toxicities not considered a safety risk 
for the subject at the Investigatorâ€™s discretion).
25. Subject has an impaired ability to swallow oral medication.
26. Subject is pregnant or breast feeding.
27. Subject has any condition that confounds th e ability to interpret data from the study.
28. Subject is or has an immediate family member (spouse or children) who is investigational 
site or sponsor staff directly involved with this trial, unless prospective Institutional 
Review Board (IRB) approval (by [CONTACT_66870]) is given allowing exception to this criterion for a specific subject.hat has hat has 
of of 
less theyless they
eficienceficienc y yv
medicaedica l conl con
nt participat particip
ervous systrvous sy
tic CNS metic CNS m
d anyanypripriyyor or
yy) )yyyâ‰¥ 28 dayâ‰¥ 28 day
teroid theraeroid thera
hasone (or ehasone (o
at least 14at least
frofrom m the ae 
AE] grade AE] grade â‰¤
rauma (excauma (ex
the Ithnvestnve i
an impairedn impaire
s pregnant s pregnant
ect has anyect has any
Subject iSubject i s os 
sisite or spte or siii
RevieRevie
cricri
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 46 CC-486-NSCL-001 Final: [ADDRESS_1024339] be maintained.
8.1.1. CC-486 (Oral Azacitidine)/Placebo
The study sponsor, Celgene Corporation will supply CC-[ADDRESS_1024340] of excipi[INVESTIGATOR_748966].  
8.1.2. Pembrolizumab
Pembrolizumab (50 mg lyophilized powder in single-use vial for reconstitution) for IV 
administration will be sourced by [CONTACT_4530] (Celgene Corporation) from  
 and labeled for clinical trial use.  Sufficient quantities of IP will be supplied by 
[CONTACT_749003].  Pembrolizumab will be administered in 
the clinic.
The Pharmacy Manual contains specific instructions for pembrolizumab dose calculation, 
reconstitution, preparation of the infusion fluid, and administration.
8.2. Treatment Administration and Schedule
Subjects will be randomized 1:1 to receive CC-486 plus pembrolizumab or pembrolizumab plus placebo. CC-486/placebo will be administered at a dose of [ADDRESS_1024341] arrive to the clinic in the fasting state (ie, no food 
or drink [except water] for approximately 8 - 10 hours) for all predose safety laboratory 
evaluations. Dose administration should take place after all scheduled predose safety assessments 
are completed.
Subjects will ingest CC-486/placebo with approximately 240 mL (8 ounces) of room temperature 
water.  CC-486/placebo may be tak en on an empty stomach or with food (a light breakfast or 
meal of up to approximately 600 calories).
If following CC-486/placebo administration an emesis event occurs, subjects should not take 
additional drug on that same day. It is recommended that the subject receives an antiemetic 30 
minutes prior to all subsequent CC-486 doses.
Pembrolizumab will be administered as a 30- minute IV infusion at a dose of 200 mg (4 x 50 mg 
vials) on Day 1 of a 21-day cycle. Sites should make every effort to target infusion timing to be &(/*(1([ZIP_CODE],(7$5<,1)250$7,21the e
d200-200-mg mg
Celgene anelgene an
cks. Each tcks. Each t
in nmarketemark
d in the azad in the aza
allfofor reconr recon
gene Corpoene Cor
nt quantnt quant ititiei
el.  Pembroel.  Pembr
tructions fotructions fo
fluid, andfluid, and
tration aration 
1 to receive to receive
ll be adminll be adm
e visits the visits th
waater] for apter] for ap
se adminisse admi
ed.ed.
s will inges will inge
.  CC.  CC -[ZIP_CODE]/
eal of up toeal of up to
If f foflloow
didititiii
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 47 CC-486-NSCL-001 Final: 15 May 2015as close to 30 minutes as possible. However, give n the variability of  infusion pumps from site to 
site, a window of -5 minutes and +10 minutes is permitted (i.e., infusion t ime of 24-40 minutes).
Pembrolizumab should be co-administered with CC-486.
For subjects enrolled in the PK population, the treatment administration on PK days (i.e., Day 1 
of Cycle 1 and Cycle 2) is described below:
!After performing the required overnight fast, taking antiemetic premedication with 
240 mL of water for nausea and vomiting (eg, ondansetron), and completing the 
required predose assessments (including the pr edose PK sample), subjects will ingest 
CC-486/placebo with 240 mL of room tempe rature water in the clinic a pproximately 
30 minutes after antiemetic administration on each PK dosing day.  Each dose of   
CC-486/placebo should be given at approximately the same time each day.  The exact date and time of dosing will be recorded in the source docu ments and appropriate 
CRF.
!On Day 1 of Cycle 1 only, pembrolizumab will be administered as described above, 
but administration will start after the 6 hour CC-486 PK sample co llection time-point.
Dietary restrictio ns on PK days (i.e., Day 1 of Cycle 1 and Cycle 2): 
!Subjects should be instructed to limit their coffee intake to one 8-ounce cup of black 
coffee (no cream or sugar) and to not consume alcohol, tea, chocolate, or cola beverages within 2 hours prior to collecting PK samples.
!Subjects should not ingest food for a minimum of 8 hours prior and 2 hours after CC-
486/placebo is administered.  Water can be allowed as desi red excep t for 1 hour 
before and after CC-486/placebo administration.  The only water permitted in the 1-hour period before CC-486/placebo administration is the 240 mL of water for 
antiemetic ingestion.
8.2.1. Dose Adjustment Guidelines
[IP_ADDRESS]. CC-486 (oral azacitidine)/Placebo
For CC-486/placebo, a maximum of 1 dose reducti on will be allowed from the original dose (eg, 
patients can dose reduce fro m 300 mg/placebo or al daily dose to 200 mg/placebo oral daily 
dose). Re-escalation to the higher dose is not permitted. If a subject requires more than 1 dose 
reduction for CC-486/placebo, they will be discontinued from CC-486/placebo, however, they may continue to receive pembrolizumab (and conversely, subjects who discontinue 
pembrolizumab may continue to receive CC-486/placebo) but must continue to undergo all 
safety and efficacy assessments as per  Table 2 .
CC-486/placebo may be withheld for up to [ADDRESS_1024342] is permanently discontinued from CC-486 is 14 days.For the purposes of dose 
adjustments, unacceptable toxicity will be defined as any AE that is deemed by [CONTACT_737] &(/*(1([ZIP_CODE],(7$5<,1)250$7,21gest st
mately mately 
e of   of   
y.  The exay.  The exa
appppropriropri ateate
d as describas describ
mple comple co llectlle
: 
take to oneake to
cohol, tea, cohol, tea,
K samples.K samples.
imum of 8 hmum of 
n be allon be allo wew
ministratiministrati oo
bo adminisbo adminis
elineslines
itidine)idine) /P/Pl
ximum of imum of 
e fro frm [ZIP_CODE]
to the higho the hig
[ZIP_CODE]/placeb/placeb
o receivo receiv e pe
mab may comab may c
d efficacy fficacy
86/86plpl/aceboaceb
ext cyext cy cle tocle to
The mThe m axa
day
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 48 CC-486-NSCL-001 Final: 15 May 2015to be related to CC- 486/placebo that poses a medical risk or substantial discomfort to the subject 
including, but not limited to, Grade [ADDRESS_1024343] epi[INVESTIGATOR_1865].
See Section [IP_ADDRESS] and Table 6 for dose modification guidelines for pembrolizumab drug-related 
adverse events for overlappi[INVESTIGATOR_748967].
Please refer to Table 5 for the Dose Adjustment Guidelines.
Table 5: CC-486/Placebo Dose Adjustment and Dose Delays for Toxicity
Toxicity Recommendation
Grade 2 hematologic toxicity causing delay to the 
planned start of a Cycle
Absolute Neutrophil Count (ANC) < 1.5 x 109/L
Platelets < 75 x 109/LHold CC-486/ placebo until ANC  & Platelets 
â‰¤ Grade 1
Delay â‰¤ 7 days, resume CC-486/placebo at same 
dose
Delay 8 â€“ 14 days, reduce CC-486/placebo by 100 
mg
Delay > 14 days, permanently discontinue from 
study
Grade 3 neutropenia or thrombocytopenia causing 
delay to the planned start of a Cycle ANC 0.5-0.99 
x 109/L
Platelets 25-49 x 109/LHold CC-486/ placebo unt il ANC & Platelets 
recover to â‰¤Grade 1 (ANC â‰¥ 1.5 x 109/L, Platelets 
â‰¥ 75 x 109/L)
Recovery in â‰¤ 7 days, resume CC-486/placebo at 
same dose
Recovery in 8â€“14 days, reduce CC-486/placebo by 
100 mg
No recovery by 14 days, permanently discontinue 
from study
Grade 4 neutropenia or thrombocytopenia causing 
delay to the planned start of a Cycle
ANC < 0.5 x 109/L
Platelets < 25 x 109/L
For ANC < 0.5 x 109/L
The initiation of G-CSF is left at the Investigatorâ€™s 
discretion. If initiated administer G-CSF per 
institutional practice or package insert and continue 
until ANC recovers to â‰¥ 2.0 x 109/LHold CC-486/p lacebo until ANC & Platelets 
recover to â‰¤Grade 1
(ANC â‰¥ 1.5 x 109/L, Platelets â‰¥ 75 x 109/L)
Recovery in â‰¤ 7 days, reduce CC-486/placebo by 
100 mg
No recovery by 7 days, permanently discontinue 
from study
&(/*(1(3523enia causingia causin
ee
CSF is left atCSF is left a
ated adminiated admini235,(7$5<,1)250$7,21$7$7$7 elets elet
placebo at splacebo at s
CC-486/CC-486/ plapla//
rmanently dmanently d0$
6/6/placeboplacebo// un
â‰¤â‰¤Grade 1 Grade 1
[ZIP_CODE]/L)/L)
covery in covery in â‰¤ 
ame doseame dose
RecovRecov erer
100 m100 m
NN<
5,
actice or pacctice or pa
ecovers to covers to â‰¥â‰¥23
/*
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 49 CC-486-NSCL-001 Final: 15 May 2015Table 5: CC-486/Placebo Dose Adjustment and Dose Delays for Toxicity (Continued)
Toxicity Recommendation
Grade 3 or 4 Nausea or Vomiting
Grade 3 or 4 Diarrhea
Grade 3 or 4 Fatigue/AstheniaHold until resolution to â‰¤ Grade 1 and provide 
optimal medical management
If response â‰¤72 hours (3 days), and recovery â‰¤ 7 
days, reintroduce CC -486/placebo at 200 mg
If event recurs after re-challenge at 200 mg, 
discontinue CC-486/placebo
If no recovery by 7 days, discontinue CC-
486/placebo
Grade 3 or 4 any other non-hematologic toxicity Hold until resolution to â‰¤ Grade 1 and provide 
optimal medical management
If recovery â‰¤ 7 days, reintroduce CC-486/placebo 
at 200 mg
If event recurs after re-challenge at 200 mg, 
discontinue CC-486/placebo
If no recovery by 7 days, discontinue CC-
486/placebo
Renal dysfunction - For any unexplained 
reductions in serum bicarbonate levels to < 20 
mEq/L or unexplained elevations of BUN and/or serum creatinine (> 20%) from baselineHold until resolution to â‰¤ baseline level (+/- 20%) 
Reduce CC-486 dose in the next cycle of treatment 
to the next lower dose level 
If similar unexplained renal and/or electrolyte 
disturbances subsequently persist or recur, 
discontinue CC-486
ANC = absolute neutrophil count; ASCO = American Society of Clinical Oncology; BUN = blood urea nitrogen; ESMO =
European Society for Medical Oncology; G-CSF = granulocyte colony stimulating factor.
Note: The initiation of G-CSF is left at the Investigatorâ€™s discretion.
Note: Granulocyte colony s timulating factor (G-CSF) should only be utilized in accordance to ASCO or ESMO 
recommendations.
Note: If Grade 3 or 4 neutropenia associated with fever or Grade â‰¥ 3 thrombocytopenia with clinically significant bleeding 
occurs at any time, the dose adjustment guidelines for Grade 4 hematological toxicity should be enacted.
Note: If neutropenia is associated with fever and severe diarrhea, subject should be managed appropriately according to the local 
practice. In case of recurrence of the diarrhea with neutropenia and fever, the continuation of the subject in the study should  be 
discussed on a case-by-case basis with the sponsorâ€™s study monitor.
[IP_ADDRESS]. Pembrolizumab
Adverse events associated with pembrolizumab exposure may represent an immunologic 
etiology.  These adverse events may occur shortly after the first dose or several months after the 
last dose of treatment. Pembrolizumab must be withheld for drug-related toxicities and severe or 
life-threatening AEs as per Table 6 below. Dose reductions are not permitted for pembrolizumab. &(/*(1([ZIP_CODE],(7$5<,1)250$7,21CCC--$7
 1 and prov1 and pro
troduce CCroduce 
re-challengchalle
486/6placeboeb /
ry by [ADDRESS_1024344]
d$5
235,
American SoAmerican So
gygy; G; G--CSF = CSF =
at the at th InvestigInvest
ting ffactor (Gactofff
penia associatpenia associ
dose adjustmedose adjustme
associatedassociated ww
of recurrence of recurrence
casecase-by--by-case ase 
PembrPembr
verse eveerse eve nn
etitiolologyogy.  T.  T
last doseast dos
th
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 50 CC-486-NSCL-001 Final: 15 May 2015Table 6: Dose Modification Guidelines for Pembrolizumab Drug-Related Adverse 
Events
ToxicityHold 
Treatment 
For GradeTiming for Restarting 
Treatment Treatment Discontinuation
Diarrhea/Colitis2-3Toxicity resolves to 
Grade 0-1.Toxicity does not resolve within [ADDRESS_1024345] dose.
3-4Permanently discontinue
(see exception below)1 Permanently discontinue
Type 1 diabetes 
mellitus (T1DM), if 
new onset, or HyperglycemiaT1DM or
3-4Hold pembrolizumab for 
new onset Type [ADDRESS_1024346] dose or inability to 
reduce corticosteroid to 10 mg or 
less of prednisone or equivalent per 
day within 12 weeks.
4 Permanently discontinue Permanently discontinue
HypothyroidismTherapy with 
pembrolizumab can be 
continued while thyroid replacement therapy is institutedTherapy with pembrolizumab can be 
continued while thyroid replacement 
therapy is instituted.
Infusion Reaction 3-4 Permanently discontinue Permanently discontinue&(Infusion Renfusion R&(/*(1([ZIP_CODE],(7$5<,1)250$7,21t per per $7e0$esolve withiesolve withi
e..50
tly discontiny disco)2
a 
nce ce Resume pemResum
patients apatients 
metabmetab,1
$5
ves to ves to
Therapy wiTherapy w
izumab can izumab can
nued while ued while 
docrine replocrine rep
therapy is intherapy is7$
33To2
15
11((1roidismism(1(11(1
&(&
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 51 CC-486-NSCL-001 Final: 15 May 2015Table 6: Dose Modification Guidelines for Pembrolizumab Drug-Related Adverse 
Events (Continued)
ToxicityHold 
Treatment 
For GradeTiming for Restarting 
Treatment Treatment Discontinuation
Pneumonitis2Toxicity resolves to 
Grade 0-1Toxicity does not resolve within [ADDRESS_1024347] dose or inability to 
reduce corticosteroid to 10 mg or 
less of prednisone or equivalent per day within 12 weeks.
4 Permanently discontinue Permanently discontinue
Note: Permanently discontinue for any severe or Grade [ADDRESS_1024348] or ALT increases by 
[CONTACT_55559] 50% relative to baseline and lasts for at least [ADDRESS_1024349] cycle, each drug may be given independently on a cyclical regimen according to 
the protocol-defined dose interruptions/delays for CC-486/placebo or pembrolizumab as defined 
in Section 8.2.1 above. Dosing interruptions are permitted in the case of medical / surgical events 
or logistical reasons not related to study ther apy (eg, elective surgery, unrelated medical events, 
patient vacation, and/or holidays). Subjects should be placed back on study therapy within 3 
weeks of the scheduled interruption, unless otherwise discussed with the Sponsor. The reason for interruption should be documented in the patient's study record.
8.2.2. Overdose
Overdose, as defined for this protocol, refe rs to blinded CC-486 and/or pembrolizumab. 
For purposes of this trial, an overdose of pembrolizumab will be defined as any dose of 1,[ADDRESS_1024350], regardless of any &(/*(1([ZIP_CODE],(7$5<,1)250$7,21t perper$7
ueue0$resolve withresolve with
se or inabilior inabil
osteroid to 1osteroid to 
dnisone or enisone
hin 12 weekin 12 week50
mamanently dntly d,1
Toxicity dToxicity
weeks oweeks
redured
lele<
$5
y discontinuy discontin(75,(de [ADDRESS_1024351] 
rug mug m ay be ay b
e interruptie interrup
.Dosing inDosing in
s not relates not relate
, and/or hol, and/or ho
scheduled scheduled 
n shoulshoul d bd b
. OveOv
Overdose, aOverdose, a
For puror pur
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 52 CC-486-NSCL-001 Final: [ADDRESS_1024352] number assignment and 
accountability tool only.
8.4. Packaging and Labeling
The labels for IPs may include, but are not limited to, sponsor name, address and telephone 
number, the protocol number, IP name, dosage form and strength (where applicable), amount of 
IP per container, lot number, expi[INVESTIGATOR_5695] (where applicable), medication identification/kit number, dosing instructions, storage conditions, and required caution statements and/or 
regulatory statements as  applicable. Addition al information may be included on the label as 
applicable per local regulations.
8.5. Investigational Product Accountability and Disposal 
Celgene (or designee) will review with the Inve stigator and relevant site personnel the process 
for Investigational Product return, disposal, and/or destruction including responsibilities for the 
site versus the responsibilities of Celgene (or designee).
8.6. Investigational Product Compliance
Accurate recording of all IPs administered will be made in the appropriate section of the subjectâ€™s case report form (CRF) and source documents. The Investigator or designee is accountable for the compliance of all study-specific IPs either administered or in their custody 
during the course of the study.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21s 
nd nd 
ddress and ddress and
where appliere appli
dicatation idid
cautcautioion stan s
n may be inmay be i
ntability antability a
estestigator aigator a
, and/or desand/or de
ne (or desige (or des
oduct Comoduct Com
administereadminister
CRF) and CRF) and
pliance of apliance o
he studyhe study ..
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 53 CC-486-NSCL-001 Final: 15 May [ZIP_CODE]. CONCOMITANT MEDICATIONS AND PROCEDURES
9.1. Permitted Concomitant Medications and Procedures
9.1.1. CC-486 (oral azacitidine)
In general, the use of any c oncomitant medication/therapi[INVESTIGATOR_72608].
All concomitant treatments, including blood and blood products, must be reported on the CRF. 
Subjects may be administered supportive and palliative care (eg, pain control, anti-nausea, anti-
diarrheal) as clinically indicated throughout the study. 
Myeloid growth factors (granulocyte col ony stimulating factor [G-CSF] and granulocyte 
macrophage colony-stimulating factor [GM-CSF]) should be administered according to 
American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO) guidelines only for the treatment of neutropenic infections.
Antiemetics are not required during the study, except for subjects enrolled in the PK population; 
at the Investigatorâ€™s discretion, subjects not enrolled in the PK population may also receive prophy lactic antiemetic therapy (eg, a serotonin [5-H T3] receptor antagonist such as  
ondansetron) approximately [ADDRESS_1024353] sign of diarrhea.  Pre-
medication with antidiarrheal medication for subs equent doses of CC-486 may be appropriate at 
the Investigatorâ€™s discretion.
9.1.2. Pembrolizumab Supportive Care
Subjects should receive appropriate supportive care measures as deemed necessary by [CONTACT_422515].  Suggested supportive care measures for the management of adverse events 
with potential immunologic etiology are outlined below and in greater detail in the events of clinical interest (ECI) guidance in Appendix C . Where appropriate, these guidelines include the 
use of oral or intravenous treatment with corticosteroids as well as additional anti-inflammatory 
agents if symptoms do not improve with administration of corticosteroids.  Note that several courses of steroid tapering may be necessary as symptoms may worsen when the steroid dose is 
decreased. For each disorder, attempts should be made to rule out other causes such as metastatic 
disease or bacterial or viral infection, which might require additional supportive care. The
treatment guidelines are intended to be applied when the Investigator determines the events to be 
related to pembrolizumab. 
Note: if after the evaluation the event is determined not to be related, the Investigator is 
instructed to follow the ECI reporting guidance but does not need to follow the treatment 
guidance (as outlined in the ECI guidance). Refer to Table 6 for dose modification guidelines 
for pembrolizumab. 
It may be necessary to perform conditional procedures such as bronchoscopy, endoscopy, or skin 
photography as part of evaluation of the event. Suggested conditional procedures, as appropriate, 
can be found in the ECI guidance.&(/*(1([ZIP_CODE],(7$5<,1)250$7,21CRF. CRF. 
usea, antsea, ant i-i-
ranulocyte anulocyte
according taccording 
or Medir Med cal
enronlled inled in
populatpopula ion
ceptor antageptor anta
se of CCe of CC -48
prescribed aprescribe
equent dosequent do
CareCare
upportive cupportiv
upportive cupportive c
lologygy are ou are ouyy
nce nce ininAppeAppe
treatmatment wt
not improvnot impro
aperingering mama
ach disordeach disorde
terierial or vial or v i
guiuidelines adelines a
o pembrolio pembrol
Note: if aftNote: if aft
instructeinstruct
guiuidad
fofo
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 54 CC-486-NSCL-001 Final: 15 May [ZIP_CODE].1.2.1. Management of pneumonitis
These guidelines may also be used for cases  of pneumonitis that may not be related to 
pembrolizumab.
!For Grade 2 events, treat with systemic corticosteroids. When symptoms improve to 
Grade 1 or less, steroid taper should be started and continued over no less than 4 
weeks.
!For Grade 3-4 events, immediately treat with intravenous steroids.  Administer 
additional anti-inflammatory measures, as needed.
!Add prophylactic antibiotics for opportunistic infections in the case of prolonged 
steroid administration
[IP_ADDRESS]. Management of Diarrhea/Colitis
Subjects should be carefully monitored for signs and symptoms of enterocolitis (such as diarrhea, 
abdominal pain, blood or mucus in stool, with or without fever) and of bowel perforation (such 
as peritoneal signs and ileus).  
!All subjects who experience diarrhea/colitis should be advised to drink liberal 
quantities of clear fluids.  If sufficient oral fluid intake is not feasible, fluid and 
electrolytes should be substituted via IV infusion.  For Grade 2 or higher diarrhea, 
consider GI consultation and endoscopy to confirm or rule out colitis.
!For Grade 2 diarrhea/colitis that persists greater than 3 days, administer oral 
corticosteroids. 
!For Grade 3 or 4 diarrhea/colitis that persists > 1 week, treat with intravenous steroids 
followed by [CONTACT_78018].  
!When symptoms improve to Grade 1 or less, steroid taper should be started and 
continued over no less than 4 weeks.
[IP_ADDRESS]. Management of type 1 diabetes mellitus (if new onset, including diabetic 
ketoacidosis [DKA]) or â‰¥ Grade 3 Hyperglycemia, if associated with ketosis 
(ketonuria) or metabolic acidosis (DKA)
!For type 1 diabetes mellitus (T1DM) or Grade 3-4 Hyperglycemia
oInsulin replacement therapy is recommended for type 1 diabetes mellitus and 
for Grade 3-4 hyperglycemia associated with metabolic acidosis or ketonuria.
oEvaluate patients with serum glucose and a metabolic panel, urine ketones, 
glycosylated hemoglobin, and C-peptide.
[IP_ADDRESS]. Management of hypophysitis
!For Grade 2 events, treat with corticosteroids. When symptoms improve to Grade 1 or 
less, steroid taper should be started and continued over no less than 4 weeks. Replacement of appropriate hormones may be required as the steroid dose is tapered.nged ed 
litlitis (such is (such 
owel perfowel pe
advised todvised to
ake is not fake is no
n.  For Gra.  For Gra
nfirmnfirm  or ruorm
greater thgreater th an
hat persihat persi stssts
roids.  roids.  
to Grade 1 to Grad
han 4 weekan 4 wee
ype 1 diaby[INVESTIGATOR_5836] 1 diab
DKA]) or KA]) or â‰¥â‰¥
or metaboor metab
e 1 di 1 diabetesabetes
ooInsulin Insul
fofor Gr G
oo
[IP_ADDRESS].[IP_ADDRESS].
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 55 CC-486-NSCL-001 Final: 15 May 2015!For Grade 3-4 events, treat with an initial dos e of IV corticosteroids followed by [CONTACT_749004]. When symptoms improve to Grade 1 or less, steroid taper should be started and continued over no less than 4 weeks. Replacement of appropriate 
hormones may be required as the steroid dose is tapered.
[IP_ADDRESS]. Management of hyperthyroidism or hypothyroidism
Thyroid disorders can occur at any time duri ng treatment. Monitor patients for changes in 
thyroid function (at the start of treatment, periodically during treatment, and as indicated based on clinical evaluation) and for clinical signs and symptoms of thyroid disorders.
!Grade 2 hyperthyroidism events (and Grade 3-4 hypothyroidism):
oIn hyperthyroidism, non-selective beta-blockers (eg, propranolol) are 
suggested as initial therapy.
oIn hypothyroidism, thyroid hormone rep lacement therapy, with levothyroxine 
or liothyroinine, is indicated per standard of care.
!Grade 3-4 hyperthyroidism 
oTreat with an initial dose of IV corticos teroid followed by [CONTACT_78019]. 
When symptoms improve to Grade 1 or less, steroid taper should be started 
and continued over no less than 4 weeks. Replacement of appropriate 
hormones may be required as the steroid dose is tapered.
[IP_ADDRESS]. Management of hepatic abnormalities
!For Grade 2 events, monitor liver function tests more frequently until returned to 
baseline values (consider weekly).
oTreat with IV or oral corticosteroids
!For Grade 3-4 events, treat with intravenous corticosteroids for 24 to 48 hours. 
!When symptoms improve to Grade 1 or less, a steroid taper should be started and 
continued over no less than 4 weeks.
[IP_ADDRESS]. Management of renal failure or nephritis
!For Grade 2 events, treat with corticosteroids.
!For Grade 3-4 events, treat with systemic corticosteroids.
!When symptoms improve to Grade 1 or less, steroid taper should be started and 
continued over no less than 4 weeks.
[IP_ADDRESS]. Management of infusion reactions
See Appendix C for guidelines for subjects who experience an infusion reaction associated with 
administration of pembrolizumab.
9.2. Prohibited Concomitant Medications and Procedures
The following concomitant medications are prohibited during the course of the study:&(/*(1([ZIP_CODE],(7$5<,1)250$7,21))are are 
 with levotwith lev
olllolowed by[CONTACT_426]
s, steroid s, steroid ta
. ReplacemReplacem
oiid dose is d dose 
unction testnction tes
y).).
corticorticostercost
eat with intat with in
mprove to Gprove to G
o less than o less tha
ent of renant of rena
ade 2 eventde 2 event
Grade 3Grade 3 --4
When symWhen sym
coontntinuinu
[IP_ADDRESS].2.8. MM
See SeeAppAp
min
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 56 CC-486-NSCL-001 Final: 15 May 2015!Cytotoxic, chemotherapeutic, targeted, horm onal, or investigational agents/therapi[INVESTIGATOR_748968].
!Vidaza (azacitidine inj ection), decitabine, or other d emethylating agents.
!Other PD-1 or PD-L1 inhibitors
!Radiation therapy
oNote:  Radiation therapy to a symptomatic solitary lesion or to the brain may 
be considered on an exceptional case by [CONTACT_44883].  The subject must have clear measurable disease outside the radiated 
field.  Administration of palliative radiation therapy will be considered 
clinical progression for the purposes of determining PFS.
!Live vaccines within [ADDRESS_1024354] dose of trial treatment and while 
participating in the trial.  Examples of live vaccines include, but are not limited to, the 
following: measles, mumps, rubella, chicken pox, yellow fever, seasonal flu, H1N1 
flu, rabies, b acillus C almette-Guerin (BCG), and t yphoid vaccine. Seasonal influenza 
vaccines for injection are generally killed virus vaccines and are allowed. However, 
intranasal influenza vaccines (eg, Flu - Mist
Â®) are live attenuated vaccines, and are 
not allowed.
!Glucocorticoids for any purpose other than  to modulate symptoms from an event of 
clinical interest, use as a pre-medication for ch emotherapeutic agents specified in the 
protocol, or for use as a pre-med ication in subjects with a known history of an IV 
contrast allergy administered as part of CT radiography. Replacement doses of 
steroids (for example, prednisone 5-7.5 mg  daily) are permitted while on study. 
Subjects who, in the assessment by [CONTACT_737], require the use of corticosteroids for any other clinical management shoul d be discussed with medical monitor.
9.3. Required Concomitant Medications and Procedures
Not applicable.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21adiated diated 
ed 
and while and while 
re not limitre not limit
, seasonal fseasonal f
ccine.ne.SeasSe
and are allond are all
attenuated ttenuated
modulate sydulate s
chememothotherae
n subjects wsubject
fCT radiCT radi ogo
7.5 m7.5 m g daig damm
by[CONTACT_749005] d
tant Medant Med
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 57 CC-486-NSCL-001 Final: 15 May 201510. STATISTICAL ANALYSES
10.1. Overview
This is a placebo-controlled, double-blind, randomized, phase 2 trial designed to estimate the 
efficacy and safety/tolerability of CC-[ADDRESS_1024355] ical analysis methods will be documented in the statistical analysis plan (SAP).
10.2. Study Population Definitions
10.2.1. Intent-To-Treat Population
The intent-to-treat (ITT) population will consist of all randomized subjects.  All efficacy 
analyses will be based on the ITT population, unless otherwise specified.  The efficacy analyses will be performed according to treatment assigned at randomization.
10.2.2. Safety Population
The safety population will cons ist of any enro lled sub jects who received at least [ADDRESS_1024356] imates of the difference in efficacy and safety 
between CC-486 plus pembrolizumab and placebo plus pembrolizumab. 
Approximately 90 subjects will be randomized 1:[ADDRESS_1024357] occurred.
The table below demonstrates the hypothetical power of testing the null hypothesis H0: Î»T/Î»C=1, 
against the two sided alternative H0: Î»T/Î»Câ‰ 1,assuming that time to PFS events in both treatment &(/*(1([ZIP_CODE],(7$5<,1)250$7,21s s 
ects.  All eects.  All f
ified.  The ed.  The 
on.n.
cts who rcts who r ece
atatioion, unlen, un
on the treaon the tre
de all rande all r d
e pharmacoe pharmaco
lationlation
populatpopulat ioin w
onsent for onsent for 
ollected andollected and
ample Sizample Siz
maryy goalgoalyy ofofll
en CCen C -[ADDRESS_1024358]
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 58 CC-486-NSCL-001 Final: [ADDRESS_1024359] rate of the survival distribution in 
the experimental arm (CC-486+pembrolizumab).
Table 7: Hypothetical Power and Resulting Two-sided 90% CI of Hazard Ratio
Combo Treatment Median PFS (month) 5.5 5.0 4.6
Total PFS events 74 75 76
Power (%) w/two-sided Î±=0.[ZIP_CODE].4 71.7 59.4
HR with [two-s ided 90% CI] 0.55 [0.38,0.81] 0.60 [0.41,0.88] 0.65 [0.45,0.95]
1These calculations assume the median PFS in pembrolizumab alone is 3.0 months ( Garon, 2014 ). And lost to 
follow-up (to assess PFS events) rate is 10% at the end of study. 
The power calculations are conducted with East 5.4. 
10.4. Background and Demographic Characteristics
Subjectsâ€™ age, height, weight, and baseline characteristics will be summarized using descriptive 
statistics, while gender, race and other categorical variables will be provided using frequency tabulations.  Medical history data will be summarized using frequency tabulations by [CONTACT_53428].
10.5. Subject Disposition
Subject disposition (analysis population allocat ion, entered, discontinued, along with primary 
reason for discontinuation) will be summarized using frequency and percent for both treatment 
and follow-up phases.  A summary of subjects enrolled by [CONTACT_27707]. Protocol deviations will be summarized using frequency tabulations.
10.6. Efficacy Analysis
10.6.1. Primary Efficacy Endpoint
The primary endpoint PFS will be defined as the time from the randomization date to disease 
progression assessed by [CONTACT_749006] 1.[ADDRESS_1024360] assessment prior to receiving the 
anti-cancer therapy. Subjects with 2 or more missing response assessments prior to a visit with documented disease progression (or death) will be censored at the last visit where the subject 
was documented to be PFS event-free.  A sensit ivity analysis will be performed with censoring 
rules that follow the principles of assigning the date of event based on the time of the first evidence of objective progression or death regardless of violations, discontinuation of IP or 
change of therapy. 
PFS will be summarized by [CONTACT_295520]-fr ee survival time (including two-sided 90% 
confidence interval [CI]) for each  treatment group and within each strata.  The hazard ratio and a &(/*(1([ZIP_CODE],(7$5<,1)250$7,[ZIP_CODE]$[ZIP_CODE],0.95],0.95]$7$70$$7d lost to lost to 
mmarized usmarized u
e provided provided
quenquen cyc tabuy
,, entered, d entered, d
using frequusing fre
ts enrolled ts enrolled
uency tabuluency tabu
EndpointEndpoint
will be dewill be de
yyIInvestnv igatiga
r occurs firoccurs fi
e alive and e alive and
e date of thdate of t
nted progreted progre
ncer therapyncer therap
mmented diented di
as documeas docume
rulues that that 
videnviden
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 59 CC-486-NSCL-001 Final: 15 May 2015two-sided 90% CI will be estimated by [CONTACT_749007], and 
any stratification factors as model covariates.  The Kaplan-Meier curve for PFS will be presented
for each treatment group and strata.
10.6.2. Secondary Endpoints
[IP_ADDRESS]. Overall Survival
Overall survival (OS) will be defined as the time from the date of rando mization to the date of 
death (any cause).  Subjects who are alive will be censored at the last time that the subject was 
known to be alive. The OS analysis may also be conducted at the time when 70 deaths occur, in 
addition to when the primary analysis is performed.
Medians of overall survival including two-sided 90% CI for each treatment group w ill be 
calculated.  The hazard ratio and a two-sided 90% CI will be estimated using Cox proportional 
hazard model with treatment, and all stratification factors in the model.  The Kaplan-Meier curve 
for survival will be presented for each strata and treatment group.
[IP_ADDRESS]. Overall Response Rate (ORR)
Overall response rate is the percentage of sub jects that achieve a confirmed complete or partial 
response as assessed by [CONTACT_749008] 1.1 guideline. This rate will be 
presented for each treatment group and strata.  The 90% CI of the response rates will be 
provided.  A two-sided 90% CI of the Response rate differences between pembrolizumab plus 
placebo and pembrolizumab plus CC -486 arm, with each strata and overall w ill be provided.
[IP_ADDRESS]. Disease Control Rate (DCR)
The percentage of disease control (i.e., confirmed SD, CR or PR) according to RECIST 1.[ADDRESS_1024361] meet 
the minimum duration of 18 weeks from randomization.
[IP_ADDRESS]. irPFS, irORR and irDCR per irRECIST
Exploratory endpoints such as irPFS, irORR, and irDCR assessed by [CONTACT_749009].
10.6.3. Subgroup Analysis
The effect of treatment on the efficacy variable OS, PFS, and DCR may be investigated within 
subgroups defined by [CONTACT_749010].
The methods described in previous statistical analysis sections will be used for each subgroup 
separately. A forest plot may also be provided.
10.7. Safety Analysis
Safety analysis will be performed using the safe ty population. Safety and tolerability will be 
monitored through continuous reporting of all AEs and SAEs, laboratory abnormalities, and 
incidence of subjects experiencing adverse events resulting in dose reductions, dose &(/*(1([ZIP_CODE],(7$5<,1)250$7,21as 
cur, in ur, in 
will will be be 
ox proportioox proporti
KaplanKapl -MeMe
confirmedconfirmed
on 1.1 guiden 1.1 gui
ofof the theff respre
fferences beferences b
ach achstrata tra
firirmed med SD,SD,
.  When SD.  When 
oom m randorand m
rrDCR perDCR per
as as irirPFS, PFS, ir
ed using staed using
roup Analroup Ana
f treatment f treatment
s defined bdefined b
mmethods desethods d
paratelyarately . A. AA
[IP_ADDRESS].
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 60 CC-486-NSCL-001 Final: 15 May 2015interruptions, and/or premature discontinuation of study drugs. TEAEs, TEAEs leading to death 
or discontinuation from treatment, events assessed as Grade 3 or Grade 4,  vital signs, weight, 
clinical laboratory information, and concomitant medications/procedures will be tabulated and 
summarized.
Treatment-emergent adverse events will be coded according to MedDRA. All TEAEs will be 
summarized by [CONTACT_14340], frequency, severity grade based 
on the CTCAE (Version 4.0) and relationship to treatment. Serious adverse events, events of interest, and events leading to discontinuation or death will be listed separately.
10.8. Pharmacokinetic Analysis
When appropriate, plasma PK samples collected will be analyzed for CC-486 concentration determination using a validated high-performance liquid chromatography/tandem mass spectrometric method.
10.8.1. Plasma Concentrations
By-subject listing of pharmacokinetic blood sample collection times as well as derived sampling 
time deviations will be provided.  CC-486 plasma concentrations will be summarized using 
descriptive statistics (N, arithmetic mean, standard deviation, standard error, minimum, median, maximum, percent coefficient of variation, geometric mean, and geometric percent coefficient of 
variation) for each cycle, if/when appropriate.  Concentrations that are below the limit of 
quantitation (BLQ) will be treated as zero for th e computation of descriptive statistics. Missing 
concentrations and concentrations from blood samples collected more than Â± 10% of nominal 
time will be omitted from the calculation of descriptive statistics.
Individual subject concentration-time data and mean concentration-time data for each cycle will 
be graphically presented on linear and semi-logarithmic scales.
Following single dose administration, predose samples that are BLQ or missing will be assigned 
a numerical value of zero for the calculation of AUC .  Any anomalous concentration values 
observed at predose will be identified in the clinical study report (CSR) and used for the 
computation of AUC.  Pharmacokinetic parameters will be computed if the anomalous value is
not greater than 5% of the C
max.  If the anomalous value is greater than 5% of C max, the computed 
pharmacokinetic parameters for the given subject will be dropped from the pharmacokinetic 
analysis.  
Any other BLQ concentrations will be assigned a value of zero if they precede quantifiable 
samples in the initial portion of the profile.  A BL Q value that occurs between quantifiable data 
points, especially prior to C max, will be evaluated to determine if an assigned concentration of 
zero makes sense, or if reanalysis or exclusion of the data is warranted.  Following C max, BLQ 
values embedded between 2 quantifiable data points will be treated as missing when calculating 
AUC.  BLQ values occurring at the end of the collection interval (after the last quantifiable 
concentration) will be treated as missing data.  If consecutive BLQ concentrations are followed by [CONTACT_27712], these quantified 
values will be excluded from the pharmacokinetic analysis by [CONTACT_27713] a value of missing, 
unless otherwise warranted by [CONTACT_27714]-time profile.  For the purpose of analysis, these 
trailing BLQ values may be designated as zero in the dataset if the pharmacokinetic program &(/*(1([ZIP_CODE],(7$5<,1)250$7,21tration tration 
mmass ass 
as well as ds well as d
will be sumwill be sum
andard erroandard erro
and geomeand geom
tions that ations that a
putation of putation of 
les collecteles collec
riptive statiiptive stat
d mean cod mean co
mimi-lologarigarithmthmiii
predose sapredos
lculatcu ioion ono
ntified in thntified in th
acokineticacokinetic
Cmamaxx.  If.  ththf
meters for thmeters for t
concentratconcentrat
e inite init ial poial po
pecially pricially pri
akes sense, kes sense,
es embeddees embedd
AUC.  BLQAUC.  BLQ
concentraoncentra
y quay qua
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 61 CC-486-NSCL-001 Final: 15 May 2015used to do the analysis (such as WinNonlinÂ®) will treat trailing zero values as missing when 
calculating AUC.
Actual sampling times will be used in the calcu lations of pharmacokinetic parameters that will be 
derived using noncompartmental methods with Phoenixâ„¢ WinNonlinÂ®Professional Version 6.3, 
or higher,   Graphics may be prepared 
with SAS Version 9.1, or higher; or Excel 2007, or higher; Phoenixâ„¢ WinNonlinÂ®Professional 
6.3, or higher; or S-Plus 8.2., or higher .
10.8.2. Pharmacokinetic Parameters
The following PK parameters will be calculated for CC-486:
AUC inf Area under the plasma concentration-time curve from Time 0 extrapolated 
to infinity, calculated as [AUC t+ Ct/âˆ€z].  Ct is the last quantifiable 
concentration. No AUC extrapolation will be performed with unreliable 
âˆ€z.  If AUC %Extrap is â‰¥25%, AUC inf will not be reported
AUC t Area under the plasma concentration-time curve from Time [ADDRESS_1024362] quantifiable concentration, calculated by [CONTACT_27715].
C
max Maximum observed plasma concentration, obtained directly from the 
observed concentration versus time data.
Tmax Time to C max, obtained directly from the observed concentration versus 
time data.
t1/2 Terminal phase half-life in plasma, calculated as [(ln 2)/ âˆ€z].  t 1/2will only 
be calculated when a reliable estimate for âˆ€zcan be obtained.  
CL/F Apparent total clearance, calculated as [Dose/AUC inf]. 
Vz/F Apparent volume of distribution, calculated as [(CL/F)/ âˆ€z].
The following PK parameters for CC-486 will be calculated for diagnostic purposes and listed, 
but they will not be summarized:
âˆ€z Apparent terminal rate constant, calculated by [CONTACT_27716]-concentration versus time curve in plasma.  Visual assessment will be used to identify the terminal linear phase of the 
concentration versus time profile.  A minimum of three data points will be 
used for calculation.  
âˆ€z will not be estimated if the terminal phase of the log-concentration 
versus time profile does not exhibit a linear decline phase, or if the 
regression coefficient < 0.8.  &(/*(1([ZIP_CODE],(7$5<,1)250$7,210 extrapola0 extrapola
uantifantifiable iable fff
ed with unred with unr
eportedeported
ve from Tie from T
ulated by [CONTACT_749011]
e halfe half --ffflife ili
d when a rwhen a r
rent ent totaltota clll
Apparent vApparent v
K parameterparameter
ot be summt be sum
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 62 CC-486-NSCL-001 Final: 15 May 2015âˆ€z lower Lower limit of time (h) included in the calculation of âˆ€z. 
âˆ€z N Number of data points used in the calculation of âˆ€z.
âˆ€z upper Upper limit of time (h) included in the calculation of âˆ€z.
Rsq Regression coefficient for calculation of âˆ€z.  
AUC % Extrap Percentage of AUC infdue to extrapolation from  the last quantifiable t ime 
point to infinity.
10.8.3. PK Analyses
By-subject listing of pharmacokinetic parameters will be provided.  The pharmacokinetic 
parameters will also be summarized using desc riptive statistics (N, arithmetic mean, standard 
deviation, standard error, minimum, median, maximum, percent coefficient of variation, geometric mean, and geometric percent coefficient of variation) for each cycle.  Also, when 
appropriate, graphical representations (i.e., scatter plots, box plots, etc) may be used to visualize
the results.
The effect of pembrolizumab on the PK of CC-486 will be assessed using graphic comparison 
and descriptive stats.
Exploratory analysis may be conducted to i nvestigate the relationship between PK parameters 
and efficacy endpoints.
10.9. Interim Analysis
No interim analysis of efficacy is planned for this study.
10.10. Other Topi[INVESTIGATOR_1102]
10.10.1. Data Monitoring Committee
An independent Data Monitoring Committee (iDMC) will be established and will include 
medical oncologists and a statistician, all of whom are not otherwise involved in the study 
conduct.  During the course of the study, the DMC will review the safety data regularly. The first DMC meeting will occur when [ADDRESS_1024363] of this trial will be overseen by a Steering Committee (SC), presided over by [CONTACT_749012] [INVESTIGATOR_748969] &(/*(1([ZIP_CODE],(7$5<,1)250$7,21me 
acokinetic acokineti
c mc mean, staean, s
nt of variatnt of variat
ch cycle.  Ah cycle.  
etc) may beetc) may be
ssessed usissessed us
the relatthe relat ioi
d for this sd for this
CommitteCommitte
onitoring Conitoring
nd a statid a st stii
he course ofe course of
willwilloccur woccur wll
wiwiththiiisubsesubsehh
MC ChairmaC Chairma
ased only oased only o
ned in the Dned in the 
embers forembers for
DMC chaDMC cha
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 63 CC-486-NSCL-001 Final: 15 May 2015countries participating in this study.  The SC w ill serve in an advisory capacity to the Sponsor.  
Operational details for the SC will be detailed in a separate SC charter.
Note: The SC is separate from the DMC.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 64 CC-486-NSCL-001 Final: [ADDRESS_1024364]â€™s health, including 
laboratory test values (as specified by [CONTACT_14540] 11.3), regardless of etiology. Any 
worsening (i.e., any clinically significant adverse ch ange in the frequency or intensity of a pre-
existing condition) should be cons idered an AE.  A diagnosis or syndrome should be recorded on 
the AE page of the CRF rather than the indi vidual signs or symptoms of the diagnosis or 
syndrome. 
Abuse, withdrawal, sensitivity or toxicity to an investigational product should be reported as an 
AE. Overdose, accidental or intentional, whether or not it is associated with an AE should be reported on the overdose CRF. (See Section 8.2.2 for the definition of overdose.) Any sequela 
of an accidental or intentional overdose of an investigational product should be reported as an 
AE on the AE CRF. If the sequela of an overdose is an SAE, then the sequela must be reported on an SAE report form and on the AE CRF. The overdose resulting in the SAE should be 
identified as the cause of the event on the SAE report form and CRF but should not be reported 
as an SAE itself.
In the event of overdose, the subject should be monitored as appropriate and should receive 
supportive measures as necessary. There is no known specific antidote for CC-486 and 
pembrolizumab overdose. Actual treatment should depend on the severity of the clinical situation and the judgment and experience of the treating physician.
All subjects will be monitored for AEs during the study.  Assessments may include monitoring 
of any or all of the following parameters:   the subjectâ€™s clinical symptoms, laboratory, 
pathological, radiological or surgical findings , physical examination findings, or findings from 
other tests and/or procedures.
All AEs will be recorded by [CONTACT_292004] [ADDRESS_1024365]â€™s source documents.  All SAEs must be reported to Celgene Drug Safety  within 24 hours of the Investigatorâ€™s knowledge 
of the event by [CONTACT_6972], or other appropriate method, using the SAE Report Form, or approved 
equivalent form.
In addition, adverse events known as pembrolizumab Events of Clinical Interest (ECI) must also 
be recorded on the Adverse Event CRFs and re ported within 5 days of the Investigatorâ€™s 
knowledge of the event, regardless of whether or not the Investigator considers the event related to the IP. If the event meets serious criteria (SAE), the event must also reported to Celgene Drug 
Safety within 24 hours by [CONTACT_6972], or other appropriate method, using the SAE Report Form, or 
approved equivalent form as outlined in Section 11.5. This includes the reporting of  any 
pembrolizumab ECIs that become known to the investigator > 30 days to â‰¤[ADDRESS_1024366] 
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21y
prepre--
corded on rded o
s or s or 
be reportebe reporte
th an AE shh an AE sh
overdose.)erdose
should be should be
n the sequelthe seque
ltting ing in the
and CRF bund CRF b
ored as appored as app
wn specificwn specifi
ould dependuld depen
ing physiciing physici
during the sduring the
ters:  the suters:  the
cal findingsfindingsl
ythe Investthe Invey
st dose of et dose o
me thereafteme therea
rded on theded on the
eported to eported to 
by[CONTACT_749013]
t form.form.
ditioition, n,adveadv
recorded oecorded o
knowlknowl edgeedge
o theo the IPI
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 65 CC-486-NSCL-001 Final: [ADDRESS_1024367] initiates a 
new anticancer therapy, whichever is earlier, whether or not related to pembrolizumab. 
See Section 11.5.1 (or Section 11.7) as well as Appendix C for detailed guidance on the 
reporting of pembrolizumab ECIs.  
11.2. Evaluation of Adverse Events
A qualified Investigator will evaluate all adverse events as to: 
11.2.1. Seriousness 
A serious adverse event (SAE) is any AE occurring at any dose that:
!Results in death;
!Is life-threatening (i.e., in the opi[INVESTIGATOR_689], the subject is at immediate 
risk of death from the AE);
!Requires inpatient hospi[INVESTIGATOR_27588] 
(hospi[INVESTIGATOR_19357], regardless of length of stay);
!Results in persistent or significant disability/incapacity (a substantial disruption of the 
subjectâ€™s ability to conduct normal life functions);
!Is a congenital anomaly/birth defect;
!Constitutes an important medical event.
Important medical events are defined as thos e occurrences that may not be immediately life 
threatening or result in death, hospi[INVESTIGATOR_059], or disability, but may jeopardize the subject or 
require medical or surgical intervention to prevent one of the other outcomes listed above.  
Medical and scientific judgment should be exercised in deciding whether such an AE should be considered serious.
Events not considered to be SAEs are hospi[INVESTIGATOR_5315]:
!A standard procedure for protocol therapy administration.  However, hospi[INVESTIGATOR_493051] a comp lication of therapy administration will be 
reported as an SAE. 
!Routine treatment or monitoring of the studi ed indication not associated with any 
deterioration in condition.
!The administration of blood or platelet transfusion as routine treatment of studied 
indication.  However, hospi[INVESTIGATOR_27589] a complication 
of such transfusion remains a reportable SAE.
!A procedure for protocol/disease-related investigations (eg, surgery, scans, 
endoscopy, sampling for laboratory tests, bone marrow sampling).  However, hospi[INVESTIGATOR_27590] a complication of such procedures 
remains a reportable SAE.
!Hospi[INVESTIGATOR_27591], practical, or social 
reasons, in absence of an AE.&(/*(1([ZIP_CODE],(7$5<,1)250$7,21ct is at immis at imm
g g hospi[INVESTIGATOR_748970] l
itty y (a subst(a subst
;
ccurrences ccurrences 
or disabilior disabili
prevent onprevent on
d be exercisbe exerci
Es are hospEs are hosp
edure for prdure for 
hospi[INVESTIGATOR_748971]. an SAE
ne treatmene treatmen
ririoratioration inon
The adminThe admin
indicatndicat i
ofof su sff
!!
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 66 CC-486-NSCL-001 Final: 15 May 2015!A procedure that is planned (i.e., planned prior to starting of treatment on study); 
must be documented in the source document and the CRF.  Hospi[INVESTIGATOR_205271] d hospi[INVESTIGATOR_272] a complication remains a reportable SAE.
!An elective treatment of or an elective pr ocedure for a pre-existing condition 
unrelated to the studied indication, that has not worsened from baseline. 
!Emergency outpatient treatment or observation that does not result in admission, 
unless fulfilling other seriousness criteria above.
If an AE is considered serious, both the AE page/screen of the CRF and the SAE Report Form 
must be completed.
For each SAE, the Investigator will provide information on severity, start and stop dates, 
relationship to IP, action taken regarding IP, and outcome.
11.2.2. Severity / Intensity
For both AEs and SAEs, the Investigator must assess the severity / intensity of the event. 
The severity / intensity of AEs will be gra ded based upon the subjectâ€™s symptoms according to 
the current active minor version of the Commo n Terminology Criteria for Adverse Events 
(CTCAE, Version 4.0); 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40
Adverse events that are not defined in the CTCAE should be evaluated for severity / intensity 
according to the following scale:
!Grade 1 = Mild â€“ transient or mild discomfort; no limitation in activity; no medical 
intervention/therapy required
!Grade 2 = Moderate â€“ mild to moderate limitation in activity, some assistance may be 
needed; no or minimal medical intervention/therapy required
!Grade 3 = Severe â€“ marked limitation in activity, some assistance usually required; 
medical intervention/therapy required, hospi[INVESTIGATOR_27594]
!Grade 4 = Life threatening â€“ extreme limitati on in activity, signi ficant assistance 
required; significant medical intervention/therapy required, hospi[INVESTIGATOR_27595]
!Grade 5 = Death - the event results in death
11.2.3. Causality 
The Investigator must determine the relationship between the administration of IP and the 
occurrence of an AE/SAE as Not Suspected or Suspected as defined below:
Not suspected: a causal relationship of the adverse event to IP administration is 
unlikely or remote , or other medications, therapeutic 
interventions, or underlying conditions provide a sufficient 
explanation for the observed event.rm m 
ates, ates, 
sitytyiofof the e tff
tâ€™s symptoms sympto
teria fer or Aor Af
licaticatioions/ctns/ct
ld be evaluld be eval
scoscomfomfort; nrt; n
moderate moderate 
dical intervdical interv
arked limitarked limi
n/therapy r/therapy r
threateninghreatening
gnificant megnificant m
ableble
e 5 = Deathe 5 = Deat
Causality Causality
vestigator mvestigator m
urrence of aurrence of 
NoNo
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 67 CC-486-NSCL-001 Final: 15 May 2015Suspected: there is a reasonable possibility that the administration of IP 
caused the adverse event.  â€˜Reasonable possibilityâ€™ means there 
is evidence to suggest a causal relationship between the IP and 
the adverse event.
Causality s hould be a ssessed and provided for every AE/SAE based on currently available 
information.  Causality is to be reassessed and provided as additional information becomes 
available.
If an event is assessed as suspected of being related to a comparator, ancillary or additional IP 
that has not been manufactured or provided by [CONTACT_27718], please provide the name [CONTACT_208924].
11.2.4. Duration
For both AEs and SAEs, the Investigator will provide a record of the start and stop dates of the 
event.
11.2.5. Action Taken
The Investigator will report the action taken with IP as a result of an AE or SAE, as applicable 
(eg, discontinuation, interruption, or reduction of  IP, as appropriate) and report if concomitant 
and/or additional treatments were given for the event. 
11.2.6. Outcome
The Investigator will report the outcome of the event for both AEs and SAEs.
All SAEs that have not resolved upon discontinuation of the subjectâ€™s participation in the study 
must be followed until recovered (returned to baseline), recovered with sequelae, or death (due to the SAE). 
11.3. Abnormal Laboratory Values
An abnormal laboratory value is considered to be an AE if the abnormality:
!results in discontinuation from the st udy;
!requires treatment, modification/ interruption of IP dose, or any other therapeutic 
intervention; or
!is judged to be of significant clinical importance, eg, one that indicates a new disease 
process and/or organ toxicity, or is an exacerbation or worsening of an existing condition.
Regardless of severity grade, only laboratory abnormalities that fulfill a seriousness criterion 
need to be documented as a serious adverse event.  
If a laboratory abnormality is one component of a diagnosis or syndrome, then only the diagnosis 
or syndrome should be recorded on the AE page/screen of the CRF.  If the abnormality was not a 
part of a diagnosis or syndrome, then the labor atory abnormality should be recorded as the AE. If &(/*(1([ZIP_CODE],(7$5<,1)250$7,21IP P 
nd stop datnd stop da
of an AE oof an A
opriate)opriate anan
event for boevent for 
ntntinuatioinuatio n n
ed to baselied to baseli
ratory Varatory Va
ue is considue is cons
contconinuatuatio
treatmeatm ent,ent
vententioion; orn; or
s s judged tojudged to
process aprocess a
condiondiii
egardless oegardless o
need to beneed to be
al al
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 68 CC-486-NSCL-001 Final: 15 May 2015possible, the laboratory abnormali ty should be rec orded as a medical term and not simply as an 
abnormal laboratory result (eg, record thro mbocytopenia rather than decreased platelets).
11.4. Pregnancy
All pregnancies, suspected pregnancies and lactation occurring in  either a female subject of 
childbearing potential or partner of a male subject are immediately reportable events.
11.4.1. Females of Childbearing Potential
Pregnancies, suspected pregnancies (including elevated Î²-hCG or a positive pregnancy test in a 
female of childbearing potential regardless of age or disease state) and lactation of a female 
subject that occur during the trial or within 120 days of completing the trial (or longer if required 
by [CONTACT_5277]), or [ADDRESS_1024368] 
notify Celgene Drug Safety imm ediately about the outcome of the pregnancy (either normal or 
abnormal outcome) using the Pregnancy Follow- up Report Form, or approved equivalent form.
The female subject should be referred to an obstetrician-gynecologist, preferably one 
experienced in reproductive toxicity fo r further evaluation and counseling.
If the outcome of the pregnancy was abnormal (eg, spontaneous abortion), the Investigator 
should report the abnormal outcome as an AE.  If the abnormal outcome meets any of the serious criteria, it must be reported as an SAE to Ce lgene Drug Safety by [CONTACT_6972], or other appropriate 
method, within 24 hours of the Investigatorâ€™s knowledge of the event using the SAE Report 
Form, or approved equivalent form.
All neonatal d eaths that occur within [ADDRESS_1024369] to 
causality, as SAEs.  In addition, any infant d eath after 30 days that the Investigator suspects is 
related to the in utero exposure to the IP should also be reported to Celgene Drug Safety by [CONTACT_6972], or other appropri ate method, within 24 hours of the Investigatorâ€™s knowledge of the 
event using the SAE Report Form, or approved equivalent form.
11.4.2. Male Subjects
If a female partner of a male subject taking investigational product becomes pregnant while the 
subject is receiving investigational product or within [ADDRESS_1024370] dose of IP (or longer if required by [CONTACT_5277]). The ICF will address any country-
specific requirements, as needed.&(/*(1([ZIP_CODE],(7$5<,1)250$7,21in a n a 
ale e 
r if requiredr if require
nititiates newiates ne
events.  events.  
suspected psuspected 
gSafSafetetfffy yim
eport Formport Form
n of the prn of the
ofof the preg the preff
ort Form, ort Form,
cianian--gynecgyne
valaluatuatlllion anna
al (eal (eg,g,sponspon
AEAE.  .  If theIf the
o Celo Cel gene gene
sttigatorâ€™s knigatorâ€™s
mm..
within 30within [ADDRESS_1024371] taking
advised todvised to
bstetribstetr
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 69 CC-486-NSCL-001 Final: 15 May 201511.5. Reporting of Serious Adverse Events
Any AE that meets any criterion for an SAE requires the completion of an SAE Report Form in 
addition to being recorded on the AE page/screen of the CRF.  Any serious adverse event, or 
follow up to a serious adverse event, including death due to any cause other than progression of 
the cancer under study that occurs to any subject from the time the consent is signed through [ADDRESS_1024372] 
initiates new anticancer therapy, whichever is earlier, whether or not related to the Sponsor's 
product  must be reported to Celgene Drug Safety within 24 hours of the Investigatorâ€™s knowledge of the event by [CONTACT_6972], or other appropriate method, using the SAE Report Form, 
or approved equivalent form.  This instruction pe rtains to initial SAE reports as well as any 
follow-up reports.
The Investigator is required to ensure that the data on these forms is accurate and consistent.  
This requirement applies to all SAEs (regardle ss of relationship to study drugs) that occur during 
the study (from the time the subject signs informed  consent until [ADDRESS_1024373] dose of 
either IP) or any SAE made known to the Investig ator at anytime thereafter that are suspected of 
being related to IP.  SAEs occurring prior to treatment (after signing the ICF) will be captured.
The SAE report should provide a detailed description of the SAE and include a concise summary
of hospi[INVESTIGATOR_27598].  If a subject died and an autopsy has been 
performed, copi[INVESTIGATOR_27599] d eath certificate are to be sent to Celgene Drug 
Safety as soon as these become available.  Any follow-up data should be detailed in a subsequent SAE Report Form, or approved equivalent form, and sent to Celgene Drug Safety.  
Where required by [CONTACT_19666], the Investigator is responsible for informing the IRB/Ethics 
Committee (EC) of the SAE and providing them with all relevant init ial and follow-up 
information about the event. The Investigator must keep copi[INVESTIGATOR_748972]/EC.
11.5.1. Safety Queries
Queries pertaining to SAEs will be communicated from Celgene Drug Safety to the site via 
facsimile or electronic mail.  The response time is expected to be no more than five (5) business days.  Urgent queries (eg, missing causality assessment) may be handled by [CONTACT_648].
11.6. Expedited Reporting of Adverse Events
For the purpose of regulatory reporting, Celgene Drug Safety will determine the expectedness of events suspected of being related to CC-486 based on the Investigator Brochure.
In the [LOCATION_002], all suspected unexpected serious adverse reactions (S[LOCATION_003]Rs) will be 
reported in an expedited manner in accordance with 21 CFR 312.32.
For countries within the European Economic Area (EEA), Celgene or its authorized 
representative will report in an expedited manner to Regulatory Authorities and Ethics 
Committees concerned, suspected unexpected serious adverse reactions (S[LOCATION_003]Rs) in accordance 
with Directive 2001/20/EC and the Detailed Guidance on collection, verification and presentation of adverse reaction reports arising from clinical trials on investigational products for 
human use (ENTR/CT3) and also in accordance with country-specific requirements.&(/*(1([ZIP_CODE],(7$5<,1)250$7,21orm, m, 
anyy
consistent.onsistent
) that occurthat occu
er ther the le last ast
fter that are er that 
he ICF)he ICF) wiwi
and includnd includ
died and andied an
e are to be sare to be s
p data shoudata sh
sent to Celgsent to Celg
tor is respotor is resp
m witm wit h all rh all 
or must keeor must kee
and the IRBand the IRB
l be cobe co mmummu
The respoThe respo
missing camissing ca
ited Repoed Repo
of regulatoof regulato
cted of beincted of bein
nited Statesd State
ted in an exted in an ex
or countrior countri ee
representepresent
ommomm
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 70 CC-486-NSCL-001 Final: [ADDRESS_1024374].
Events of  disease progression for the disease under study (including deaths due to disease 
progression for indications that are considered to be fatal) will be assessed as expected adverse 
events and will not be reported as expedited safety reports to regulatory authorities.
Celgene or its authorized representative sh all notify the Investigator of the following 
information:
!Any AE suspected of being related to the use of IP in this study or in other studies 
that is both serious and unexpected (i.e., S[LOCATION_003]R);
!Any finding from tests in laboratory animals that suggests a significant risk for 
human subjects including reports of mutagenicity, teratogenicity, or carcinogenicity.
Where required by [CONTACT_19666], the Investigator shall notify his/her IRB/EC promptly of 
these new serious and unexpected AE(s) or significant risks to subjects.
The Investigator must keep copi[INVESTIGATOR_748973]/EC.  (See Section 15.[ADDRESS_1024375] retention 
information).
Celgene Drug Safety Contact [CONTACT_7171]:For Celgene Drug Safety contact [CONTACT_3031], please refer to the Serious Adverse Event Report 
Form Completion Guidelines or to the Pregnancy Report Form Completion Guidelines.
11.7. Pembrolizumab Events of Clinical Interest
Selected adverse events are also known as Events of Clinical Interest (ECI) and must be recorded 
as such on the Adverse Event CRFs and reported within 5 days of the Investigatorâ€™s knowledge 
of the event, regardless of whether or not the Investigator considers the event related to the IP. Ifthe event meets serious criteria (SAE), the event must also reported to Celgene Drug Safety 
within [ADDRESS_1024376] for this trial include, but are not limited to :
1. an overdose of pembrolizumab, as defined in Section 8.2.2 - Overdose, that is not 
associated with clinical symptoms or abnormal laboratory results. See Section 11.1 for a 
description of how overdoses of pembrolizumab are to be documented (with or without 
associated adverse events).
2. an elevated AST or ALT lab value that is greater than or equal to 3X the upper limit of 
normal and an elevated total bilirubin lab value that is greater than or equal to 2X the upper 
limit of normal and, at the same time, an alkaline phosphatase lab value that is less than 2X 
the upper limit of normal, as determined by [CONTACT_453115]-specified laboratory testing or 
unscheduled laboratory testing.*&(/*(1([ZIP_CODE],(7$5<,1)250$7,21didies e
t risk for risk for 
carcinogencarcinog
B/EC promB/EC prom
n on file incon file inc
fofor recordcor
refer to therefer to the
Report FReport F orr
Clinical IClinical I
as Events oas Events o
nd reportednd reported
or not the Ir not the 
(SAE), the (SAE), the 
or other apor other ap
as outlined outlined
rest foest fo r thii
se of pembrse of pemb
wiwiththiii clinicaclinih
oon of how n of how
iated advered adver
an elevaan elev
normnorm alal an anll
limit omit o
ththee
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 71 CC-486-NSCL-001 Final: 15 May 2015*Note:  These criteria are based upon availab le regulatory guidance documents. The purpose 
of the criteria is to specify a threshold of abnormal hepatic tests that may require an 
additional evaluation for an underlying etiology.  
There are additional ECIs identified in the Appendix C guidance document which also need to be 
reported to the Sponsor within 5 days of the Inve stigatorâ€™s knowledge of the event by [CONTACT_749014], regardless of whether or not the Investigator considers the event 
related to the IP, and if deemed serious (SAE), also reported to Celgene Drug Safety within [ADDRESS_1024377] additional 
testing to rule out other etiologic causes.  If lab results or symptoms indicated a possible immune-related ECI then additional testing s hould be performed to rule out other etiologic 
causes.  If no other cause was found, then it is assumed to be immune-related.
In addition, any pembrolizumab ECIs that become known to the investigator >30 days to â‰¤[ADDRESS_1024378] be reported to the sponsor within 5 days of the Investigatorâ€™s knowledge 
of the event by [CONTACT_749015]. If the event is deemed serious (SAE), it 
must also be reported to Celgene Drug Safety within 24 hours by [CONTACT_6972], or other appropriate 
method, using the SAE Report Form, or approved equivalent form as outlined in Section 11.5.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21munemune --relrelateate
ddidititiional onal 
a possible possible
other etiother eti olo
ated.ated.
sttigator >3igator >
t dose of pedose of p
whether orwheth
ysysofof the In the Inff
ffthte evente event
4 hours by4 hours by
[CONTACT_749016] 
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 72 CC-486-NSCL-001 Final: [ADDRESS_1024379] :
!Adverse Event
!Progressive Disease
!Symptomatic deterioration (global deterioration of h ealth status)
!Physician decision
!Withdrawal by [CONTACT_1130]
!Death
!Lost to follow-up
!Protocol violation
!Other (to be specified on CRF)
The reason for discontinuation of tr eatment shoul d be recorded in the CRF and in the source 
documents.
The decision to discontinue a subject from tr eatment remains the responsibility of the treating 
physician, which will not be delayed or refused by [CONTACT_456].  However, prior to discontinuing 
a subject, the Investigator may contact [CONTACT_617256].
12.2. Study Discontinuation
The following events are considered sufficient reasons for discontinuing a subject from the study:
!Adverse Event
!Progressive disease
!Withdrawal by [CONTACT_1130]
!Death
!Lost to follow-up
!Protocol violation
!Other
The reason for st udy discontinuation s hould be recorded in the CRF and in the source 
documents.&(/*(1([ZIP_CODE],(7$5<,1)250$7,21corded in thorded in
ententremainremain
d by [CONTACT_749017] b
DeathDeath
!!Lost tost t
!!PP
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 73 CC-486-NSCL-001 Final: [ADDRESS_1024380] the responsible Clinical Research 
Physician/Medical Monitor or designee by [CONTACT_27722](s) listed on the Emergency 
Contact [CONTACT_27723] (after title page).
In the unlikely event that the Clinical Research Physician/Medical Monitor or designee cannot be 
reached, please contact [CONTACT_27724] (after title page).This global Emergency 
Call Center is available 24 hours a day and 7 days a week. The representatives are responsible for obtaining your call-back information and c ontacting the on call Celgene/contract research 
organization (CRO) Medical Monitor, who will then contact [CONTACT_27726].
Note: The back-up 24-hour global emergency contact [CONTACT_292053](s) or Medical Monitor or designee for 
emergency calls. 
13.2. Emergency Identification of Investigational Products
The blind must not be broken during the course of the study unless in the opi[INVESTIGATOR_689], it is absolutely necessary to safely treat the subject. IF it is medically imperative to 
know what IP the subject is receiving, IP should be  temporarily discontinued if, in the opi[INVESTIGATOR_15960], continuing IP can negatively affect the outcome of the subjectâ€™s treatment.
The decision to break the blind in emergency situations remains the responsibility of the treating 
physician, which will not be delayed or refused by [CONTACT_1034]. However, the Investigator may contact [CONTACT_81695], mainly in the 
interest of the subject.
The Investigator should ensure that the code is broken only in accordance with the protocol.  The 
Investigator should promptly notify the Medical Monitor of the emergency unblinding and the 
reason for breaking the blind, which should be c learly documented by [CONTACT_292054]â€™s source documentation.
Emergency unblinding should only be performed by [CONTACT_292055] (PIN), and the Investigator should call IRT 
for unblended dose information.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21not be ot b
ed on d on 
EmEmergencyergenc
esponsibleesponsible
ract researcact resear
nlynlybby[CONTACT_749018] s e d
or or designr or desig
nal Produnal Pro
dydyunless inunless inyy
he subject. Ie subject. I
temporarilytemporari
fect the outcect the out
y situations y situations
fused by [CONTACT_749019]
y notify the notify the 
ind, which d, which 
mentatmentat ion.
ding sding s houlhouldd
inding persinding per
d dose infodose info
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 74 CC-486-NSCL-001 Final: [ADDRESS_1024381], evaluation, and 
documentation of this study are designed to ens ure that Celgene, its authorized representative, 
and Investigator abide by [CONTACT_23663] (GCP), as described in International 
Conference on Harmonisation (ICH) Guideline E6 and in accordance with the general ethical principles outlined in the Declaration of Helsi nki. The study will receive approval from an 
IRB/EC prior to commencement. The Investigator w ill conduct all aspects of this study in 
accordance with applicable national, state, and local laws of the pertinent regulatory authorities.
14.2. Investigator Responsibilities
Investigator responsibilities are set out in the ICH Guideline for Good Clinical Practice and in the local regulations.  Celgene staff or an authorized representative will evaluate and approve all Investigators who in turn will select their staff.
The Investigator should ensure that all persons assi sting with the study ar e adequately informed 
about the protocol, amendments, study treatments, as well as study-related duties and functions, including obligations of confidentiality of Celgene information. The Investigator should maintain 
a list of Sub-investigators and other appropriately qualified persons to whom he or she has 
delegated significant study-related duties.
The Investigator is responsible for keepi[INVESTIGATOR_007] a record of all subjects who sign an informed consent 
document and are screened for entry into the study.  Subjects who fail screening must have the 
reason(s) recorded in the subjectâ€™s source documents.
The Investigator, or a designated member of the Investigatorâ€™s staff, must be available during 
monitoring visits to review data, resolve queries and allow direct access to subject records (eg, 
medical records, office charts, hospi[INVESTIGATOR_1332], and study-related charts) for source data verification.  The Investigator must ensure timely and accurate completion of CRFs and queries.
The information contained in the protocol and amendments (with the exception of the 
information provided by [CONTACT_184689]) is considered Celgene confidential 
information.  Only information that is previously disclosed by [CONTACT_184690] a public registry 
website may be freely disclosed by [CONTACT_184691], or as outlined in the Clinical 
Trial Agreement.  Celgene protocol, amendment and IB information is not to be made publicly 
available (for example on the Investigatorâ€™s or their institutionâ€™s website) without express written 
approval from Celgene.  Information proposed  for posting on the Investigatorâ€™s or their 
institutionâ€™s website must be submitted to Celgene for review and approval, providing at least [ADDRESS_1024382] and/or their caregiver as agreed by [CONTACT_1560].
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21in 
authoriauthori titiiieses
ical Practiccal Practic
evaluate anvaluate
study are audy are 
studystudy -relaterel
atioonn. The I. The
fied personsfied person
ord of all surd of all su
study.  Subjtudy.  Subj
documents.ocuments
ber of the Iner of the I
olve querieolve quer
ospi[INVESTIGATOR_198477]
d in the pron the pro
yy Celgene Celgeneyy
nfformormfff ataioionn
reely discloreely disclo
ent.  Celnt.  Cel genge
for exampleor example
fromomf  CelCelm g
utitionâ€™s webonâ€™s web
siness daysness days
AtAt the tim the tim
vestvest
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 75 CC-486-NSCL-001 Final: [ADDRESS_1024383] and/or a subjectâ€™s legal representative 
prior to any study related procedures.
Documentation that informed consen t occurred prior to the study subjectâ€™s entry into the study 
and of the informed consent process should be recorded in the study subjectâ€™s source documents including the date.  The original ICF signed and dated by [CONTACT_292057]â€™s entry into the study, must be maintained 
in the Investigatorâ€™s study files and a copy given to  the study subject.  In addition, if a protocol is 
amended and it impacts on the content of the informed consent, the ICF must be revised.  Study 
subjects participating in the study when th e amended protocol is implemented must be re-
consented with the revised version of the ICF.  The revised ICF signed and dated by [CONTACT_292058] s ubject must be maintained  in the Investigatorâ€™s 
study files and a copy given to the study subject.
14.4. Confidentiality
Celgene affirms the subject's right to protection against invasion of privacy and to be in 
compliance with ICH and other local regulations (whichever is most stringent). Celgene requires 
the Investigator to permit Celgene's representatives and, when necessary, representatives from 
regulatory authorities, to review and/or copy any medical records relevant to the study in 
accordance with local laws.
Should direct access to medical records require  a waiver or authorization separate from the 
subjectâ€™s signed ICF, it is the responsibility of the Investigator to obtain such permission in writing from the appropriate i ndividual.
14.5. Protocol Amendments
Any amendment to this protocol must be approved by [CONTACT_184693]/Medical Monitor.  Amendments will be submitted to the IRB/EC for written approval.  
Written approval must be obtained before implementation of the amended version occurs.  The 
written signed approval from the IRB/EC should specifically reference the Investigator name, protocol number, study title and amendment number(s) that is applicable. Amendments that are 
administrative in nature do not require IRB/IEC approval but will be submitted to the IRB/IEC 
for information purposes.
14.6. Institutional Review Board/Independent Ethics Committee Review 
and Approval
Before the start of the study, the study protoc ol, ICF, and any other appropriate documents will 
be submitted to the IRB/EC with a cover letter or a form listing the documents submitted, their 
dates of issue, and the site (or region or area of jurisdiction, as applicable) for which approval is sought. If applicable, the documents will also be submitted to the authorities in accordance with 
local legal requirements.
IP can only be supplied to an Investigator by [CONTACT_72648] a nd legal requirements for starting the study has been received by &(/*(1([ZIP_CODE],(7$5<,1)250$7,21ol is ol is
Study Study 
re-
the studythe study
Investnvest igatoigato
privacyivacy ananydd
ost stringenst stringen
necessary, necessa
cords relevcords relev
iver or authver or au
InvestInve igatoiga
st be approvt be app
endments wndments 
ned beforened before
m m ththe IRB/Ee IRB
tlle and ameand 
re do not ree do not re
poses.poses.
nstitutionnstitution
anand Appd App
e the start oe the start o
submitted tubmitted t
dates of issdates of iss
sought. ought
al
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 76 CC-486-NSCL-001 Final: [ADDRESS_1024384] of the 
members of the IRB/EC and their occupation and qualifications. If the IRB/EC will not disclose 
the names, occupations and qualifications of the committee members, it should be asked to issue 
a statement confirming that the composition of the committee is in accordance with GCP. For example, the IRB General Assurance Number may be accepted as a substitute for this list. 
Formal approval by [CONTACT_1201]/EC should mention the protocol title, number, amendment number 
(if applicable), study site (or region or area of jurisdiction, as applicable), and any other 
documents reviewed. It must mention the date on which the decision was made and must be 
officially signed by a commi ttee memb er. Before the first subject is enrolled in the study, all 
ethical and legal requirements must be met.
The IRB/EC and, if applicable, the authorities, must be informed of all subsequent protocol 
amendments in accordance with local legal requirements. Amendments must be evaluated to 
determine whether formal approval must be sought and whether the ICF should also be revised.
The Investigator must keep a record of all comm unication with the IRB/EC  and, if applicable, 
between a Coordinating Investigator [INVESTIGATOR_72616] /EC. This statement also applies to any 
communicatio n between the Investigator (or Coordinating Investigator, if applicable) and 
regulatory authorities.
Any advertisements used to recruit subjects for the study must be reviewed by [CONTACT_27734]/EC prior to use.
14.7. Ongoing Information for Institutional Review Board / Ethics 
Committee
If required by [CONTACT_27735]/EC, the Investigator must submit to the IRB/EC:
!Information on serious or unexpected adverse events as soon as possible; 
!Periodic reports on the progress of the study;
!Deviations from the protocol or anything that may involve added risk to subjects.
14.8. Termination of the Study
Celgene reserves the right to terminate this st udy prematurely at any time for reasonable medical 
or administrative reasons. Any premature discont inuation  will be appropriately documented 
according to local requirements (eg, IRB/EC, regulatory authorities, etc).
In addition, the Investigator or Celgene has the right to discontinue a single site at any time 
during the study for medical or administrative reasons such as:
!Unsatisfactory enrollment;
!GCP noncompliance;
!Inaccurate or incomplete data collection;
!Falsification of records;
!Failure to adhere to the study protocol.&(/*(1([ZIP_CODE],(7$5<,1)250$7,21otocol ocol 
aluated to aluated to 
also be revalso be rev
and, if appand, if app
o applies toapplie
r, if applicar, if applic
be reviewee revi
nanal Reviel Revie
vestigator mestigator 
pected advepected adv
gress of thegress of the
otocolotoco  or aorl
of the Stuof the S
ht to terminht to term
sons. Anyons. Any py
requiremerequireme
e InvestInvest igaig
studytudy ffyyor mor mff
!!UnsatUnsat ii
!!GG
!
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 77 CC-486-NSCL-001 Final: 15 May 201515. DATA HANDLING AND RECORDKEEPI[INVESTIGATOR_1645] 
15.1. Data/Documents
The Investigator must ensure that the records and documents pertaining to the conduct of the 
study and the distribution of the investigat ional product are complete, accurate, filed and 
retained.  Examples of source documents include: hospi[INVESTIGATOR_1097]; clinic and office charts; 
laboratory notes; memoranda; subjectâ€™s diaries or evaluation checklists; dispensing records; recorded data from automated instruments; copi[INVESTIGATOR_27602]; microfiche; X-ray f ilm and re ports; and records kept at the pharmacy, and 
the laboratories, as well as copi[INVESTIGATOR_27603]-ROM.
15.2. Data Management
Data will be collected via CRF and entered into the clinical database per Celgene standard operating procedures (SOPs). This data will be electronically verified through use of
programmed edit checks specified by [CONTACT_6098].  Discrepancies in the data will be brought 
to the attention of the clinical team, and investigational site personnel, if necessary.  Resolutions 
to these issues will be reflected in the database.  An audit trail within the system will track all changes made to the data.
15.3. Record Retention
Essential documents must be retained by [CONTACT_184694]. The Investigator must retain these documents for the time period described above or according to local laws or requirements, whichever is longer. Essential 
documents include, but are not limited to, the following:
!Signed informed consent documents for all subjects;
!Subject identification code list, screening log (if applicable), and enrollment log;
!Record of all communications between the Investigator and the IRB/EC;
!Composition of the IRB/EC;
!Record of all communications between the Investigator, Celgene, and their authorized 
representative(s);
!List of Sub-investigators and other appropriately qualified persons to whom the 
Investigator has delegated significant study-related duties, together with their roles in 
the study, curriculum vitae, and their signatures;
!Copi[INVESTIGATOR_3110] (if paper) and of documentation of corrections for all subjects;
!IP accountability records;
!Record of any body fluids or tissue samples retained;
!All other source documents (subject records, hospi[INVESTIGATOR_1097], laboratory records, 
etc.); &(/*(1([ZIP_CODE],(7$5<,1)250$7,21on as n as 
macy, and cy, and
elgene elgene stanstan
hrough use ugh us
es in the das in the d
nnel, if necenel, if nec
wiiththiiin the sin 
stigator acctigator acc
must retainmust reta
r requiremr requirem
the follothe follo ww
documents documen
codecode list, slist, 
mmummu nicatinica o
ofof the IRBe IRf
f all coall co mmmm
sentative(ssentative(s ))
ist of Subist of Sub
InvestInvest igaiga
thhe stues t u
!!CoCo
!
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 78 CC-486-NSCL-001 Final: 15 May 2015!All other documents as listed in Section 8 of the ICH consolidated guideline on GCP 
(Essential Documents for the Conduct of a Clinical Trial).
The Investigator must notify Celgene if he/she wishes to assign the essential documents to 
someone else, remove them to another location or is unable to retain them for a specified period.  
The Investigator must obtain approval in writi ng from Celgene prior to destruction of any 
records. If the Investigator is unable to meet this obligation, the Investigator must ask Celgene 
for permission to make alternative arrangements. Details of these arrangements should be 
documented. 
All study documents should be made availabl e if required by [CONTACT_27737]. 
Investigator/Institution should take measures to prevent accidental or premature destruction of 
these documents.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21tiontionofof
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 79 CC-486-NSCL-001 Final: [ADDRESS_1024385] to current GCP and SOPs.
16.1. Study Monitoring and Source Data Verification
Celgene ensures that appropriate monitoring procedures are performed before, during and after the study.  All aspects of the study are reviewed with the Investigator and the staff at a studyinitiation visit and/or at an Investigator meeting.  Prior to enrolling subjects into the study, a 
Celgene representative will review the protoc ol, CRFs, procedures for obtaining informed 
consent, record keepi[INVESTIGATOR_007], and reporting of AEs/SAEs with the Investigator.  Monitoring will include on-site visits with the Investigat or and his/her staff as  well as any appropriate 
communications by [CONTACT_2319], email, fax, or telephone.  During monitoring visits, the facilities, 
investigational product storage area, CRFs, s ubjectâ€™s source documents, and all other study 
documentation w ill be inspected/reviewed by [CONTACT_27738].
Accuracy will be checked by [CONTACT_12939] a direct comparison of 
the entries made onto the CRFs against the appropriate source documentation.  Any resulting 
discrepancies will be reviewed with the Investigator and/or his/her staff.  Any necessary 
corrections will be made directly to the CRFs or via queries by [CONTACT_11219]/or his/her staff. Monitoring procedures require that informed consents, adherence to inclusion/exclusion 
criteria and documentation of SAEs and their proper recording be verified.  Additional 
monitoring activities may be outlined in a study-specific monitoring plan.
16.2. Audits and Inspections
In addition to the routine monitoring procedure s, a Good Clinical Practice Quality Assurance 
unit exists within Celgene.  Representatives of this unit will conduct audits of clinical research 
activities in accordance with Celgene SOPs  to evaluate compliance with Good Clinical Pract ice 
guidelines and regulations.
The Investigator is required to permit direct access to the facilities where the study took place, 
source documents, CRFs and applicable supporting records of study subject participation for 
audits and inspections by [CONTACT_1744]/IECs, re gulatory authorities (eg, FDA, EMA, H ealth Canada) and 
company authorized representatives.  The Investigator should make every effort to be available for the audits and/or inspections.  If the Inves tigator is contact[CONTACT_72652], he/she should contact [CONTACT_27740].
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21y
y, aa
med med 
iing will ng will iii
pripriate ate 
the facilitthe facilit iei
nd all other d all other 
e in accordan acco
that ihas a diad
documentdocume
r his/her stahis/her st
ries by [CONTACT_749020], adhonsents, adh
per recordiner recordin
y--specispeci fic mfic 
proceduresprocedu
sentatives osentatives o
elgene SOPlgene SOP
red to permred to pe
RFs and apRFs and a
oons by [CONTACT_749021]
s and/or inss and/or ins
an inspectn inspect
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 80 CC-486-NSCL-001 Final: [ADDRESS_1024386] authorship, will be based on 
several considerations, including, but not limited to, contribution to protocol development, study 
recruitment, data qu ality, participation in d ata analysis, participation in study steering committee 
(when applicable) and contribution to abstract, presentation and/or publication development.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21ttific ific 
pplies to plies to 
edical edical 
se developmse develop
nd maynd may bbye
d id its results resulii tsl
stries, as wries, as w
ealalthtlll authouthh
t authorshipt authorsh
ibution to pi[INVESTIGATOR_198478] p
, participati participat
entation andentation a
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 81 CC-486-NSCL-001 Final: [ADDRESS_1024387] supportive care (BSC) vs 
BSC in inoperable non-small cell lung cancer â€“ a  randomized trial with quality of life as the 
primary outcome. Br J Cancer. 2000;83(4):447-453.
Bang YJ. The potential for crizotinib in non-small cell lung cancer: a perspective review. Ther 
Adv Med Oncol. 2011;3(6):279-291.
Brahmer JR, Pardoll DM. Immune checkpoint inhibitors: making immunotherapy a reality for 
the treatment of lung cancer. Cancer Immunol Res. 2013;1(2):85-91.
Brahmer JR, Horn L, Antonia SJ, et al. Survival and long-term follow-up of the phase I trial of 
nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with previously treated 
advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2013;(suppl; abstr 8030).
Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of anti-PD-L1 antibody in 
patients with advanced cancer. N Engl J Med. 2012;366(26):2455-2465.
Bria E, Cuppone F, Ciccarese M, et al. Weekly docetaxel as second line chemotherapy for 
advanced non-small-cell lung cancer: meta-analysis of rando mized trials. Cancer Tr eat Rev. 
2006;32(8):583-587.
Crino L, Mosconi AM, Scagliotti G, et al. Gemcitabine as second-line treatment for advanced 
non-small-cell lung cancer: a phase II trial. J Clin Oncol. 1999;17(7):2081-2085.
Edge SB, By[CONTACT_3238], Compton CC, et al. AJCC cancer  Staging Manual. 7th Ed. Springer, 2009.
Eisenhauer E, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: 
revised RECIST guideline (vers ion 1.1). Eur J Ca ncer. 45(2): 228-247.
ESMO Clinical Practice Guidelines: Metas tatic Non-Sm all-Cell Lung Cancer. Available at: 
www.esmo.org/Guidelines/Lung-Cancer/Metastatic-Non-Small-Cell-Lung-Cancer . Accessed 
11Feb2015.
Fossella FV, DeVore R, Kerr RN, et al. Rando mized phase III trial of  docetaxel versus 
vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol. 2000;18(12):2354-2362.
Garcia-Manero G, Gore SD, Cogle C, et al. Phase I study of oral azacitidine in myelodysplastic 
syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol. 2011;29(18):2521-2527.
Garon EB, Leighl NB, Rizvi NA, et al. Safety and clinical activity of pembrolizumab in 
previously treated patients (pts) with non-small cell lung cancer (NSCLC) [abstract]. In: Proceedings of the 2014 ASCO Annual Meeting; 2014 May 30-Jun 3; Chicago, IL. J Clin Oncol.
32:5s, 2014 (suppl; abstr 8020).
Gilotrif [package insert]. Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, [LOCATION_003]. 
Revised April 2014.
Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalance Worldwide in 2012. 
Available at: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
. Accessed 11Feb2015&(/*(1([ZIP_CODE],(7$5<,1)250$7,21for or f
se I trise I tri alal ofoll
sly treated sly treated 
str 8030).r 8030).
L1 antibodL1 antibod
..
d line chemd line che
eed tritrals. CC
s secondsecond -li
ool.l. 1999;17 1999;1
ncer Staginncer Stagi
ew responsew respons
ur J Cancerr J Cance
etastatitastat c NN
ancer/Metancer/Met2
r RN, et al.r RN, et al
in patin pat ieients
ng chemothng chemot
Gore SD, CGore SD, 
onic myeloonic myelo
:2521:2521 --25272527
B, Leighl NLeighl 
ously treateously treate
oceedings oceedings o
32:5s, 2012:5s, 201
ilotriilotri
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 82 CC-486-NSCL-001 Final: [ADDRESS_1024388] FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus 
docetaxel in patients with non-small-cell lung can cer previously treated with chemotherapy. J 
Clin Oncol. 2004;22(15):1589-1597.
Harvey RD. Immunologic and clinical effects of ta rgeting PD-1 in lung cancer. Clin Pharmacol 
Ther. 2014;96(2):214-223.
Juergens RA, Wrangle J, Vendetti FP, et al. Combination epi[INVESTIGATOR_748974]. Cancer Discov. 2011;1(7):598-607.
Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell 
lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008;372(9652):1809-1818.
Lang-Lazdunski L. Surgery for nonsmall cell lung cancer. Eur Respir Rev. 2013;22(129):382-
404.
Miranda RB, Jones PA. DNA methylation: the nuts and volts of repression. J Cell Physiol. 
2007;213(2):384-390.
NCCN Practice Guidelines in Oncology: Non-Small Cell Lung Cancer v.4.2014.  Available at: 
http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf . Accessed 11Feb2015.
Nishimura H, Honjo T, Minato N. Facilitation of Î² selection and modification of positive 
selection in the thymus of PD-1-deficient mice. J Exp Med 2000;191(5):891-898.
Perol M, Ciuleanu TE, Arrieta O. REVEL: A randomized, double-blind, phase III study of 
docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease 
progression after one prior platinum-based therapy. J Clin Oncol. 2014; 32 (5s): suppl; abstr 
LBA8006.
Peterson P, Park K, Fossella FV, et al. Is pemetrexed more effective in adenocarcinoma and 
large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III 
trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): P2-328 [abstract]. In: 12th World Conference on Lung Cancer. J of Thoracic 
Oncol 2007;2([ADDRESS_1024389] 4):S851.
Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus 
placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 
3, double-blind, randomised controlled trial. Lancet Oncol. 2014; 15(2): 143 -155.
Sculier JP, Lafitte JJ, Berghmans T, et al. A phase II trial testing gemcitabine as second-line 
chemotherapy for non small cell lung cancer. Lung Cancer. 2000;29(1):67-73.
Shaw AT, Kimm D-W, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-
positive lung cancer. N Engl J Med. 2013;368(25):2385-2394.
Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best 
supportive care in patients with non-small-cell lung cancer previously treated with platinum-
based chemotherapy. J Clin Oncol. 2000;18(10):2095-2103.
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et  al. Erlotinib in previously treated non-small-
cell lung cancer. N Engl J Med. 2005;353 (2):123-132. &(/*(1([ZIP_CODE],(7$5<,1)250$7,21ell ll 
8.8.
29)29):382:382-
Cell Physioell Physi
v.4.2014.  v.4.2014
ssed 11Febed 11Feb
mmodificatodificat
000;191(5)000;191(5
d, double-, double b
B) versus DB) versus 
ng cancer (ng cancer 
apy. J Clin Opy. J Clin O
pemetrexepemetrexe
us cell carcius cell carc
previously reviously
act]. In: 12tact]. In: [ADDRESS_1024390] F
supportivupportiv
sedsed
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 83 CC-486-NSCL-001 Final: [ADDRESS_1024391]. 2000;80(7):1031-1041.
Tarceva [package insert]. OSI Pharmaceuticals, LLC, Northbrook, IL, [LOCATION_003] an affiliate of 
Astellas Pharma US, Inc., 2012.
Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive car e in previously treated 
patients with refractory advanced non-small -cell lung cancer: results from a randomised, 
placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 
2005;366(9496):1527-1537.
Topalian SL. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J 
Med. 2012;366(26):2443-2454.
Topaloglu, O, Hoque, MO, Tokumaru, Y, et al.  Detection of promoter hypermethylation of 
multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer. Clin Cancer Res. 2004;10(7):2284â€“2288.
Xalkori [package insert]. Pf izer Labs, [LOCATION_001], NY, [LOCATION_003], revised Aug, 2011.
Zeng L, Jarrett C, Brown K, et al. Insulin-like growth factor binding protein-3 (IGFBP-3) plays a 
role in the anti-tumorigenic effects of 5-Aza-2â€™-deoxycytidine (AZA) in breast cancer cells. Exp 
Cell Res. 2013;319(14):2282-2295.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21N Engl J N Engl J 
thylatthylat ioion on
g cancer. Clg cancer. C
Aug, Aug, 2011.2011.
ing proteing protein
(AZA) in b(AZA) 
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 84 CC-486-NSCL-001 Final: 15 May 201519. APPENDICES
19.1. Appendix A: RECIST 1.1
The following information is extracted/summarized from Eisenhauer, 2009 , New response
evaluation criteria in solid tumors:  Revised RECIST guideline (version 1.1). Please refer to the 
primary reference for further information.
19.1.1. Definitions
At screening, tumor lesions/lymph nodes will be categorized as measurable or non-measurable.
[IP_ADDRESS]. Measurable Disease
Tumor Lesions: Must be accurately measured in at least one dimension (longest diameter in the 
plane of measurement is to be recorded) with a minimum size of:
![ADDRESS_1024392] scan (CT scan slice thickness no greater than 5 mm)
!10 mm caliper measurement by [CONTACT_461] (lesions which cannot be accurately 
measured with calipers should be recorded as non-measurable)
![ADDRESS_1024393] X-ray
Malignant Lymph Nodes: To be considered pathologically enlarged and measurable, a lymph 
node must be â‰¥ [ADDRESS_1024394] scan (CT scan slice thickness 
recommended to be no greater than 5 mm). At baseline and in follow-up, only the short axis will 
be measured and followed.
19.1.2. Tumor Response Evaluation19.1.2.1. Target Lesions
When more than one measurable tumor lesion is present at baseline all lesions up to a maximum 
of 5 lesions total (and a maximum of 2 lesions per organ) representative of all involved organs 
should be identified as target lesions and will  be recorded and measured at baseline. Target
lesions should be selected on the basis of their size (lesions with the longest diameter), be 
representative of all involved organs, but in addi tion should be those that lend themselves to 
reproducible repeated measurements. Note that  pathological nodes must meet the measurable 
criterion of a short axis of â‰¥ [ADDRESS_1024395] scan and only the short axis of these nodes will 
contribute to the baseline sum. All other pathological nodes (those with short axis â‰¥ 10 mm but 
< 15 mm) should be considered non-target lesions. Nodes that have a short axis < 10 mm are 
considered non-pathological and should not be recorded or followed. At baseline, the sum of the 
target lesions (longest diameter of tumor lesions plus short axis of lymph nodes:  overall 
maximum of 5) is to be recorded.
After baseline, a value should be provided on the CRF for all identified target lesions for each 
assessment, even if very small. If extremely small and faint lesions cannot be accurately 
measured but are deemed to be present, a default value of 5 mm may be used. If lesions are too 
small to measure and indeed are believed to be absent, a default value of 0 mm may be used.&(/*(1([ZIP_CODE],(7$5<,1)250$7,21asurabsurab le.le.
est diest d ametemete
n 5 mm)n 5 mm)
which cannwhich cann
measurable)measura
cally enlargcally enlarg
by[CONTACT_749022] 2imum of
rget lrget l esiesons
cted on the ted on the
l invol invo lved lved 
peated measeated mea
short axis ohort axis 
to the baseo the base
m) should bm) should 
idered nondered non
arget lesioarget lesio nn
maximummaximum
ter
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 85 CC-486-NSCL-001 Final: 15 May 201519.1.2.2. Non-target Lesions
All non-measurable lesions (or sites of disease) plus any measurable lesions over and above 
those listed as target lesions are considered non-target lesions. Measurements are not required 
but these lesions should be noted at baseline and should be followed as â€œpresent,â€ â€œabsent,â€ or â€œunequivocal progression.â€
[IP_ADDRESS]. Response Criteria
Target and non-target lesions are evaluated for re sponse separately, and then the tumor burden as 
a whole is evaluated as the overall response.
[IP_ADDRESS].1. Target Lesion Response
Target lesions will be assessed as follows:
!Complete Response (CR).  Disappearance of all target lesions. Any pathological 
lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.
!Partial Response (PR).  At least a 30% decrease in the sum of diameters of target 
lesions, taking as reference the baseline sum diameters.
!Progressive Disease (PD).  At least a 20% increase in the sum of diameters of target 
lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum 
must also demonstrate an absolute increas e of at least 5 mm. (Note:  the appearance 
of one or more new lesions is  also considered progression).
!Stable Disease (SD).  Neither sufficient shrinkage to qualify for PR nor sufficient 
increase to qualify for PD, taking as reference the smallest sum of diameters while on 
study.
[IP_ADDRESS].2. Non-target Lesion Response
Non-target lesions will be assessed as follows:
!Complete Response (CR).  Disappearance of all non-target lesions and normalisation 
of tumor marker level. All lymph nodes must be non-pathological in size (< 10 mm short axis).
!Non-CR/Non-PD.  Persistence of one or more non-target lesion(s) and/or 
maintenance of tumor marker level above the normal limits.
!Progressive Disease (PD).  Unequivocal progression (see comments below) of 
existing non-target lesions. (Note: the appearance of one or more new lesions is also 
considered progression).
When the Subject Also Has Measurable Disease:   In this setting, to achieve â€œunequivocal 
progressionâ€ on the basis of the non-target disease, there must be an overall level of substantial 
worsening in non-target disease such that, even in presence of SD or PR in target disease, the 
overall tumor burden has increased sufficiently to merit discontinuation of therapy. A modest â€œincreaseâ€ in the size of one or more non-target lesions is usually not sufficient to quality for &(/*(1([ZIP_CODE],(7$5<,1)250$7,21as as 
ny pathoy patho lolog
n in short ain short a
um of diamum of dia
rs.
se in the suse in the su
on studyn study (th(thyy
to the relto the rel aa
ase of at lease of at le
nsidered prnsidered pr
fficient shrifficient shr
king as refeking as refe
ResponseResponse
sessed as fosessed as f
sponse (CRsponse (C
mmarker larker eveev
xis).xis).
nn--CR/NonCR/Non
maintenancmaintenan
!!Progrerogre
exisexis
When tWhen 
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 86 CC-486-NSCL-001 Final: [ADDRESS_1024396] Has Only Non-measurable Disease:   This circumstance arises in some 
Phase [ADDRESS_1024397] measurable disease. The same 
general concepts apply here as noted above; however, in this instance there is no measurable 
disease assessment to factor into the interpretation of an increase in non-measurable disease burden. Because worsening in non-target disease cannot be easily quantified (by [CONTACT_108]:  if all 
lesions are truly non-measurable) a useful test that can be applied when assessing subjects for 
unequivocal progression is to consider if the increase in overall disease burden based on the change in non-measurable disease is comparable in magnitude to the increase that would be 
required to declare PD for measurable disease: ie, an increase in tumor burden representing an 
additional 73% increase in â€œvolumeâ€ (which is  equivalent to a 20% increase diameter in a 
measurable lesion). Examples include an increase in  a pleural effusion from â€œtraceâ€ to â€œlarge,â€ 
an increase in lymphangitic disease from localized to widespread, or may be described in 
protocols as â€œsufficient to require a change in therapy.â€ If â€œunequivocal progressionâ€ is seen, the subject should be considered to have had overall PD at that point. While it would be ideal to 
have objective criteria to apply to non-measurable disease, the very nature of that disease makes 
it impossible to do so: therefore, the increase must be substantial.
[IP_ADDRESS].3. Overall Response
Overall response should be assessed according to Table 8 for subjects with target lesions, and
Table 9 for subjects with only non-target lesions.
Table 8: Time Point Response: Subjects With Target (Â± Non-target) Disease
Target Lesions 
Response Non-target Lesion Response New Lesions Overall Response
CR CR No CR
CR Non-CR/ non-PD No PR
CR Not evaluated No PR
PR Non-PD or not all evaluated No PR
SD1Non-PD or not all evaluated No SD
Not all evaluated Non-PD No NE
PD Any Yes or No PD
Any PD Yes or No PD
Any Any Yes PD
CR = complete response, NE = inevaluable, PD = progressive disease, PR = partial response, SD = stable disease&(/nyy(/*(1(3NonNon-PD D35235,(7$5<,1)250$7,21all all 
or r 
the he 
uld be ld be 
esentesent ing anng an
meter in a meter in a 
ttraceâ€ to â€œaceâ€ to â€œ
be describee describe
progressioprogress
hile it wouile it wou
ry nature ofy nature o
al.al.
lele88fofor subr su
ts With Tats With Ta
Lesion Respsion Resp5,
23 R/ nonR/ non --PDPD52 ot evaluatedevaluated35(31(NonNon1(1(1(1( dd N(1111
*(/*(/&(CR = compCR = comp
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 87 CC-486-NSCL-001 Final: 15 May 2015Table 9: Time Point Response: Subjects With Non-target Disease Only
Non-target Lesion Response New Lesions Overall Response
CR No CR
Non-CR/ non-PD No Non-CR/non-PD1)a
Not all evaluated No NE
Unequivocal PD Yes or No PD
Any Yes PD
CR = complete response, PD = progressive disease, NE =  inevaluable
aâ€œNon-CR/non-PDâ€ is preferred over â€œstable diseaseâ€ for non-target disease since SD is increasingly used as 
endpoint for assessment of efficacy in some trials so to assign this category when no lesions can be measured is 
not advised.
[IP_ADDRESS]. Symptomatic Deterioration
Subjects with a global deterioration of health status requiring discontinuation of treatment 
without objective evidence of disease progression at that time should be reported as â€˜symptomatic deteriorationâ€™. Every effort should be made to document objective progression 
even after discontinuation of treatment. Symptom atic deterioration is not a descriptor of an 
objective response: it is a reason for stoppi[INVESTIGATOR_12003]. The objective response status of such subjects is to be determined by [CONTACT_12157]-target disease.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21$7$7$70$$7$used as ed as 
e measured ie measured i
uatioion of n of tr
d be reportebe report
ment objecment objec
tion is on is not 
 The objecThe objec
and nonnd non -tar
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 88 CC-486-NSCL-001 Final: 15 May 201519.2. Appendix B: irRECIST
Table 10: Imaging Guidance for Standard RECIST 1.1 and Immune-related (ir) RECIST
&(priprietet0$7,21e Corporae Corpora
21

('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 89 CC-486-NSCL-001 Final: 15 May 2015Table 10: Imaging Guidance for Standard RECIST 1.1 and Immune-related (ir) RECIST (Continued)
&(priprietet7,21e Corporae Corpora
21

('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 90 CC-486-NSCL-001 Final: 15 May 2015Table 10: Imaging Guidance for Standard RECIST 1.1 and Immune-related (ir) RECIST (Continued)
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21e Corporae Corpora
21
priprietet

('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 91 CC-486-NSCL-001 Final: 15 May 2015Table 10: Imaging Guidance for Standard RECIST 1.1 and Immune-related (ir) RECIST (Continued)
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21e Corporae Corpora
21
priprietet

('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 92 CC-486-NSCL-001 Final: 15 May 2015Table 10: Imaging Guidance for Standard RECIST 1.1 and Immune-related (ir) RECIST (Continued)
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21e Corporae Corpora
21
priprietet

('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 93 CC-486-NSCL-001 Final: 15 May 2015Table 10: Imaging Guidance for Standard RECIST 1.1 and Immune-related (ir) RECIST (Continued)
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21e Corporae Corpora
21
priprietet

('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 94 CC-486-NSCL-001 Final: 15 May 2015Table 10: Imaging Guidance for Standard RECIST 1.1 and Immune-related (ir) RECIST (Continued)
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21e Corporae Corpora
21
priprietet
(/
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 95 CC-486-NSCL-001 Final: 15 May 2015Table 10: Imaging Guidance for Standard RECIST 1.1 and Immune-related (ir) RECIST (Continued)
priprietet7,21e Corporae Corpora
21

('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 96 CC-486-NSCL-001 Final: 15 May 2015Table 10: Imaging Guidance for Standard RECIST 1.1 and Immune-related (ir) RECIST (Continued)
&(priprietet7,21e Corporae Corpora
21

('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 97 CC-486-NSCL-001 Final: 15 May 2015Table 10: Imaging Guidance for Standard RECIST 1.1 and Immune-related (ir) RECIST (Continued)
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21e Corporae Corpora
21
priprietet

('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 98 CC-486-NSCL-001 Final: 15 May 201519.3. Appendix C: Events of Clinical Interest (ECI) Guidance Document
19.3.1. Overview
The purpose of this appendix is to provide st udy sites with guidance on the identif ication and 
management of ECIs associated with pembrolizumab.
Based on the literature review, and considerat ion of mechanism of action of pembrolizumab, 
potential immune-related adverse events (irAEs) are the primary Event of ECI. Immune-related 
AEs are adverse events associated with the treatment of patients with immunotherapy treatments that appear to be associated with the immune therapyâ€™s mechanism of action. Based on these 
potential irAEs, the Sponsor has defined a lis t of specific adverse event terms (ECIs) that are 
selected adverse experiences that must be reported to Sponsor within 5 days from the time the 
Investigator/physician is aware of such an occurrence, regardless of whether or not the 
Investigator/physician considers the event to be  related to IP. ECIs may be identified through 
spontaneous patient report and/or upon review of subject data. Table [ADDRESS_1024398] is not comprehensive for all potential 
immune-related events, it is possible that AEs othe r than those listed in this document may be 
observed in patients receiving pembrolizumab. Therefore any Grade 3 or higher event that the 
Investigator/physician considers to be immune-related should be reported as an ECI regardless of 
whether the specific event term is in Table 11 and reported to Sponsor within 5 days from the 
time the Investigator/physician is aware of such an occurrence. Adverse events that are both an 
SAE and an ECI should be reported on both the eCRF and also reported to Celgene Drug Safety 
within 24 hours by [CONTACT_6972], or other appropriate method, using the SAE Report Form, or approved equivalent form as outlined in Section 11.5.
Table 11: Events of Clinical Interest
Pneumonitis (reported as ECI if  â‰¥ Grade 2)
Acute interstitial pneumonitis Inter stitial lung dis ease Pneumonitis
Colitis (reported as ECI if â‰¥ Grade 2 or any grade resulting in dose modification or use of systemic steroids to 
treat the AE)
Intestinal Obstruction Co litis Colitis mic roscopic
Enterocolitis Enterocolitis hemorrhagic Gastrointestinal perforation
Necrotizing colitis Diarrhea
Endocrine (reported as ECI if  â‰¥ Grade 3 or â‰¥ Grade 2 and resulting in dose modification or use of systemic 
steroids to treat the AE)
Adrenal Insufficiency Hyperthyroidism Hypophysitis
Hypopi[INVESTIGATOR_90573], if â‰¥Grade 3 and associated with ketosis or 
metabolic acidosis (DKA) &hyhyroroyyyidid&(/*nal Insufficienal Insufficie/*(1([ZIP_CODE],(7$5<,1)250$7,21ments ents
ese ese
hat are hat are 
mmththe time te time 
ot the ot the 
ententified throified thr
ovides the lovides the 
ehensive foensive fo
sted in this d in this
GrGrade [ADDRESS_1024399]
de 2)2)23IntInt52525252ade 2 or anyade 2 or a3555
(31( s(1 reported as eported as 
o treat the Aeat the A*(/*
Hypopi[INVESTIGATOR_748975](/&(
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 99 CC-486-NSCL-001 Final: 15 May 2015Table 11: Events of Clinical Interest (Continued)
Endocrine (reported as ECI)
Type 1 diabetes mellitus (if new onset)
Hematologic (reported as ECI if  â‰¥ Grade 3 or any grade resulting in dose modification or use of systemic 
steroids to treat the AE)
Autoimmune hemolytic anemia Aplastic anemia Thrombotic Thrombocytopenic 
Purpura (TTP)
Idiopathic (or immune) Thrombocytopenia Purpura  (ITP)Disseminated Intravascular 
Coagulation (DIC)Haemolytic Uraemic Syndrome 
(HUS)
Any Grade 4 anemia regardless of underlying mechanism
Hepatic (reported as ECI if  â‰¥ Grade 2, or any grade resulting in dose modification or use of systemic steroids 
to treat the AE)
Hepatitis Autoimmune hepatitis Transaminase elevations (ALT 
and/or AST)
Infusion Reactions (reported as ECI for any grade)
Allergic reaction Anaphylaxis Cytokine release syndrome
Serum sickness Infusion reactions Infusion-like reactions
Neurologic (reported as ECI for any grade)
Autoimmune neuropathy Guillain-Barre syndrome Demyelinating polyneuropathy
Myasthenic syndrome
Ocular (report as ECI if  â‰¥ Grade 2 or any grade resulting in dose modification or use of systemic steroids to 
treat the AE)
Uveitis Iritis
Renal (reported as ECI if  â‰¥ Grade 2)
Nephritis Nephritis autoimmune Renal Failure
Renal failure acuteCreatinine elevations (report as ECI if â‰¥Grade 3 or any grade 
resulting in dose modification or use of systemic steroids to treat the 
AE)
Skin (reported as ECI for any grade)
Dermatitis exfoliative Erythema multiforme Stevens-Johnson syndrome
Toxic epi[INVESTIGATOR_90574] (reported as ECI if â‰¥ Grade 3)
Pruritus Rash Rash generalized
Rash maculo-papular
Any rash considered clinically significant in the physicianâ€™s judgment 
Other (reported as ECI for any grade)
Myocarditis Pancreatitis Pericarditis
Any other Grade 3 event which is considered immune-related by [CONTACT_099]&(/h maculomaculo -papa(/*(1([ZIP_CODE],tistis5,(7$5<,1)250$7,217ome me 77$70$ systemic steystemic st50
inase elevationase elevati
AST)AST)25
1) Cytokine okiney,1<InfusiIn<<<5<5<5<5< ndromendrome$57$ulting in doseting in do(75,35Nephep222352CC52525252
or any gradeor any gra(31( necrolysisecrolysis(1 ted as ECI id as ECI i*(/*(/ AnyAn rash cosh coy&(herh&
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 100 CC-486-NSCL-001 Final: 15 May 2015Each of the events above is described within this guidance document, along with site 
requirements for reporting these events to th e Sponsor.  In addition, the guidelines include 
recommendations on the management of these ECIs. These guidelines are intended to be applied 
when the Investigator determines the events to be related to pembrolizumab. Note: if after the 
evaluation the event is determined not to be related, the Investigator is instructed to follow the 
ECI reporting guidance but does not need to follow the treatment guidance (below). Therefore, 
these recommendations should be seen as guidelines and the treating physician should exercise individual clinical judgment based on the patient.  For any question of dose modification or other 
treatment options, the specific language in the protocol should be followed.  Any questions 
pertaining to the collection of this information or management of ECIs s hould be directed to your 
local Sponsor contact. 
[IP_ADDRESS]. Dose Modification/Discontinuation
The treatment guidance provides specific direction when to hold and/or discontinue 
pembrolizumab for each immune-related adverse event.   Of note, when the guidance states to 
â€œdiscontinueâ€ pembrolizumab this is the permanent discontinuation of treatment with 
pembrolizumab. â€œHoldâ€ means to stop treating with  pembrolizumab but resumption of treatment 
may be considered assuming the patient m eets the criteria for resumption of treatment.
19.3.2. ECI Reporting Guidelines
Events of clinical interest are selected non-serious and serious adverse experiences that must be 
reported to Sponsor within 5 days for NON-SERIOUS events
regardless of attribution to study 
treatment.  The AEs listed in this document and any event that meets the ECI criteria (as noted) in Table 11 or in the respective protocol (event term and Grade) must be reported regardless of 
physician-determined causality with IP and whether or not considered immune-related by [CONTACT_24201] (unless otherwise specified).   Physicians/study  coordinators/designated site personnel 
are required to record these experiences as ECIs on the Adverse Event CRF and to provide 
supplemental information (such as medical history, concomitant medications, investigations, 
etc.) about the event.  
NOTE:  Any event that meets the criteria for SERIOUS adverse event (SAE), must be 
reported to the Celgene Drug Safety within 24 hours by [CONTACT_6972], or other appropriate 
method, using the SAE Report Form, or approved equivalent form as outlined in Section 11.5.
!Please refer to the CRF Completion Guidelines. 
!Please refer to protocol for details on reporting timelines and reporting of overdose 
19.3.3. ECI Categories and Terms
This section describes the ECI categories and outlines subject management guidelines when an 
ECI is reported.
[IP_ADDRESS]. Pneumonitis
The following AE terms, if considered â‰¥ Grade 2, are considered ECIs and should be reported to 
the Sponsor on the Adverse Event CRF within 5 da ys if determined to be a non-serious event:r r 
to yto your our 
ntinue in
guidance sguidance 
eatment watmen
but resumput resump
mptmpi[INVESTIGATOR_748976]7$y event thay event tha
term and Germ and 
whether or nwhether or n5,hyhysicians/ssicians/s
s as ECIs oas ECIs 
medical histedical hi
ets the critets the crit
Drug Safetrug Safet
E Report FE Report 
e refer to te refer to t
PlPlease referease refer
ECI CCI C
is sects sect ioon n 
ECI iEC s reps rep
3
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 101 CC-486-NSCL-001 Final: 15 May 2015!Pneumonitis
!Interstitial lung disease
!Acute interstitial pneumonitis 
If symptoms indicate possible new or worsening cardiac abnormalities additional testing and/or a 
cardiology consultation s hould be considered. 
All attempts should be made to rule out other cau ses such as metastatic disease, bacterial or viral 
infection.  It is important that patients with a suspected diagnosis of pneumonitis be 
managed as per the guidance below until treatment-related pneumonitis is excluded.  
Treatment of both a potential infectious etiology and pneumonitis in parallel may be warranted.  Management of the treatment of suspected pneumonitis with steroid treatment should not be delayed for a therapeutic trial of antibiotics.   If an alternative diagnosis is 
established, the patient does not require management as below; however the AE should be reported regardless of etiology.
NOTE:  Any event that meets the criteria for SERIOUS adverse event (SAE), must be reported 
to the Celgene Drug Safety within 24 hours by [CONTACT_6972], or other appropriate method, using the SAE Report Form, or approved equivalent form as outlined in Section 11.5.
Course of Action
Grade 2 events:
!Report as ECI
!Hold pembrolizumab
!Consider pulmonary consul tation with bronchoscopy and biopsy/bronchoalveolar 
lavage (BAL)
!Consider infectious disease (ID) consult
!Conduct an in person evaluation approximately twice per week
!Consider frequent chest X-ray as part of monitoring
!Treat with systemic corticosteroids at a dose of 1 to 2 mg/kg/day prednisone or 
equivalent.  When symptoms improve to Grade 1 or less, steroid taper should be 
started and continued over no less than 4 weeks.  
!Permanently discontinue for inability to redu ce corticosteroid dose to 10 mg or less of 
prednisone or equivalent per day within 12 weeks.   
!Second epi[INVESTIGATOR_55517] â€“ discontinue pembrolizumab if upon re-challenge the 
patient develops a second epi[INVESTIGATOR_575394] 2 or higher pneumonitis.
Grade 3 and 4 events:
!Report as ECI
!Discontinue pembrolizumab
!Hospi[INVESTIGATOR_28068]&(/*(1([ZIP_CODE],(7$5<,1)250$7,21be 
d treatmend treatmen
agnosis gnosis is is 
E should beE should 
SAE), musAE), m
propriate mropriate m
tioion 11.511.5
wiwiththiii broncbronchh
e (e (IDID))cons
evaluatevaluat ioonn
cchest Xhest X -r
stemic cortstemic co
.  When sym.  When 
and continuand continu
mmanentanent ly lyd
prednisone prednisone
!!SecondSecond
patipati
Grade 3 anGrade 3 an
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 102 CC-486-NSCL-001 Final: 15 May 2015!Bronchoscopy with biopsy and/or BAL is recommended.
!Immediately treat with intravenous steroids (methylprednisolone 125 mg IV). When 
symptoms improve to Grade 1 or less, a high dose oral steroid (prednisone 1 to 2 
mg/kg once per day or dexamethasone 4 mg every 4 hours) taper should be started 
and continued over no less than 4 weeks.
!If IV steroids followed by [CONTACT_749023] 48 to 72 hours, treat with additional anti-inflammatory measures. Discontinue 
additional anti-inflammatory measures upon symptom relief and initiate a prolonged 
steroid taper over 45 to 60 days. If symptoms worsen during steroid reduction, initiate a retapering of steroids starting at a higher dose of 80 or 100 mg followed by a more 
prolonge d taper and administer additional anti-inflammatory measures, as needed.
!Add prophylactic antibiotics for opportunistic infections.
NOTE:  Any event that meets the criteria for SERIOUS adverse event (SAE), must be reported 
to the Celgene Drug Safety within 24 hours by [CONTACT_6972], or other appropriate method, using the 
SAE Report Form, or approved equivalent form as outlined in Section 11.5.
[IP_ADDRESS]. Diarrhea/Colitis
The following AE terms, if considered â‰¥ Grade 2 or resulting in dose modification or use of 
systemic steroids to treat the AE, are considered ECIs and should be reported to the Sponsor on 
the Adverse Event CRF within 5 days if determined to be a non-serious event:
!Colitis 
!Colitis microscopic
!Enterocolitis
!Enterocolitis hemorrhagic 
!Gastrointestinal perforation
!Intestinal obstruction 
!Necrotizing colitis
!Diarrhea
All attempts should be made to rule out othe r causes such as metastatic disease, bacterial or 
parasitic infection, viral gastroenteritis, or the first manifestation of an inflammatory bowel 
disease by [CONTACT_323843], stool cultures, a Clostridium difficile titer and endoscopy.   However the AE should be reported regardless of etiology.
Course of Action
Grade 2 Diarrhea/Colitis (4-6 stools/day over baseline, dehydration requiring IV fluids < 24 
hours, abdominal pain, mucus or blood in stool):  
!Report as ECI
!Hold pembrolizumab&(/*(1([ZIP_CODE],(7$5<,1)250$7,21ged ed 
iniintitiiate ate 
yya mmy ore ore 
s neededs needed ..
E), must be ), must be
riate methoiate m
11.511.5..
ggin dose min dose m
d should bed should be
be a nonbe a non --ss
rationration
ion ion 
colioltiis
oululd be madd be ma
ctioion, viraln, viral
exxaminataminat ioi
opyop.   How How
urse of Acurse of Ac
Grade 2 DGrade 2 D
ours, ours,
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 103 CC-486-NSCL-001 Final: 15 May 2015!Symptomatic Treatment
!For Grade 2 diarrhea that persists for greater than 3 days, and for diarrhea with blood 
and/or mucus, 
oConsider GI consultation and endoscopy to confirm or rule out colitis 
oAdminister oral corticosteroids (prednisone 1-2 mg/kg once daily or 
equivalent)
!When symptoms improve to Grade 1 or less, steroid taper should be started and 
continued over no less than 4 weeks.   
!Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of 
prednisone or equivalent per day within 12 weeks.
!If symptoms worsen or persist > 3 days treat as Grade 3
Grade 3 Diarrhea/Colitis (or Grade 2 diarrhea that persists for > 1 week):
!Report as ECI
!Hold pembrolizumab
!Rule out bowel perforation.  Imaging wi th plain films or CT can be useful
!Recommend consultation with gastroenterologist and confirmation biopsy with 
endoscopy
!Treat with intravenous steroids (methylprednisolone 125 mg) followed by [CONTACT_5019]-dose 
oral steroids (prednisone 1 to 2 mg/kg on ce per day or dexamethasone 4 mg every 4 
hours).  When symptoms improve to Grade 1 or less, steroid taper should be started and continued over no less than 4 weeks.  Taper over 6 to 8 weeks in patients with 
diffuse and severe ulceration and/or bleeding.
!Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of 
prednisone or equivalent per day within 12 weeks.
!If IV steroids followed by [CONTACT_5019]-dose oral steroids does not reduce initial symptoms 
within 48 to 72 hours, consider treatment with additional anti-inflammatory measures 
as described in the literature ( Topalian, 2012 ). Discontinue additional anti-
inflammatory measures upon symptom relief and initiate a prolonged steroid taper over 45 to 60 days. If symptoms worsen during steroid reduction, initiate a retapering 
of steroids starting at a higher dose of 80 or 100 mg followed by a more  prolonged 
taper and administer additional anti-inflammatory measures as needed. 
Grade 4 events: 
!Report as ECI
!Permanently discontinue pembrolizumab
!Manage as per Grade 3&(/*(1([ZIP_CODE],(7$5<,1)250$7,21g or lg or l ess ofess o
ms or CT cms or C
gist and conist and con
prednisopredniso lo
kg once perg once pe
e to Grade e to Grade 
n 4 weeks. n 4 weeks
n and/or bland/or b
ue for inabifor inabi
alent per daalent per da
llolowed by [CONTACT_749024]
72 hours, co72 hours,
ed in the lited in the 
matorymatory mmyyeea
45 to 60 d45 to 60 d
steroisteroiff ds stds s
taper andaper and
4 events: 4 events: 
!R
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 104 CC-486-NSCL-001 Final: 15 May 2015NOTE:  Any event that meets the criteria for SERIOUS adverse event (SAE), must be reported 
to the Celgene Drug Safety within 24 hours by [CONTACT_6972], or other appropriate method, using the 
SAE Report Form, or approved equivalent form as outlined in Section 11.5.  
[IP_ADDRESS]. Endocrine
The following AE terms, if considered â‰¥Grade 3 or if â‰¥Grade 2 and require 
holding/discontinuation/ modification of pembrolizumab dosing, are considered ECIs and should 
be reported to the Sponsor on the Adverse Event CRF within 5 days if determined to be a non-serious event:
!Adrenal insufficiency
!Hyperthyroidism
!Hypophysitis
!Hypopi[INVESTIGATOR_297] 
!Hypothyroidism
!Thyroid disorder 
!Thyroiditis 
All attempts should be made to rule out other cau ses such as brain metastases, sepsis and/or 
infection.  However the AE should be reported regardless of etiology.
Hypophysitis or other symptomatic endocrinopathy other than hypo- or hyperthyroidism
Grade 2-4 events:
!Report as ECI if appropriate
!Hold pembrolizumab
!Rule out infection and sepsis with appropriate cultures and imaging.
!Monitor thyroid function or other hormonal level tests and serum chemistries more 
frequently until returned to baseline values.
!Pi[INVESTIGATOR_748977] (MRIs with gadolinium and selective 
cuts of the pi[INVESTIGATOR_748978]).
!Treat with prednisone 40 mg orally or equiv alent per day.  When symptoms improve 
to Grade 1 or less, steroid taper should be started and continued over no less than 4 
weeks.  Replacement of appropriate hormones may be required as the steroid dose is 
tapered. 
!Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of 
prednisone or equivalent per day within 12 weeks. 
!Hypophysitis with clinically significant adrenal insufficiency and hypotension, 
dehydration, and electrolyte abnormalities (such as hyponatremia and hyperkalemia) constitutes adrenal crisis.&(/*(1([ZIP_CODE],(7$5<,1)250$7,21as brain mas brain m
ess of etioess of etio lol
athy other athy other
(7
sepsis witsepsis wi h
nctnctioion or on or 
returned toeturned t
and imaginand imagin
he pi[INVESTIGATOR_748979]).osis).
reat wireat wi ththipphh
to Grade o Grade
weekseeks
taptap
!!
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 105 CC-486-NSCL-001 Final: 15 May 2015!Consultation with an endocrinologist may be considered.
Hyperthyroidism and Hypothyroidism
Thyroid disorders can occur at any time duri ng treatment. Monitor patients for changes in 
thyroid function (at the start of treatment, periodically during treatment, and as indicated based 
on clinical evaluation) and for clinical signs and symptoms of thyroid disorders.
Grade 2 hyperthyroidism, Grade 2-4 hypothyroidism events:
!Report as ECI if appropriate (see Table 11 )
!Monitor thyroid function or other hormonal level tests and serum chemistries more 
frequently until returned to baseline values.
!Thyroid hormone and/or steroid replacement ther apy to manage adrenal insufficiency.
!Therapy with pembrolizumab can be continued while treatment for the thyroid 
disorder is instituted. 
!In hyperthyroidism, non-selective beta-blocker s (eg, propranolol) are suggested as 
initial therapy. 
!In hypothyroidism, thyroid hormone replacement therapy, with levothyroxine or 
liothyroinine, is indicated per standard of care. 
!Consultation with an endocrinologist may be considered.
Grade 3 hyperthyroidism events:
!Report as ECI
!Hold pembrolizumab
!Rule out infection and sepsis with appropriate cultures and imaging.
!Treat with an initial dose of methylpredniso lone 1 to 2 mg/kg intravenously followed 
by [CONTACT_88316] 1 to 2 mg/kg per day.  When symptoms improve to Grade 1 or 
less, steroid taper should be started and continued over no less than 4 weeks. 
Replacement of appropriate hormones may be required as the steroid dose is tapered.
!Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of 
prednisone or equivalent per day within 12 weeks.
Grade 4 hyperthyroidism events:
!Report as ECI
!Discontinue pembrolizumab
!Manage as per Grade 3
NOTE:  Any event that meets the criteria for SERIOUS adverse event (SAE), must be reported 
to the Celgene Drug Safety within 24 hours by [CONTACT_6972], or other appropriate method, using the 
SAE Report Form, or approved equivalent form as outlined in Section 11.5.  &(/*(1([ZIP_CODE],(7$5<,1)250$7,21more more 
al insufficieinsuffici
r the thyr the thy roiroy
nolonolol)l) are s are
erapy, withrapy,
consideredonsider
s witwith apprh app
e of mof methyethy
to 2 mg/kgto 2 mg/kg
should beshould be
f appropriaappropria
ly discontily discon
one or equione or equi
thyhyroiroiyydismdism
Report as Report as 
!!Diiscosco
!!MM
NOTE:  NOTE
theh
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 106 CC-486-NSCL-001 Final: 15 May 2015Type 1 diabetes mellitus (if new onset) and â‰¥ Grade 3 Hyperglycemia
The following AE terms are considered ECIs and should be reported to the Sponsor on the 
Adverse Event CRF within 5 days if determined to be a non-serious event:
!Type 1 diabetes mellitus (T1DM), if ne w onset, including diabetic ketoacidosis 
(DKA) 
!Grade 3 or higher hyperglycemia, if associated with ketosis (ketonuria) or metabo lic 
acidosis (DKA).
Immune-mediated diabetes may present as new ons et of type 1 diabetes or an abrupt worsening 
of pre-existing diabetes associated with laboratorial evidence of beta cell failure. All attempts 
should be made to rule out other causes such as type 2 diabetes mellitus (T2DM), T2DM decompensation, steroid-induced diabetes, physiologic stress-induced diabetes, or poorly 
controlled pre-existing diabetes (either T1DM or T2DM), but events meeting the above criteria 
should be reported as ECIs regardless of etiolo gy. The patients may present with hyperglycemia 
(abrupt onset or abrupt decompensation) with  clinical evidence of diabetic ketoacidosis or 
laboratory evidence of insulin deficiency, such as ketonuria, laboratory evidence of metabolic 
acidosis, or low or undetected c-peptide.
Course of ActionT1DM should be immediately treated with insulin.
Type 1 diabetes mellitus or Grade 3-4 hyperglycemia events:
!Report as ECI if appropriate (see Table 11 )
!Hold pembrolizumab for new onset type 1 diabetes mellitus or Grade 3-4 
hyperglycemia associated with evidence of beta cell failure, and resume 
pembrolizumab when patients are clinically and metabolically stable. 
!Insulin replacement therapy is recommended for type 1 diabetes mellitus and for 
Grade 3-4 hyperglycemia associated with metabolic acidosis or ketonuria. 
!Evaluate patients with serum glucose and a metabolic panel, urine ketones, 
glycosylated hemoglobin, and C-peptide. 
!Consultation with an endocrinologist is recommended.
!Consider local testing for islet cell antibod ies and antibodies to  GAD, IA-2, ZnT8, 
and insulin may be obtained.
NOTE:  Any event that meets the criteria for SERIOUS adverse event (SAE), must be reported 
to the Celgene Drug Safety within 24 hours by [CONTACT_6972], or other appropriate method, using the 
SAE Report Form, or approved equivalent form as outlined in Section 11.5.  
19.3.4. Hematologic
The following AE term, if considered Grade â‰¥3 or requiring dose modification or use of 
systemic steroids to treat the AE, are considered an ECI and should be reported to the Sponsor on 
the Adverse Event CRF within 5 days if determined to be a non-serious event:&(/*(1([ZIP_CODE],(7$5<,1)250$7,21ic c
worsening orsening 
l attempts l attempts
, T2DM , T2DM 
s, or poorlys, or poorly
ng the abovng the abov
sent wint wi thtii hyh
betbetic ketoaic ketoa
atorytoevideevidy
mia events:mia events:
ableble1111))
nset tnset t ype 1ype
iththievidencevidenhh
tients are clients are
theraptherap y yis ris r
lycemia asslycemia ass
ents with seents with
ed hemogloed hemog
ltattatioionnwiwiththiii
onsider loconsider loc
and insuliand insuli
E:  Any eveE:  Any eve
he Celgenehe Celgene
SAE ReporSAE Repor
.3.434
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 107 CC-486-NSCL-001 Final: 15 May 2015!Autoimmune hemolytic anemia
!Aplastic anemia
!Disseminated Intravascular Coagulation (DIC)
!Haemolytic Uraemic Syndrome (HUS)
!Idiopathic (or immune) Thrombocytopenia Purpura (ITP)
!Thrombotic Thrombocytopenic Purpura (TTP)
!Any Grade 4 anemia regardless of underlying mechanism
All attempts should be made to rule out other causes such as metastases, sepsis and/or infection.   
Relevant diagnostic studies such as peripheral blood smear, reticulocyte count, LDH, haptoglobin, bone marrow biopsy or Coombâ€™s test, etc., should be considered to confirm the 
diagnosis. However the AE should be reported regardless of etiology.
Course of Action
Grade 2 events:
!Report as ECI
!Hold pembrolizumab
!Prednisone 1-2 mg/kg daily may be indicated
!Consider hematology consul tation.
!Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of 
prednisone or equivalent per day within 12 weeks.
Grade 3 events:
!Report as ECI
!Hematology consultati on. 
!Hold pembrolizumab   Discontinuation shoul d be considered as per specific protocol 
guidance.
!Treat with methylprednisolone 125 mg iv or prednisone 1-2 mg/kg orally (or 
equivalent) as appropriate
!Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of 
prednisone or equivalent per day within 12 weeks.
Grade 4 events:
!Report as ECI
!Hematology consultation
!Discontinue pembrolizumab for all solid tu mor indications; refer to protocol for 
hematologic malignancies.&(/*(1([ZIP_CODE],(7$5<,1)250$7,21infectnfect ioion. n.
H, H, 
confirm thconfirm th
y y to reduceto reduc
wiwiththiiiin 12 win 12 w
tition. on.
mab   Discmab   Di
hmmhethylprethylp
alent) as appalent) as ap
rmmanentanent lyly
prednisonprednison
4 events:4 events:
!!RR
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 108 CC-486-NSCL-001 Final: 15 May 2015!Treat with methylprednisolone 125 mg iv or prednisone 1-2 mg/kg orally (or 
equivalent) as appropriate
NOTE:  Any event that meets the criteria for SERIOUS adverse event (SAE), must be reported 
to the Celgene Drug Safety within 24 hours by [CONTACT_6972], or other appropriate method, using the 
SAE Report Form, or approved equivalent form as outlined in Section 11.5.
19.3.5. Hepatic
The following AE terms, if considered â‰¥ Grade 2 or greater (or any grade with dose modification 
or use of systemic steroids to treat the AE), are considered ECIs and should be reported to the 
Sponsor on the Adverse Event CRF within 5 days if determined to be a non-serious event:
!Autoimmune hepatitis 
!Hepatitis 
!Transaminase elevations
All attempts should be made to rule out other cause s such as metastatic disease, infection or 
other hepatic diseases. However the AE should be reported regardless of etiology.
Drug-induced Liver Injury (DILI)
In addition, the event must be reported as a drug-induced liver injury (DILI) ECI, if the patient 
meets the laboratory criteria for potential DILI defined as: 
!An ALT or AST lab value that is greater than or equal to three times (3X) the upper 
limit of normal (ULN) and 
!An elevated total bilirubin lab value that is greater than or equal to two times (2X) 
ULN and
!At the same time, an alkaline phosphatase lab value that is less than 2X ULN,
!As a result of with in-protocol-specific testing or unscheduled testing.
Note that any hepatic immune ECI meeting DILI criteria should only be reported once as a DILI 
event.  
Course of Action
Grade 2 events:
!Report as ECI
!Hold pembrolizumab when AST or ALT > 3.[ADDRESS_1024400] and/or total bilirubin 
> 1.[ADDRESS_1024401].
!Monitor liver function tests (LFTs) more fre quently until returned to baseline values 
(consider weekly).
oTreat with 0.5-1 mg/kg/day methylpre dnisolone or oral equivalent and when 
LFT returns to Grade [ADDRESS_1024402] 1 month, &(/*(1([ZIP_CODE],(7$5<,1)250$7,21ion on
the e 
nt:
disease, indisease, 
ss of etioof etio lol
ver ier injurynjury (D(y
: 
than or equhan or e
ue that is grue that is g
ne phosphane phospha
rotocolrotoco -spesp
ECI meetECI meet
s:
Report asReport as
!!Hololdd
>>
!
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 109 CC-486-NSCL-001 Final: 15 May 2015consider prophylactic antibiotics for opportunistic infections, and resume 
pembrolizumab per protocol.
!Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of 
prednisone or equivalent per day within 12 weeks.
!Permanently discontinue pembrolizumab for patients with liver metastasis who begin 
treatment with Grade [ADDRESS_1024403] or ALT increases â‰¥50% 
relative to baseline and lasts â‰¥1 week.
Grade 3 events:
!Report as ECI
!Discontinue pembrolizumab when AST or ALT > 5.[ADDRESS_1024404] and/or total 
bilirubin > 3.[ADDRESS_1024405].  
!Consider appropriate consultation and liver biopsy to establish etiology of hepatic 
injury, if necessary
!Treat with high-dose intravenous glucoc orticosteroids for 24 to 48 hours.  When 
symptoms improve to Grade 1 or less, a steroid taper with dexamethasone 4 mg every 
4 hours or prednisone at 1 to 2 mg/kg should be started and continued over no less 
than 4 weeks. 
!If serum transaminase levels do not decrease 48 hours after initiation of systemic 
steroids, oral my cophenolate mofetil 500 mg every 12 hours may be given. Infliximab 
is not recommended due to its potential for hepatotoxicity.
!Several courses of steroid tapering may be necessary as symptoms may worsen when 
the steroid dose is decreased.
!Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of 
prednisone or equivalent per day within 12 weeks.
Grade 4 events: 
!Report as ECI
!Permanently discontinue pembrolizumab
!Manage patient as per Grade 3 above
NOTE:  Any event that meets the criteria for SERIOUS adverse event (SAE), must be reported 
to the Celgene Drug Safety within 24 hours by [CONTACT_6972], or other appropriate method, using the 
SAE Report Form, or approved equivalent form as outlined in Section 11.5.
19.3.6. Neurologic
The following AE terms, regardless of grade, are c onsidered ECIs and should be reported to the 
Sponsor on the Adverse Event CRF within 5 days if determined to be a non-serious event:
!Autoimmune neuropathy
!Demyelinating polyneuropathy&(/*(1([ZIP_CODE],(7$5<,1)250$7,21total total 
ioiolologygy ofofyhff
24 to 48 ho24 to 48 h
with dexameth dexam
ted and coned an
48 hours a8 hours
mg every 1mg every
ffor hepatoor hepatofff
may be nemay be ne
r inabilitinabil y y
t per day wper day w
y discontiny discontin
e patient ase patient as
event that mvent that 
ene Drug Sne Drug S
port Form, t Form
3.6..6. NeNe
The foThe fo llollo
ponponss
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 110 CC-486-NSCL-001 Final: 15 May 2015!Guillain-Barre syndrome
!Myasthenic syndrome
All attempts should be made to rule out othe r causes such as metastatic disease, other 
medications or infectious causes. However the AE should be reported regardless of etiology.
Course of Action
Grade 2 events:
!Report as ECI
!Moderate (Grade 2) â€“ consider withholding pembrolizumab. 
!Consider treatment with prednisone 1-2 mg/kg orally daily as appropriate
!Consider neurology consul tation. Consider biopsy for confirmation of diagnosis.
!Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of 
prednisone or equivalent per day within 12 weeks.
Grade 3 and 4 events:
!Report as ECI
!Discontinue pembrolizumab
!Obtain neurology consul tation.  Consider biopsy for confirmation of diagnosis.
!Treat with systemic corticosteroids at a dose of 1 to 2 mg/kg prednisone or equivalent 
once per day. If condition worsens consider intravenous immunoglobulin (IVIG) or other immunosuppressive therapi[INVESTIGATOR_748980] 1 or less, steroid taper should be started and continued over 
no less than 4 weeks.
NOTE:  Any event that meets the criteria for SERIOUS adverse event (SAE), must be reported 
to the Celgene Drug Safety within 24 hours by [CONTACT_6972], or other appropriate method, using the 
SAE Report Form, or approved equivalent form as outlined in Section 11.5.
19.3.7. Ocular
The following AE terms, if considered Grade â‰¥2 or requiring dose modification or use of 
systemic steroids to treat the AE, is considered an ECI and should be reported to the Sponsor on the Adverse Event CRF within 5 days if determined to be a non-serious event:
!Uveitis
!Iritis 
All attempts should be made to rule out other causes such as metastatic disease, infection or 
other ocular disease (eg, glaucoma or cataracts). However the AE should be reported regardless 
of etiology.
Course of Action
Grade 2 events: &(/*(1([ZIP_CODE],(7$5<,1)250$7,21ee
of diagnosiof diagno
ose to 10 mse to 10 m
opsy for coopsy for c
dose of 1 tdose of 1 t
onsider onsider intin
es as per es as per lolo
less, steroidess, steroid
criteria forcriteria fo
hhinin24 hou24 hou
ved equivaved equiv
termterms, if cos, if c
ds to treat tds to treat t
Event CRFEvent CRF
UveitUveit isis
!!IriIrititiii
All All attemattem ppmmm
other octher o
t
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 111 CC-486-NSCL-001 Final: 15 May 2015!Evaluation by [CONTACT_308656].
!Treat with topi[INVESTIGATOR_90543]  1% prednisolone acetate suspension and 
iridocyclitics.
!Discontinue pembrolizumab as per protocol if symptoms persist despi[INVESTIGATOR_748981].
Grade 3 events:
!Evaluation by [CONTACT_308656] 
!Hold pembrolizumab and consider permanent discontinuation as per specific protocol 
guidance.
!Treat with systemic corticosteroids such as prednisone at a dose of 1 to 2 mg/kg per 
day.  When symptoms improve to Grade 1 or less, steroid taper should be started and 
continued over no less than 4 weeks.
!Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of 
prednisone or equivalent per day within 12 weeks.
Grade 4 events: 
!Evaluation by [CONTACT_308656] 
!Permanently discontinue pembrolizumab
!Treat with corticosteroids as per Grade 3 above
NOTE:  Any event that meets the criteria for SERIOUS adverse event (SAE), must be reported 
to the Celgene Drug Safety within 24 hours by [CONTACT_6972], or other appropriate method, using the SAE Report Form, or approved equivalent form as outlined in Section 11.5.
19.3.8. Renal
The following AEs if â‰¥ Grade 2 are considered ECIs and should be reported to the Sponsor on 
the Adverse Event CRF within 5 days if determined to be a non-serious event:
!Nephritis
!Nephritis autoimmune
!Renal failure
!Renal failure acute
Creatinine elevations â‰¥ Grade 3 or any grade with dose m odification or use of systemic steroids 
to treat the AE.
All attempts should be made to rule out other cau ses such as obstructive uropathy, progression of 
disease, or injury due to other chemothera py agents.  A renal consultation is recommended. 
However the AE should be reported regardless of etiology.
Course of Action
Grade 2 events:&(/*(1([ZIP_CODE],(7$5<,1)250$7,21protocol rotocol 
o 2 m2 mg/kg pg/kg mm
uld be startuld be sta
d dose to 1dose to
ommended ommended
 above above
ERIOUS adRIOUS a
by [CONTACT_749025]
t form as ot form as o
are consideare consid
in 5 days ifn 5 days if
autoimmunautoimmu
l failurefailure
Renal Renal failurfailur
ne elevatlevat ioio
at the AE.at the AE
All All attemattem ptsptmm&didisease, sease, 
owe
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 112 CC-486-NSCL-001 Final: 15 May 2015!Hold pembrolizumab
!Treatment with prednisone 1-2 mg/kg orally daily.
!Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of 
prednisone or equivalent per day within 12 weeks.
Grade 3-4 events: 
!Discontinue pembrolizumab
!Renal consultation with consideratio n of ultrasound and/or biopsy as appropriate
!Treat with systemic corticosteroids at a dose of 1 to 2 mg/kg prednisone IV or 
equivalent once per day.  
When symptoms improve to Grade 1 or less, steroid taper should be started and continued over 
no less than 4 weeks.
NOTE:  Any event that meets the criteria for SERIOUS  adverse event (SAE), must be reported 
to the Celgene Drug Safety within 24 hours by [CONTACT_6972], or other appropriate method, using the 
SAE Report Form, or approved equivalent form as outlined in Section 11.5.
19.3.9. Skin
Rash and Pruritus
The following AEs should be considered as ECIs, if â‰¥ Grade 3 and should be reported to the 
Sponsor on the Adverse Event CRF within 5 days if determined to be a non-serious event:
!Pruritus
!Rash
!Rash generalized
!Rash maculo-papular
!In addition to CTCAE Grade 3 rash, any rash that is considered clinically significant, 
in the physician's judgment, should be treated as an ECI. Clinical significance is left to the physician to determine, and could possibly include rashes such as the 
following: 
orash with a duration > 2 weeks; OR 
orash that is > 10% body surface area; OR 
orash that causes significant discomfort not relieved by [CONTACT_12523][INVESTIGATOR_748982].
NOTE:  Any event that meets the criteria for SERIOUS adverse event (SAE), must be reported 
to the Celgene Drug Safety within 24 hours by [CONTACT_6972], or other appropriate method, using the 
SAE Report Form, or approved equivalent form as outlined in Section 11.5.&(/*(1([ZIP_CODE],(7$5<,1)250$7,21or 
continued ocontinued 
AE), mAE), m ust btbm
opriate metopriate m
on 11.511.5..
Grade 3 anGrade 3 a
f determinef determin
CAE GradeCAE Grade
n's judgmen judgmen
cian to deterian to det
: 
rash witrash wit h
oorash rash
oo
NOTE:  AnyNOTE:  An
to the Ceo the Ce
AE RAE R
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 113 CC-486-NSCL-001 Final: 15 May 2015Other Skin ECIs
The following AEs should always be reported as ECIs, regardless of grade, and should be 
reported to the Sponsor on the Adverse Event CRF within 5 days if determined to be a non-
serious event:
!Dermatitis exfoliative
!Erythema multiforme
!Stevens-Johnson syndrome
!Toxic epi[INVESTIGATOR_528087], the AE should be reported regardless of etiology.
Course of Action
Grade 2 events:
!Symptomatic treatment should be given such  as topi[INVESTIGATOR_308611] (eg, 
betamethasone 0.1% cream or hydrocortis one 1%) or urea-containing creams in 
combination with oral anti-pruritics  (eg, diphenhydramine hydrochloride [HCl] or 
hydroxyzine HCl). 
!Treatment with oral steroids is at physicianâ€™s discretion for Grade 2 events.
Grade 3 events:
!Hold pembrolizumab.
!Consider dermatology consul tation and biopsy for confirmation of diagnosis.
!Treatment with oral steroids is recommended, starting with 1 mg/kg prednisone or 
equivalent once per day or dexamethasone  4 mg four times orally daily.  When 
symptoms improve to Grade 1 or less, steroid taper should be started and continued 
over no less than 4 weeks.
!Permanently discontinue for in ability to reduce corticosteroid dose to 10 mg or less of 
prednisone or equivalent per day within 12 weeks.
Grade 4 events:
!Permanently discontinue pembrolizumab.
!Dermatology consultation and consider ation of biopsy and clinical dermatology 
photograph.
!Initiate steroids at 1 to 2 mg/kg prednisone or equivalent.  When symptoms improve 
to Grade 1 or less, steroid taper should be started and continued over no less than 4 weeks.
[IP_ADDRESS]. Immediate Evaluation for Potential Skin ECIs
A. Photographs:&(/*(1([ZIP_CODE],(7$5<,1)250$7,21ocorticosterortico
cocontntainingaining
inenhydrochhydro
creticretion fon forf
and biopsynd biopsy
recommenecommen
examexam ethasetha
ade 1 or lesade 1 or 
eks.eks.
ontinue for ontinue for 
equivalent puivalent p
nentently discly disc
rmmatolatologyogy
photograpphotograp
!!Iniittiiiatiat
to Gto G
.3.939
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 114 CC-486-NSCL-001 Final: 15 May 2015Every attempt should be made to get a photograph of the actual ECI skin lesion or rash as soon 
as possible. 
!Take digital photographs of: 
othe head (to assess mucosal or eye involvement), 
othe trunk and extremities, and 
oa close-up of the skin lesion/rash.
!If possible, a ruler should be placed alongside the site of a skin occurrence as a fixed 
marker of distance. 
!The time/date stamp should be set in the 'ON' position for documentation purposes. 
!Photographs should be stored with the subjectâ€™s study records. 
!The Sponsor may request copi[INVESTIGATOR_308612]. The local study contact (eg, clinical 
research associate [CRA]) will provide guidance to the site, if needed. 
B. Past Medical History:
Collect past medical history relevant to the even t. Any pre-existing conditions not previously 
reported (eg, drug allergy) s hould be entere d into the Medical History electronic case report form 
(eCRF). 
C. Vitals Signs and Standard Laboratory Tests:
Measure vital signs and record on the Vital Signs CRF.  Perform standard laboratory tests (CBC 
with differential and serum chemistry panel, including LFTs). 
D. Dermatology Consult
Refer the subject to a dermatologist as soon as possible. 
!For a â€œsevere rashâ€, the subject must be seen within 1-2 days of reporting the event. 
!For clinically significant rash, the subject should be seen within 3-[ADDRESS_1024406] results.
NOTE:  Any event that meets the criteria for SERIOUS adverse event (SAE), must be reported 
to the Celgene Drug Safety within 24 hours by [CONTACT_6972], or other appropriate method, using the 
SAE Report Form, or approved equivalent form as outlined in Section 11.5.
19.3.10. Other
The following AEs, regardless of grade, are considered ECIs and should be reported to the 
Sponsor on the Adverse Event CRF within 5 days if determined to be a non-serious event:
!Myocarditis
!Pericarditis&(/*(1([ZIP_CODE],(7$5<,1)250$7,21xed xed 
purposes. purposes. 
contact (egcontact (
needed. needed. 
ngcondicondi titiiiio
HistoryHistory ele
RF.  PerfoRF.  Perfo
luding LFTluding LFT
oon as possoon as po
subject muubject mu
icant rash, tcant rash, t
ubmibmit a bit a biii
nced in revinced in re
vide thde th e dere de
phs and labphs and lab
event that event that 
gene Drug ne Drug 
eport Formeport Form
9.3.10..3.10. OO
The foThe fo llol
ons
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 115 CC-486-NSCL-001 Final: 15 May 2015!Pancreatitis
!Any additional Grade 3 or higher event wh ich the physician considers to be immune 
related
All attempts should be made to rule out othe r causes.  Therapeutic specialists should be 
consulted as appropriate. However the AE should be reported regardless of etiology.
Course of Action
Grade 2 events or Grade 1 events that do not improve with symptomatic treatment:
!Withhold pembrolizumab.  
!Systemic corticosteroids may be indicated. 
!Consider biopsy for confirmation of diagnosis.
!If pembrolizumab held and corticosteroid required, manage as per Grade 3 below.
Grade 3 events:
!Hold pembrolizumab
!Treat with systemic corticosteroids at a dose of 1 to 2 mg/kg prednisone or equivalent 
once per day.  
!When symptoms improve to Grade 1 or less, steroid taper should be started and 
continued over no less than 4 weeks.  
!Permanently discontinue for inability to redu ce corticosteroid dose to 10 mg or less of 
prednisone or equivalent per day within 12 weeks. Otherwise, pembrolizumab 
treatment may be restarted and the dose modified as specified in the protocol
Grade 4 events:
!Treat with systemic corticosteroids at a dose of 1 to 2 mg/kg prednisone or equivalent 
once per day.  
!Discontinue pembrolizumab
NOTE:  Any event that meets the criteria for SERIOUS adverse event (SAE), must be reported 
to the Celgene Drug Safety within 24 hours by [CONTACT_6972], or other appropriate method, using the 
SAE Report Form, or approved equivalent form as outlined in Section 11.5.
19.3.11. Infusion Reactions
Signs and symptoms usually develop during or shortly after drug infusion and generally resolve 
completely within 24 hours of completion of infusion.
The following AE terms, regardless of grade, are c onsidered ECIs and should be reported to the 
Sponsor on the Adverse Event CRF within 5 days if determined to be a non-serious event:
!Allergic reaction
!Anaphylaxis
!Cytokine release syndrome&(/*(1([ZIP_CODE],(7$5<,1)250$7,21r Gr Grade 3 brade 3
2 mg/kg pr2 mg/kg pr
steroid tapteroid ta
o reduce co reduce 
ithhiin 12 wein 12 we
he dose mohe dose mo
ticosteroidscosteroid
mbrolizumabrolizum
meets the cmeets the
SafetSafet y ywiwithi
m, or approvm, or approv
nfusion Renfusion R
nd symptomnd symptom
pletely wiletely wi thtii
he fohe fo llollowinwi
SponsorSponsor
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 116 CC-486-NSCL-001 Final: 15 May 2015!Serum sickness
!Infusion reactions
!Infusion-like reactions
Please note, the AE should be reported regardless of etiology.
Course of Action
Table 12 shows treatment guidelines for subjects who experience an infusion reaction associated 
with the administration of pembrolizumab.
Table 12: Infusion Reactions
NCI CTCAE Grade TreatmentPremedication at 
Subsequent Dosing
Grade 1
Mild reaction; infusion 
interruption not indicated; 
intervention not indicatedIncrease monitoring of vital signs as medically 
indicated until the subject is deemed medically 
stable in the opi[INVESTIGATOR_689].None
Grade 2
Requires infusion 
interruption but responds 
promptly to  symptomatic 
treatment (eg, 
antihistamines, NSAIDS, 
narcotics, IV fluids); prophylactic medications indicated for â‰¤24 hrsStop Infusion.
Additional appropriate medical therapy may 
include but is not limited to:
!IV fluids
!Antihistamines
!NSAIDS
!Acetaminophen
!Narcotics
Increase monitoring of vital signs as medically 
indicated until the subject is deemed medically stable in the opi[INVESTIGATOR_689].
If symptoms resolve within one hour of 
stoppi[INVESTIGATOR_13056], the infusion may be restarted at 50% of the original infusion rate 
(eg, from 100 mL/hr to 50 mL/hr).  Otherwise 
dosing will be held until symptoms resolve and the subject should be premedicated for the next 
scheduled dose.
Subjects who develop Grade [ADDRESS_1024407] may be 
premedicated 1.5 hrs.
(Â± 30 minutes) prior to 
infusion of 
pembrolizumab with:
Diphenhydramine 50 mg 
p.o. (or equivalent dose of 
antihistamine).
Acetaminophen 500-1000 
mg p.o. (or equivalent 
dose of antipyretic).
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21d d 
dication at dication at
equent Dosequent Dos0
ee25
,1
y may y may 
toring of vittoring of 
ntil the til the subjebj
the opi[INVESTIGATOR_748983] a
(eg,fromfr
dosindos
thetheSubSu,1,1,1
(/1(,1
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 117 CC-486-NSCL-001 Final: 15 May 2015Table 12: Infusion Reactions (Continued)
NCI CTCAE Grade TreatmentPremedication at 
Subsequent Dosing
Grades 3 or 4
Grade 3:
Prolonged (i.e., not rapi[INVESTIGATOR_38194]/or brief 
interruption of infusion); recurrence of symptoms following initial 
improvement; 
hospi[INVESTIGATOR_14138] 
(eg, renal impairment, 
pulmonary infiltrates)
Grade 4:
Life-threatening; pressor 
or ventilatory support 
indicatedStop Infusion.
Additional appropriate medical therapy may 
include but is not limited to:
â€¢ IV fluidsâ€¢ Antihistaminesâ€¢ NSAIDSâ€¢ Acetaminophenâ€¢ Narcoticsâ€¢ Oxygenâ€¢ Pressorsâ€¢ Corticosteroidsâ€¢ Epi[INVESTIGATOR_748984].
Hospi[INVESTIGATOR_13021]. Subject is 
permanently discontinued from further trial 
treatment administration.No subsequent dosing
CTCAE = Common Terminology Criteria for Adverse Events;  hr = hour; IV = intravenous(ly); NCI = National 
Cancer Institute; NSAID = non-steroidal anti-inflammatory drug;  p.o. = oral(ly)
Appropriate resuscitation equipment should be available in the room and a physician readily available during the 
period of drug administration.
For Further information, please refer to CTCAE v4.0 at http://ctep.cancer.gov
19.3.12. Follow-up to Resolution
Subjects should be followed to resolution. Th e Adverse Event CRF should be updated with 
information regarding duration and clinical course of the event. Information obtained from the consulting specialist, including diagnosis, should be recorded in the appropriate AE fields. 
Any treatments administered for the event should also be entered in the Concomitant Medication 
eCRF.
19.3.13. References
Brahmer JR, Tykodi SS, Chow LQM, Hwu WJ, et al. Safety and Activity of Antiâ€“PD-L1 
Antibody in Patients with Advanced Cancer.  N Engl J Med 2012; 366:2455-2465.
Bristol-Myers Squibb: YERVOY (ipi[INVESTIGATOR_125]): Serious and fatal immune-mediated adverse 
reactionsâ€”YERVOY Risk Evaluation and Mitigation Strategy (REMS). 
http://www.yervoy.com/hcp/rems.aspx
Bristol-Myers Squibb: YERVOY (ipi[INVESTIGATOR_125]) prescribing information revised March 2011. 
http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125377s0000lbl.pdfy y
allay 
bject is bject is 
further triurther tr
7$,1$7
vents;  vents;  hr = hhr = 
matory drugmatory drug
ilable in the rable in the r
AE v4.0E v4.0 at ht
tiontion
to resolto resol utlio
ration and cration an
ncluding dincluding d
ministered ministered 
ReferencReferenc
mer JR, Tymer JR, Ty kk
ibodyibody iiyn PnP
BriBrstolol-MM
eactieactioo
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 118 CC-486-NSCL-001 Final: 15 May 2015Hodi FS, Oâ€™Day SJ, McDermott DF, Weber RW, Sosman JA, et al. Improved Survival with 
Ipi[INVESTIGATOR_15173]. N Engl J Med 363:711-723, 2010.
Lemech C and Arkenau HT. Novel Treatments for Metastatic Cutaneous Melanoma and the 
Management of Emergent Toxicities. Clinical Medicine Insights: Oncology 2012:6 53â€“66.
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy.  Nature Reviews 
Cancer 2012; 12:252-264.
Phan GQ, Weber JS, and Sondak VK.  CTLA-4  Blockade w ith Monocl onal Antibodies in 
Patients with Metastatic Cancer: Surgical Issues. Annals of Surgical Oncology 15(11):3014â€“
3021.
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, 
Activity, and Immune Correlates of Anti-PD- 1 Antibody in Cancer. N Engl J Med 2012; 
366:2443-2454.
Weber J, Thompson JA, Hamid O, et al: A randomized, double-blind, placebo-controlled, phase 
II study comparing the tolerability and efficacy of ipi[INVESTIGATOR_748985]. Clin Cancer Res 15:5591-5598, 2009.
Weber JS Practical Management of Immune-Related Adverse Events from Immune Checkpoint 
Protein Antibodies for the Oncologist. Am erican Society of Clinical Oncology 2012; 1092-
9118/10/1-10.
Weber JS, Kahler KC, and Hauschild A. Management of Immune-Related Adverse Events and 
Kinetics of Response With Ipi[INVESTIGATOR_125]. J Clin Oncol 30. 2012. http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2012.41.6750.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,210144â€“â€“
al. Safety, al. Safety,
Med 2012; Med 2012
plplaceboacebo --conc
nistered witstered wi
IV melanoV melano
erse Eventserse Event
y y ofof Clinic Cliniff
ement of Imement of Im
n Oncol 30n Oncol 30
O.2012.41O.2012.41
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 119 CC-486-NSCL-001 Final: 15 May 201519.4. Appendix D: Table of Abbreviations
Table 13: Abbreviations and Specialist Terms
Abbreviation or 
Specialist Term Explanation
AE Adverse event
AIM Azacitidine-induced immune
AJCC American Joint Committee on Cancer
ALT Alanine aminotransferase (SGPT)
ALK Anaplastic lymphoma kinase
AML Acute myeloid leukemia
ANC Absolute neutrophil count
aPTT Activated partial thromboplastin time
ASCO American Society of Clinical Oncology
AST Aspartate aminotransferase (SGOT)
AUC Area under the concentration-time curve
AZA Azacitidine
Î²-hCG Beta-subunit of human chorionic gonadotropin
BCG Bacillus Calmette-Guerin
BLQ Below the limit of quantitation
BSC Best supportive care
BUN Blood urea nitrogen
CBC Complete blood count
CI Confidence interval
CL/F Apparent total body clearance
Cmax Maximum plasma concentration of drug
CMMoL Chronic myelomonocytic leukemia
CNS Central nervous system
CR Complete response
CRA Clinical research associate
CRO Contract resear ch organization
CRF Case report form
CSR Clinical Study Report
CT Computed tomographyF&(CROCR&(/*(1([ZIP_CODE],(7$5<,1)250$7,21$7$7$7$70$$
[ZIP_CODE]
1),1<,curveurve5<$5horionic gonhorionic gon7$uerinrin(7
of quantitatiof quantitati5,( tive careive car35urea nitrogena nitrogen23 mplete bloomplete blo52 ConfidencConfidenc35(ApparAppar(((31(MM1(1((1((1*(/*RAA(/&(&
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 120 CC-486-NSCL-001 Final: 15 May 2015Table 13: Abbreviations and Specialist Terms (Continued)
Abbreviation or 
Specialist Term Explanation
CTCAE Common Terminology Criteria for Adverse Events
DCR Disease control rate
DIC Disseminated Intravascular Coagulation
DILI Drug-induced liver injury
DKA Diabetic ketoacidosis
DLT Dose-limiting toxicity
DNA Deoxyribonucleic acid
DNMT1 DNA methyltransferase-[ADDRESS_1024408]
ECG Electrocardiogram
ECOG Eastern Cooperative Oncology Group
eCRF Electronic case report form
EEA European Economic Area
EGFR Endothelial growth factor receptor
ESMO European Society for Medical Oncology
EOT End of treatment
EU European Union
FFPE Formalin fixed paraffin embedded
FAB French American British
FDA Food and Drug Administration
GCP Good Clinical Practice
G-CSF Granulocyte colony-stimulating factor
GM-CSF Granulocyte macrophage colony-stimulating factor
GI Gastrointestinal
GITR Glucocorticoid-induced tumor necrosis factor receptor
HBV Hepatitis B virus&(GMGM&(/*(1(3EuropeEurop35235,(7$5<,1)250$7,[ZIP_CODE]$7$7$7$052)21
<,5<$57$Oncology Gncology G(7eport formport form5,( onomic Arenomic Ar35 ialalgrowth owth23 opean Sociepean Socie52 End of treaEnd of trea353(FoFo(((1((111
*(/* CSFSF(/-CSFCSF&(&
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 121 CC-486-NSCL-001 Final: 15 May 2015Table 13: Abbreviations and Specialist Terms (Continued)
Abbreviation or 
Specialist Term Explanation
HBcAb Hepatitis B core antibody
HBeAb Hepatitis B e antibody
HBeAg Hepatitis B e antigen
HBsAg Hepatitis B surface antigen
HBsAb Hepatitis B surface antibody
HCl Hydrochloride
HCV Hepatitis C virus
HCVAb Hepatitis C virus antibody
HDAC Histone d eacetylase
HIV Human immunodeficiency virus
HR Hazard ratio
HUS Haemolytic Uraemic Syndrome
ICF Informed c onsent form
IB Investigatorâ€™s Brochure
ICH International Conference on Harmonisation
iDMC Independent Data Monitoring Committee
IDO Indoleamine 2,3-dioxygenase
ILD Interstitial lung disease
IND Investigational New Drug
INR International normalized ratio
IP Investigational Product
IRB Institutional Review Board
irAEs Immune-related adverse events
irDCR Immune-related disease control rate
irPFS Immune-related progression-free survival
irRC Immune-related response criteria
irRECIST Immune-related Response Evaluation Criteria in Solid Tumors
irORR Immune-related overall response rate
IRT Interactive response technology
ITT Intent-to-treat&(/*(1([ZIP_CODE],(7$5<,1)250$7,[ZIP_CODE]$7$7$7$70$5025)21),1
5<$57$ ce on Harme on Harm(7 MMonitonitoring oring ,(
,3,3--dioxygendioxyg5
l lung disealung dise23tigational Ntigational N2
nternationalnternatio5
Investigvest3(InstIns(((1(1(1((1((1*(/*
rRECISTrRECIST&(ORRORR&
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 122 CC-486-NSCL-001 Final: 15 May 2015Table 13: Abbreviations and Specialist Terms (Continued)
Abbreviation or 
Specialist TermExplanation
ITP Idiopathic (or immune) Thrombocytopenia Purpura
IV Intravenous
LDH Lactate dehydrogenase
LFT Liver function test
mAb Monoclonal antibody
MDS Myelodysplastic syndrome
MM Multiple myeloma
MedDRA Medical Dictionary for Regulatory Activities
MRI Magnetic resonance imaging
MTD Maximum tolerated dose
NCCN National Comprehensive Cancer Network
NCI National Cancer Institute
NSCLC Non-small cell lung cancer
NYHA [LOCATION_001] Heart Association
ORR Overall response rate
OS Overall survival
PD Pharmacodynamics
PD Progressive disease
PD-[ADDRESS_1024409] Response Evaluation Criteria in Solid Tumors&BCBC&(QDQD&(/*(1([ZIP_CODE],(7$5<,1)250$7,[ZIP_CODE]$7$7$7$70$5025)21)k,1
5<$5nn7$(7,(
amicsamics5
ve diseaseve disease23rammed cellammed cel2
ProgrammedProgramm5
Physicalysic3(ProgPro(((1(1(1((1((1*(/*
&(&
('06'RF1XPEHUCC-486
Protocol CC-486-NSCL-001 Celgene Corporation
Confidential and Propri etary 123 CC-486-NSCL-001 Final: 15 May 2015Table 13: Abbreviations and Specialist Terms (Continued)
Abbreviation or 
Specialist TermExplanation
RNA Ribonucleic acid
SAE Serious adverse event
SAP Statistical analysis plan
SC Steering Committee
SC Subcutaneous
SD Stable disease
SGOT Serum glutamic oxaloacetic transaminase 
SGPT Serum glutamic pyruvic transaminase
SOP Standard operating procedure
S[LOCATION_003]R Suspected unexpected serious adverse reaction
TEAE Treatment- emergent adverse event
T1DM Type 1 diabetes mellitus
T2DM Type 2 diabetes mellitus
TKI Tyrosine kinase inhibitor
TIL Tumor-infiltrating lymphocyte
Tmax Time to maximum concentr ation
TTP Thrombotic Thrombocytopenic Purpura
t1/[ADDRESS_1024410] Upper limit of normal
US [LOCATION_002] 
Vz/F Apparent volume of distribution
WBC White blood cell count
WHO World Health Organization
&(/*(1([ZIP_CODE],(7$5<,1)250$7,[ZIP_CODE]$7$7$7$052)2
ionion1
<,5<$57$mphocytemphocyte(7m concentram concentr5,( Thrombocythrombocy35  hhalfa-flifelife23 per limit of ner limit of n52 United StatUnited Sta35 AppareAppar3(WW(((1((11
*(1
('06'RF1XPEHU
Celgene Signing Page
This is a representation of an electronic record that was signed electronically in Livelink.
This page is the manifestation of the electronic signature(s) used in compliance with
the organizations electronic signature [CONTACT_13695].
8VHU1DPH 
7LWOH 'DWH)ULGD\0D\30(DVWHUQ'D\OLJKW7LPH0HDQLQJ$SSURYHGQRFKDQJHVQHFHVVDU\                                                
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21   